abnormalities
peripheral
affected
mri
white
local
improved
recent
computed
clinically
contrast
part
brain
review
range
count
still
30
approximately
lead
systemic
abnormal
scan
protein
central
differential
despite
onset
woman
decreased
year
18
oral
family
like
along
prior
serum
diagnostic
mass
included
rarely
where
underwent
fluid
test
form
increase
side
magnetic
50
given
response
resonance
c
knowledge
occurs
number
abdominal
body
region
according
specific
causes
chest
16
four
tests
difficult
size
bilateral
identified
under
female
pressure
involvement
analysis
factors
levels
suggested
noted
secondary
tomography
complications
primary
started
infection
biopsy
incidence
general
area
follow-up
period
evaluation
function
previously
initial
changes
acute
demonstrated
signs
related
ct
chronic
showing
different
cm
same
commonly
management
development
laboratory
mild
characterized
lesion
course
previous
loss
total
out
syndrome
caused
many
presentation
followed
system
day
type
second
male
skin
risk
up
addition
less
low
13
hospital
physical
her
complete
14
surgical
20
based
later
few
features
early
his
level
similar
condition
upper
age
weeks
positive
result
confirmed
evidence
tissue
known
large
imaging
even
b
rate
cell
medical
occur
pain
surgery
lesions
important
small
cells
reports
severe
possible
significant
she
lower
's
multiple
therapy
15
presence
days
developed
include
negative
three
al
results
treated
observed
he
et
following
over
11
increased
literature
studies
diagnosed
fig
study
figure
considered
cause
0
12
symptoms
time
usually
months
right
high
left
years
reporta
findings
well
described
including
who
9
common
[
]
performed
blood
disease
two
associated
10
rare
only
presented
8
first
more
treatment
examination
one
history
diagnosis
:
;
revealed
7
present
normal
clinical
%
6
cases
patients
report
other
reported
4
5
after
3
patient
not
2
case
or
1
1,2,5,16
1b/2
1b1
1 mcg/ml
29–32
3–10 mg/kg
5–6 mcg/ml
amgen’s
anti-tnf-α
antibodies6131029
base ○
biogen’s
biology—these
centocor’s
chemotherapy + tp
chemotherapy‚
concentrations3
cyp ○
cyp•
cytokines27211
data ○
drugs4
drug–disease
d → tp
enzymes17917
evaluation—case
expected”
exposure•
factors02810
failure3
fcγ
fda’s
gap—assess
genentech’s
hold”
idec’s
il-2rs
interactions7
introductiontherapeutic
irinotecan + bevacizumab
labeling”
language1
miscellaneous0639
modulators ○
mtx’s
neulasta®
neupogen®
nf-kβ
oatp1b1
organized1,2
phase 3
possible•
practices”
prolog—in
proteins”
protein–drug
setting•
sn-38
studiestable i
studies—study
table ii
table iiexamples
table iii
table iiiexamples
table isummary
table iv
table ivsummary
tnfγ
tocilizumab + dextromethorphan
tocilizumab + omeprazole
tocilizumab + simvastatin
total9
tp-di ○
tp-di•
tp + chemotherapy
tp → d
tp–di
tp–drug
tp–smd
 1genentech’s
 2biogen
 3centocor’s
 4tp–di
 ○
©
–small
“can
“cocktail”
“collect
“current
“guideline
“risk-based”
“well-controlled”
≤24 weeks
-fluoro-2-deoxy-d-glucose
2005n/a59/male/incidentaln/ahypodense
2005–2009authoryearsize
20074
200743/female/incidentaln/atwo
2008844/male/pelvic
20097
2009877/male/incidentalisoechoic
2009980/male/incidentaln/aiso-
22–74 years
358/male/incidentalhypoechoichypodensen/a↑
4 ms
536/female/left
5 ms
9 cm
enhancement↓
gray–purple
iron↑
sant’s
table 1sclerosing
te = 2
te = 40 ms
te = 91 ms
tr = 16000 ms
tr = 180 ms
tr = 4
tr = 690 ms
value = 4
 1sant
 2a–d
 2sant
 3c–f
 3g
 3sant
 4sant
 5sant
 6sant
“scar”
“spoke-wheel”
↑
↓
3280
9450
chambers”
“separate
0,10s
0w
300-600µ
5460
755nm
smilepro980
11-60
11-70
1311/08
3119/2006
40-99
45-88
4876
4876/06
63-88
89-93
be:10–25
egzophytic–condyloma
operated–vulvectomia
straight–and
cerbb2
t2n2m0
discussioninverted
introductionwhereas
1owing
magill’s
35x30x25
discussionosteoid
hospitals’
introductionethmoid
osteoma’
’osteoid
discussiondiverticular
introductionright-sided
-113
-133
11x8
introductionlipomas
desat”
improve”
introductiontraumatic
meter”
“counting
“mydriacyl
boyle’s
conclusionseagle’s
discussionstyloid
introductionelongation
syndrome’s
towne’s
symptoms2
106fl
110fl
133-675
20210a
brattström
introductionhyper
patient28
patient29
patient32
25mg/kg/hour
discussioncystic
introductioncystic
turner’s
introductionbudd-chiari
time“
„life
55-yearold
discussionaccessory
21-numeric
3/1
3p-syndrome
8p-syndrome-structural
discussionatrioventricular
100,000-150,000
1m
3-mounth-old
9/100,000
discussionteratoma
introductionincidence
10-3
29±0
32±0
38±0
3±l
4±0
6±1
=π
aod/2
aos/2
aos–aod
discussionaortic
gc=5
ie33
introductionabnormal
introductionaortic
mmhg-1
±0
±l
ß
ß=1n
Δa
Δao
π
–compared
“elasticity”
10-45
area»
br-ca1
introductionbreast
margins»
recidivus”
surface»
therapy”
tumors»
«more
«negative
«only
«positive
–due
“burden”
“clear”
“frontline”
“threat”
13606-1
1947
act”
following:1
hl7
introductionincreasing
introductionpatient
materials”
normalization”
seven”
standardization”
“american
“commission
“health
“international
/0001
/005
0/05
36-40
ajzen’s
bagozzi’s
colleagues’
davis’s
fishbein’s
member’s
park’s
physicians’
r=/161
r=/295
r=/477
r=/499
r=/543
r=/590
r=/605
r=/734
r=0/161
r=0/280
r=0/295
r=0/499
r=0/590
r=0/616
r=0/734
record”
selim’s
staff’s
usefulnesspesrson’s
usingpearson’s
warshaw’s
“acceptance
1,500,000
106,000
2010”
380,000-450,000
44000-98000
549
american‘s
america’s
association’s
discussionconsidering
drugs’
drug’s
outpatients’
pharmacists’
professors’
study’s
system’s
ursula’s
usa’s
value=0
“human
“pharmacy
2007”
discussionhealth
introductionorganizational
management”
manager’s
program’s
titled”
“use
10/9241
28-32
69,4
8/76
9241
9241-10
9241/10
hamborg’s
his’s
introductionhospital
iums’
lee’s
managers’
0401
062
916
applications”
design”
industry”
introductionnowadays
research–practical
status4
“access
“approach
“equipment
“quality
“verification
18-23
1=definite
3=partially
40-59
5=
60-79
=1
center”
clinic”
good’
half”
headquarters”
rahayi”
sciences”
treatment”
vakili’s
valipour”
w1-w32
websites”
‘very
“aayandeh
“addiction
“behboudi
“dr
“green
“iranian
“low”
“more
“pishgamaneh
“presidency
“unit
26-50
city”
clients’
discussionministry
doctors’
hoseini’s
introductioncutting
introductionhealthiness
isfahan’s
mc-cool’s
p-value≤0
patients’awareness
questionnaire’s
research’s
“patient
1453
1980-2009
1990-2011
1990–2011
1998-2007
20/384
20054
20384
21-years
2245
29/03/2012
3038
43042
5132
5464
572
6-16
735
7415
761/545
7954
arabia’s
attarha’s
ctr”
iran’s
medicine”
sx=1
sx=3
turkey’s
“general
“king
“medicine
“wos”
1608
area–have
bradford’s
economy”
economy”–were
interventions”
libraries’
mid-1960s
proceedings”
rates”
services”
society”
studies”
tech”
update”
“aslib
“basic
“core
“determination
“information
“knowledge
“library
“oclc
“serials”
“women’s
introductionsoftware
network”
researchers’
researcher’s
software3
václav
“computer
“generally
“project”
1,400
1350
3,000
600,000
7,500
800,000
access“
cbc–core
culture”
databases3
engineers–ieee
institutions”
introductionfor
karlstruhe–leibniz
master’s
offered“
org/index_04b6084e91a114c63430001c3253dc21_en
organization–fao
use“
we’ve
world’s
“european
“helps
“laboratory
„open
„read
„those
048
1+/-
487
icd-10
n=127
opératoire
pensée
s-20
tas-20
v16
publishing”
“ability”
“plagiarism
“there
7x8
80x60mmhg
introductionfindings
chemicals–
g26
hba0
reporthba1c
sre604k
uv-1000
α-thalassemias
β4
1basic
1measurements
2protective
3protective
4protective
alpha-1
alpha-2
alpha2
alpha2-adrenergic
beta2
beta2–adrenergic
discussiongained
ewe’s
flux–l/min
group–composed
introductionimportance
mastocyte’s
mg–aerosol
raw–l/
receptors’
szentivany’s
x±sem
0,2
0,8
101°
16d
18d
25°
2corneal
4–10
5lax
82°
99°
9k–2
a–0
discussioncataract
introductionkeratoconus
k–47
program–toric
rt-7000
simk1–simk2
sn60t9
with–3
~–5
–0
≤55
10mg/kg
150mg/kg/d
discussionglioma
fabp7
ki67/mib1
023
1various
2measured
2various
3determination
3mm
3°
4determination
5determination
69-71
6determination
7°
8000c
8°
9°
discussionapical
introductioncephalometric
males4
±2
±3
±4
‘t’
157elbow8
166axilla9
1 5
1 sensory
2138
2g/kg
2 0
2 2
367antebrachial    an
443     left
451wrist3
458 dig
5 0
5 5
852     left
854above
868antebrachial    left
8nr5
8 left
916wrist7
942
944 dig
950below
9 5
breviserb's13
elbow17
elbow19
lateral 0
medial 1
medianpalm-wrist1
quintierb'snrnr  axilla20
ulnarpalm-wrist1
v-wrist2
wrist2
1500-7000
3433-
49-51
500u/l
_3603+
introductionno
β-dystroglycan
12,752
1during
2200_2205delinst
2706dupc
3516_3517del
4024c
7,785
introductionlgmd2b
k903qfsx4
lgmd2b
r1342w
s1173x
t734sfsx17
1399g
2243g
2542g
752c
a467t
discussionsensory
g848s
introductionseveral
n846s
p587l
polg1
t251i
w748s
135/80
397
adenosine-5-monophosphate
adenosine-5-triphosphate/-diphosphate/-
ampd-1
c34t
introductionmyo-adenylate
v1-5
v4-5
0,65
0,67
125,5
190u/l
2,87
24,2
24h/24h
483
58mmhg
60/minute
acta1
cfl2
childhood–juvenile
introductionnemaline
ldh5
tnnt1
tpm2
tpm3
α-tropomyosin
19ql3
md1
*608507
0mv
1392+2t
311+1g
4-amino
474+4a
475-1g
609260
64-yearold
66-amino
69bp
757
ala738val
cmt2
cmt2-affected
cmt2a-affected
early–onset
gjb1
introductionmolecular
late–onset
leu753fs
mfn2
mitofusin-2
ng_007945
nm_014874
np_055689
pmp22
t159-q162del
29-30th
32-33
40-42
domańska-janik
fidziańska
foxo1
foxo3a
h222p/h222p
igf-1r
lap2α
lemd3
man1
net25
net39
niebrój-
połosak
s6k
sirt1-7
tgfβ/
wrocław
1*iii
11fnananana26naiii
11m38ll
147450
149t
14mnallna+36naiii
17m48llnana502*iii
19f36llnana425
21fnanananananaiv
21m48ulna+
22fnananana40nav
26fnanananananaiii
28fnanananananaiv
2f28nanana291
2f49llumn+501iv
2fnananana25naii
2fnananana30naiii
3f40lllmn-499iii
3mnananana25naii
3±8
4abbreviations
5iii
5m39llna-478iv
5mnananana30naii
6m33ll+ulumn-407iii
6±3
7m36llnana360
8*ii
8f59llumn+601iii
8iii
8m32lllmn-living9iv
9f45ll
9m48bulbarna+480
dismutase-1
iii-6
ile149thr
introductionamyotrophic
iv-11
iv-5
iv-9
msod1
protein/tdp-43
proximallmn+umn-living5iv
proximallmn-living1iv
sod1
1,5t
3-36
45-te7
6330
80-te
discussionfocal
hiv1-2
il-1β
peña
tr4600-te
1878
l5/sl
+100+32+18fvc
-32-
0age
13t
1551+1g
203449
24-195
2bmi19
3/12
3age
4225nanocturnal
455451age
465452
473722nocturnal
475652wgms
564-634
6legenda
764749fvc
765442fvc
823nabmi20
826
925
assessment455451tongue
eea1
genotype–phenotype
grade2336mwt
grade233fvc
ivs1-13t
laminin-a2
lamp2
last-1st
lc3
onsetbulbar↑
symptoms434841main
val480-ile517del
µmbiochemical
µmimmunostaining
1627dupa
191dupa
3-hydoxy-3-methylglutaryl-coenzyme-areductase
35-fold
6086629
ano5
c5b9
lgmd2l
0 v
12-directional
14 mm
2 × 2
2 × 2 × 2 mm
2 × 2 × 4 mm
2 × 2 × 6 mm
2 × 2 × 8 mm
2 × 3 × 6 mm
2 × 4 × 8 mm
30 mm
31 mm
3389
45 mm
49 mm
4 min
4 v
5 v
6 v
8 v
brainlab’s
b = 0 s/mm2
b = 700 s/mm2
cortex2vimfacial
cortex3gpifacial
matrix = 128 × 128
purple—arrows
rectangle”
reid’s
roi1stnuncontrolled
schaltenbrand–wahren
software’s
symptom–tractography
table 1motor
te = 90 ms
tr = 10,000 ms
view = 25
voltage”
yellow—arrowhead
yellow—arrowheads
 3fiber
 3–5
 4fiber
 5fiber
“high
“noise”
“radial
1439
1439t 
15 years
171 nmol mg
1960–died
1:100–200
1:2,000
200 μm
202–482
297 ± 70
2 × 10 mg
30 μm
622c 
7/18
850 g
a3401
ala-ala-phe-7-amido-4-methylcoumarin
arg208x
arg208 x
arg447his
boy’s
ca1–ca4
cln2/tpp1
dt18
envision™+kit
nc_000011
ncl2
nm_000391
phe481cys
prot −1 h−1
tpp1
val480gly
variant’s
 g
 t
03-341-18h
03:55 hours
0 l
0 m
0 m2
0 mg
0 ml
0 ml/100
0 ml”
0 × 0
0 × 10
0 × 13
0 × 14
0 × 20
0 × 8
0–1
0–100
1-800-2474446
10-196-c
10°c
11-678-24c
13-989-218
14:30 hours
150,000
1511
17:45 hours
19240093
1pt
1to
1”
22-month
24 h/7 days
2 × 4
309603
334/3334
3 cm-thick
3 × 0
455-14
500/month
55425-1636
5694
5954
5 cm-thick
5 m2
5 × 0
5 × 1
5 × 3
5–10°c
5–12 h
60319
60320
60648
6 m2
77546
7–10 days
7–14 μm
8011
90 min
91-year-old
92-year-old
9 m2
amaya’s
ba37
ba9
bank––columbia
blocks”
bloc”
b”
cdx + npdx = ddx
chest”
compacta 
controls”
diagnoses”
diagnoses”to
diagnosis”
freezers”
fsb-4740
infarct”
interest → t
interval-frozen”
leakproof”
lhetable 1comparison
nucleus––in
once/24 h
p1-als
recognized––schizophrenia”
recognized”
reticulata 
room”
sbb1
sbb10
sbb13
sbb16
sbb17
sbb18
sbb3
sbb4
sbb5
sbb7
sbb8
sites → t
slices → dry
support”
xlc140
york––are
 10b
 10posterior
 11the
 12
 12posterior
 13
 13vessel
 14
 14lower
 15
 15operational
 16
 16a
 16b
 16empty
 17
 17empty
 18a
 18b
 18cerebral
 19
 19cerebral
 1usual
 20
 20cerebral
 21a
 21serial
 22
 22eighteen
 2variant
 3one
 4standard
 5alternate
 6separation
 7slide
 8a
 8b
 8d
 8e
 8the
 9
 9the
 pars
 −70°c
“additional
“als
“area”
“bioanalyzer”
“bitran
“box-area
“box-areas”
“box-area”
“box-brain
“box-brain”
“buttonholes”
“columns”
“cutting
“diagnosis
“distributive
“freezer
“luer-lok”
“matching
“myocardial
“no
“normal
“p1-als-variant
“polyfoam
“postmortem
“protocol
“ranks”
“request
“rows”
“sandwich”
“schizophrenia”
“standard
“standardized
“ultra-low
“u”
“wheaton
−100°c
−160
−160°c
−180°c
−195°c
−20°c
−5°c
−70
−78
−78°c
1-42
10–20 s
12–17 nm
27 μm
47 μm
49 m/s
53–60 m/s
55 m/s
56–57 m/s
58 m/s
60–90 nm
bar 0
cd11c
cd11c+
f = 50 μm
f–h
h58a
mhc-1
ubiquitin–proteosome
 1a–d
 1fresh
 1h
 2fresh
 3inclusions
0579
0826
0 iu/ml
0 u/ml
1/control
100 μmfig
123i-imp
16111c
1ci
2151patient
25 μg/day
2723
2737
2751
2757control0
290 iu/l
30 s
3132
3194
3243a
3444
3840
3 iu/ml
3 u/ml
45–163 iu/l
465-base
47 μiu/ml
500 nmbiochemical
50 ng
50 μg/day
5512
59−245++nr−65/m
5 u/ml
5′-aggctaagcgttttgagctg-3′
5′-caccattctccgtgaaatca-3′
60+474neneneencephalopathy65/m
602
602c
6183
6192
61°c
62nrnr++nrparkinsonism78/m
63+290++602c
68 years
7027
70s
70 years
71 years
78nr501++nr−64/m
7 ± 1
80 μm
82 years
8344a
881
9874
adenine–thymine
ataxia84/f
a−cbar
babinski’s
cytosine–guanine
c–g
deficit73/f
genechip®
ii-3
ii-4
introductioncamptocormia
nrnrelevated++nr−55/m
nrnrnormal++nr−m
n = 100
ratio60
sanger’s
table 1enzymatic
table 2clinical
watson–crick
 1pedigree
 3histochemical
 4electron
 5c
“bent
1,500 mg
11th–14th
12/40
14 months
1:3,000
1 years
200k
30 μg/l
3–42 m
7/24
909
a9952
ar12
ar42
ben-men-1
cdkn2ab
crl4
crl4-dcaf1
dcaf1
disorders—nf1
e12
egfr/erbb2
erb2
fehon’s
guy’s
hrasg12v
hrasgv12
hsp90
jak2/stat5
kissil’s
mary’s
mdm2
merlin’s
models + mechanismsfilippo
nct00326872
nct00727233
nct00863122
nct01140360
nct01207687
nf1-associated
nf1-related
nf1fl+
nf1fl/fl
nf1nf1
nf1−/−
nf2-meningiomas
nf2-related
p15ink4b
p16ink4a
p19arf
p53/nf1
pi3-kinase
pi3k/mtor
pn’s
p ≤ 0
schwannomatosis—that
serra’s
sf-36
spred1
t2-hyperintensities
tao-1
thomas’
u674
yap1
’s
“addicted”
1,036 g
1007/s00401-013-1096-7
10 μmdistribution
12198
1430 kb
15 mmhistological
16 kb
24/30
25 μmthe
29 years
2m
48 years
4q21-23
4′,6-diamidino-2-phenylindole
7 months
a30p
a30p1severenot
a53t
a53t2severemildsevere
a53t2severemild–moderateyesnopd-likemoderate
a53t2severeseverenoseverepd-likenonedeep
at100
a–j
a–l
a–n
black/70 
b–f
ca2/3
capsulen/an/an/an/an/a+++ amygdala++++++++–++++hippocampus df–+++++–++– ca4+++++++++++ ca3+++++––++– ca2+++––––++– ca1++++++++++– subiculum++++++++++– entorhinal
capsulen/an/an/an/an/a+++ external
cb0not
cells++–––––n/a cerebellar
coeruleus+++––––++– pontine
cortex+++++++++++– transentorhinal
cortex+++++++++– caudate+++++++++++– putamen++++++++++++– globus
crescentglobulardiffusenft-likecortex frontal+++++–+++ motor+++++–++++ temporal++++++++–+++– parietal+++++++–+++– occipital–+––––– cingulate++++++++–+++– insular++++++++–+++–sub-cortical
c–e
described0not
dm5500
duplication1severenot
duplication1severeseverenonemoderatefeatures
e46k
e46 k1moderate–severemildnot
e–g
e–h
e–i
findingstdp-43
g152a
g51
g51d
g 
h50q
horn––––––– cervical
human660w-quad
h–j
iba-1
iba-1-positive
i–k
i–l
j–o
laminaenone0not
lossα-synuclein
mattern/an/an/an/an/a++++ dentate
mattern/an/an/an/an/a+–oligodendroglial
mattern/a––––++++ dorsal
matter frontaln/an/an/an/an/a++ motorn/an/an/an/an/a+++ temporaln/an/an/an/an/a++ parietaln/an/an/an/an/a++ occipitaln/an/an/an/an/a+– cingulaten/an/an/an/an/a++ internal
nigra+++––––+++ locus
nm_001146055
np_001139527
nuclei–––+–++pontine
nucleus–+++–+– substantia
nucleus–––+–++– red
nucleus–––––++ iii
nucleus–––––+– inferior
nucleus––––––– cervical
olig-2
olive+––++–+– cerebellar
p62α-synuclein
pallidus–+–––++ thalamus––++–++ subthalamic
pathologysnlcca1ca2/3patternstriatumneocortical
pathologyα-synuclein
phospho-s129
phospho-ser129
phospho-y125
polyphen-2
reportg51d1severeseveremildseverefeatures
round–oval
ser129
ser202
ser214
stagetdp-43
table 1semi-quantitative
table 2neuropathology
thr205
thr212
triplication1severeseverenoneseverefeatures
triplication1severeseverenoneseverepd-likeanot
v2010
vagus+++––––++– twelfth
y125
 1snca
 2α-synuclein
 3macroscopic
 4a–k
 4g
 4h
 4histological
 4i
 4k
 5a–d
 5characterisation
 5e
 5g
 5i
 5j
 5k
 5l
 5m–o
 6a–d
 6e–g
 6g
 6glial
 6h–j
 7b–d
 7e–l
 7m–p
 7tau
 8d–f
 8g–l
 8m–o
 8α-synuclein
α-synuclein-containing
α-synuclein-positive
α-synucleinopathy
α-synucleinphosphorylated
αb-crystallin
β-synuclein
γ-synuclein
γ-synucleinneuropathological
12 h
19 
3group
3one
4,50,000
4-group
444
450k
4one
4 gy
5-mb
5 cm2
5–10 years
5–16 years
60–70 
6 gy
8 gy
agent’s
and/or2
and/or3
celltitre-glo®
center’s
cpg’s
ddx3x
exposure–response
françois
gab1
gli2
gli2/mycn
gov/ct2/show/nct01708174
gov/show/nct01356290
gov/show/nct01878617
group’s
humanmethylation450
ic50
ic90
igf2
introductionmedulloblastoma
is—what
laboratory-friendly”
laboratory’s
lde225
medulloblastoma”
met:1
myt1l
neo1
neogenin1
or2
or4
pi3k-pathway
protein–protein
ptch+/−
screening—translating
siop-europe’s
sjmb03
sjmb12
specified”
table 1suggested
table 2suggested
table 3pros
tp53-shh
trials—implementing
weiss’
williamson’s
 1new
 2medulloblastoma
β-catenin
β-catenin+
“6-pack”
“not
“pathology
“virtual”
+++++++−+++−− ca4+++++++++++−−++− ca3++++++++++−−−++− ca2−++++++−−++++−− ca1+++++++++++++++− subiculum++++++++++++++++ entorhinal
+++ = frequent
+++ = severe
++ = moderate
01 
09/40
09/h0311/88
0n4r
10 μl
15–20 
1:5,000
1n3r
1n4r
1 mg/ml
1 μg
20 ng/ml
20–30 
25 μm
280 nm
29-
2 h
2 × 105 cells/well
2 μg
30 ml
31—1:5,000smi
32—1:500sternberger
350 nm
37 °c
3 u/μl
40 mm
48 h
4c–h
4r0n
4 h
50 mm
513 g
53 days
58-
5 h
6000b
60 min
60 s
65 °c
68 kda
892
a892
aaa›gaa
addenbrooke’s
arms 
at100-positive
bl21
cells++−+−−−−−−cerebellar
cns”
coeruleus++++++−−−++−−pontine
cortex+++++++++++++++++++ transentorhinal
cortex++++++++++++−+++++++caudate+++++++++++−+++++++putamen−+++++++++−++++++globus
crystallinnovacastramouse1:300novocastra
c–h
de3
di-aminobenzidine/h2o2
diffuseoligodendroglialastrocyticcortex frontal++++++++++++++++++++ motor++++++++++++++++++ temporal++++++++++++++++ parietal++++++++++++++++++++ occipital−+++++++++−+ cingulate++++++++++++++++sub-cortical
e10
exon11
e–k
fascia−
fgf2
fifty-three days
ftdp-17t
f–k
h2o2
i10+3
in-k298e
introductionfrontotemporal
k298e
k298e-derived
k298e-induced
ligandmouse1:100bd
m0872
mattern/a++−+n/an/an/an/a−−dentate
matter frontaln/a+++++++n/an/an/an/a+++− motorn/a++++++n/an/an/an/a+++− temporaln/a+++++n/an/an/an/a+++− parietaln/a+++++++n/an/an/an/a+++− occipitaln/a++++n/an/an/an/a+− cingulaten/a++++++n/an/an/an/a+++− amygdala+++++++++++++++++++++hippocampus dentate
methanol/0
mouse1:100dako
mouse1:200autogen
mouse1:600autogen
n296h
n296n
nigra++++++++−+++++−locus
nuclei−++++++−−+++++−dorsal
nucleus−+++++−−+++++−midbrain
nucleus−+++++−−−−+−inferior
nucleus−+++−−++−−
olive−++−+++−−−−−+cerebellar
p301l
p301s
pallidus−+++++++−+++++−meynert−+++++++−−++++++++thalamus−++++++−−+++++++ subthalamic
pcdna3
phospho-ser202/ser205
phosphoser202
phosphothr205
prk172
protein-43mouse1:800abnova
proteinrabbit1:1 kdako
right 
ser212/thr214/t217
silva/milliporeat100tau
silva/milliporerd044-repeat
studyantibodyepitope/antigenspeciesdilutionsourceat8tau
t43
table 1antibodies
table 2semi-quantitative
taumouse1:100dr
taumouse1:2,000dr
tbs/0
tegmentum−++++++−+++++−substantia
tegmentum−++++++−−+++++−pontine
thirty days
tween-20
two weeks
ukaββ-amyloid
ukp62p62
ukrd033-repeat
uktdp-43tar
ukα-synucleinα-synucleinmouse1:75novocastra
usaαb
vagus−++++−−++−−twelfth
 + = infrequent
 + = mild
 1microtubule
 2reverse
 3a–c
 3e–k
 3f–j
 3k
 3l
 3m
 3neuropathological
 3o
 3p–r
 4neuropathological
 5soluble
 6a
 6b
 6tau
 left
 legs
Δn296
αb
“generation
−80 °c
− = none
0 mb
1,217,272**  highly
1,274,358*dvl1sjs
1,283,778*mxra8  glia
1,366,009vwa1 peripheral
1,555,848mib2 exencephalyubiquitin
1,559,893mmp23cranial
1,822,526*gnb1 micrencephaly
1,952,050gabrdepilepsypro-epileptic 
1-like1p36
1/5000-1/10000
10,12-14,18,19
10,12-19
101p36
11p36
1290 g
13,18,19
13 months
17–20 weeks
1genes
1p36
1p36neuroimaging
1p36pmg
1p36subcortical
1 minute
2,229,316skifacial
2,333,870*pex10ald
2,4,9-11
2,426,824plch2mental
2,451,544*hes5 premature
2035 g
21-1p36
21p36
22-56
22 year-old
23b1p36
27,67
3,536,555tprg1l  presynaptic
3,639,716trp73 hippocampal
3-4 mm
316,008,967
316,084,440
316,226,849
316,246,919
316,397,883
316,407,435
316,448,739
322,326,101
322,397,614
322,450,044
323,531,416
323,558,989
33,72
331,207,439
331,260,521
331,277,934
331,360,772
331,540,747
331,557,423
331,716,725
331,940,703
332,149,994
33885,830
33924,207
33945,366
37 year-old
39 weeks
3histologic
3 mb
3–1
4hippocampal
500 μm
51p36
52,56
52,57,71
52-54
59-64
5terminal
5 mb
6,083,110kcnab2 defects
6,162,770*chd5  brain
6,228,225hes3 premature
6,376,413*acot7  mtle
6,402,566*hes2  expressed
6,443,591espncongenital
6,502,656*plekhglower
69,70
6 μm
71p36
750 μm
75 μm
81p36
858 g
890,958klhl17  postsynaptic
8 mb
8 months
9,15,18
925,333***  hes
969
981,355agrncms
acot7acyl-coa
agrnagrin1p36
ampd3
b’
ca1-ca3
calretinin + neurons
camta1
chd5
chd5chromodomain
circumstance 
closure***  
cmt2ac
complement = minus
cr + cells
cr + interneurons
cy3
cy5/patient
cy5/reference
d1z2
delta1p36
dlx1
dvl1dishevelled
espnespin1p36
e’
figure 1a-d
figure 2e
figure 2f-h
figure 2i
figure 3a-k
figure 3h-k
figure 3l
figure 3m
figure 3n
figure 3o
figure 4b’
fmr1
gnb1
gnb1guanine
gβ
height 
hes1
hes2
hes2hairy
hes3
hes3hairy
hes4
hes4hairy
hes5
hes5hairy
interactions 
kcnab2potassium
klhl17kelch-like
l1cam
leather”
leather”-like
map1b
map2
memory 
mib2mindbomb
microphthalmos 
mmp23bmatrix
mxra8
mxra8matrix-remodelling
n52
n52+
nmj 
nodular”
p5000-dg
p73
p731p36
pex10
pex10peroxisomal
plch2phospholipase
plekg5pleckstrin
pmg–like
polymicrogyria”
retardation neuron-specific
rp1-126a5
rp11-54o7
rp3-438 l4
rp5-1096p7
scnn1dsodium
tp73
tp73-dependent
tp73tumor
tprg1ltumor
trp73
trp73−/−
vwa1von
xq28
z1
~33
~61
~95
 activates
 5th
“coarse
“cobblestone”
“extrapolation
“festooned”
“festooning”
“four-layered”
“moroccan
“pmg-like”
“six-layered”
“two-layered”
“unlayered”
+++pattern1
+++   finely
++/+++e   regions
++ca1
++ca2
++pattern1
+0
+etoh = alcoholism
+f   intra-neuronal
+   intra-neuronal + b   intra-neuronal
+   plaque
-+b++/+++bn/a+++b++e+e+e+e++/+++bthalamus++++/++++++++++/+++c+b-b-b++/+++e++e++e++e+b-b-bcerebellum+++/++++++/+++b+++bn/a+++b++d+e++d++d+++c   ++e +e+evacuole
-129m
-129v
/+++++/+++c+++bn/a+++b+++d+/++e+++d+++d+/++e +/++e+/++estriatum+++++++++++
029
06−4
1,8,14
10782-2-ap
108 ± 156 ± 12     
109 ± 4
10 ± 6
10 ± 60-10 ± 654 ± 12     
1100–1400
1150 pg/ml
1175
129m
129mm
129mv
129v
12–13
12–60
1351 pg/ml
14,26,35
14,29,36
14-3-3clear
14-3-3 csf
14746 pg/ml14-3-3
15-item
15–35
16,30
17,29
17 kda
17 months
18,19,22
18 months
1visit
1 kda
1 + 2
1–12
1–29
1–29 months
1–4 + 
20360 pg/mlother
20 months
20–50 years
21:46:33
25-month
25/30
25 months
27-29
27 ng/ml
28 months
2lesion
2visit
2x
2 month
2–17
2–29
2–3 monthscognition
2–3 monthsweak
2–41 months
30 months
33–84 years
35:49:16
35 ng/ml
37–66
37–67
37–67 years
37−4
38,39
3clinical
3f4
3neuropathological
4,5,8-10
4-level
40–70
40–85
40–85 years
42,43
45–75
47-49
49:40:11
4g8
4punctate
4summary
4 monthsat
4 monthsbrain
4 monthscurled
4 monthsmmse
4 monthsmoca
4 monthsright
4 ± 20-9
4 ± 24 ± 2
4 ± 27
4 ± 2 months
4–108
4–108 μm
4–69
4–69 μm
4–72
4–72 μm
5,8,10
5-29
5-level
50executive
51:38:11
52:39:9
53–76
53−2
54:38:8
55 ± 11     
57 years
58 years
59 years
59 ± 11   
5comparison
5hyperphosphorylated
5 month
5 ng/mlglucose
5 ± 3
5 ± 35 ± 4
5 ± 3 months
5 ± 8
5 ± 814
60 ± 10 years
63 ± 7   
6prion
6 monthshistological
6 + 
7 ± 49 ± 7
7–9 months
80−3
88language   bnt-abbrev13
8  
8 ± 1
8 ± 114
8 ± 1 months
9   11
9 ± 4
9 ± 48
9 ± 7
a60 ± 10  
ab27766
ab5622
all 110-91
all 7379
ammon’s
anti-β-amyloid
asp178asn
atrophy1
b  prpsc
b   
b   2
b   abbreviations
b   prpsc
cases* patient
cases e200g-129v
case visit
ca = lung
cerebellum2
cerebellum5
chf = congestive
cognition   mmse26124216memory   cvlt
copy13
cortex2
cortex4
cortex 
cp13
c   finely
c   plaque-like
d178n
delay1
dementia”
deposit3
deposits1
dulbecco’s
e200
e200g
e200g+
e200g-129v
e200k
e200k-129
e200k-129m
e200k-129m-prpsc
e200k-129mm
e200k-129m m5491
e200k-129v
e200k-129v m70-86
e200k-v
f4
fage/gender37
figures 3c
figures 3d
figure 2a-f
figure 2g-i
figure 3e
figure 3h
figure 3i
figure 3j
figure 6a-b
findingsmyoclonus + in
fluencyn/a5
function   modified
f   plaque-like
glu200lys
gp   sn
hippocampi   put
hits15
hτ
hτ-positive
hτ’s
illness9 months8 months7 monthsfirst
inhibition31
is ~ 19 kda
map-2
mean 14
mean ± sd
members + for
months26
months28
movements”
mv2
n/a = not
n/d1
n/dvisuospatial   benson
ne1002
negative serum
nl 
normal 
n = 14
n = 49
n = 5
n = 58
onset129type
onset37
p-40
pagpag    
pag   
pos3
recall3
rpd = history
scjdmm1
scjdvv2
span3
tegmentum + 
thalamus2
thalamus3
trails59
type222family
type2   2c   1
vv2
yo/female67
yo/male57
yo57
yo67
z-score−2
z0334
z0458
~17 kda
~19 kda
~20 kda
 pattern
 v1947
 v40-100
   1 + 2
   2
   ca4
   mioncdn        cdn
   mt   cdn
   put
   sn   
–ca1
–ca4
“5”
“alcohol-related
“alcoholic
“ambiguous”
“e200g+”
“fast
“intermediate”
“onset”
“wm”
−/+
−/++
−/+ca4
−/+caudal
−/+layers
−/+molecular
−/+rostral
−0
−caudate+++
−middle
−rostral
1,7,8
10-nm-thick
1187-2a 
12,16,23
14 m8
15-kda
150 cm
1612c 
162-bp
1:2500
1:600
20 μm
29-32
2–5 years
33-36
39 kg
3lewy
40–70 μm
4schema
5-gtcagcatcaccttgggttt-3′
5-μm-thick
517 nm
5biochemical
5′-caacgtggagatgatcaagg-3′
5′-ggaaggcgatcttgactctg-3′
5′-gtcagcatcaccttgggttt-3′
600-bp
603 nm
6f/3d
6identification
700-bp
890 g
8–13
ammon’
and × 400
anti-p-α-synuclein
anti-β-actin
at-8
at × 200
aβ-positive
bar = 50 μm
black 
black = severe
braak’s
childhood18
cns = central
discussioninad
dj-1
dot-pattern = 1–10
dot-pattern = mild
figures 2i
figures 3a-f
figures 3i-l
figure 1a-c
figure 1d-f
figure 1g
figure 2e-g
figure 2g
figure 2h
figure 3c-f
figure 3d
figure 3m-o
figure 6c
figure 6d
gc = granule
gray = 10–20
gray = moderate
huntington’s
infant8
ipla2-via
iron1
klüver-barrera
l-dopa–induced
lb509
p-α-synuclein
p-α-synuclein-positive
park-14
pc+++2
pc+++3
pc+++4
pc+++5
pc = purkinje
pink-1
pla2g6
pla2g6-associated
pla2g6-knockout
pns = peripheral
r538c
tc99m-ecd-single-photon
tris–hcl-
x-100
x-100-soluble
y20
y23
y36
~15-
~15-kda
~30-kda
α-synuclein-reactive
α-synucleinproteins
α-synucleinto
β-actin
 20
 = 0
 = 100 μm
 = 20 μm
 = 250 μm
 = 2 μm
 = 50 μm
 g
‘torpedoes’
“brainstem-type”
“cortical-type”
“parkinsonism”
1,10-12
1818c 
1c-d
1materials
209
2intra-operative
3macro-
45 mg
4g
4pre-
6,7,9
at × 400
azd6244
gln61lys
gna11
granta-519
map–erk
mek162
mib-1-positive
nrasq61k
pd184352
phase-2
q61k
q61l
q61r
rh-18
u0126
‘mosaic’
“q61k”
-   
-   dentate
-   locus
1928
1distribution
28,38
2differentiating
3family
4,56,57
40,41
43,44
43-kda
4illustrations
5,27-29
58,59
5illustrations
6,47-50
60’s
704
70’s
72 years
8-10,16
abbreviationsaβ
antibodies tau-immunoreactive
apoƐ
bielschowsky’s
both psp and
brainstem -striatum
drunk’
e3/e3
h1/h1
iv -neuronal
layers -neuronal
lesionstdp-43-immunoreative
lrrk2
mckee’s
na   cerebellar
na   medullary
na   pons-base-++++++
na   substantia
neocortex cte
p052c
p62-positive
pathology  -ghost
pick’s
pre–tangles
profile-4-repeat
protein-43
region-tdp-43
richardson’s
tangles  -relatively
tau  -4-repeat
tdp-43-immunoreactive
‘dot-like’
‘intermediate’
‘punch
‘star-shaped’
-3 mm
1-3 mm
1198 g
14 μm
15 × 10 × 3
1:100h2
1:200h1
1:300h2
1:500h1
1:50h2
20 × 10 × 3
20 × 10 × 5 mm
24–36 hours
2 k1
30 × 30 × 20
4immunohistochemistry
5immunohistochemistry
6semithin
8,19,20
8,24
a = 200 μm
b-d = 50 μm
bars = 100 μm
bar = 1 cm
bar = 1 mm
bar = 5 mm
biotechsc-23927neu
bond-max™
b = 2 mm
c-d = 50 μm
chemiconmab348calbindin1:250h2
chemiconmab377nf
cr3/43
c = 5 μm
dakom0701cd68
dakom0762p621:100h2
dakom0775huc/hud1:160h1
dakom0776synuclein1:500offline*bd
dakom0876chromogranin1:100h2
dakom7165cd45
dakom7240nestin1:200h2
dakom7254cd341:150h2
dakoz0334hla-dr
dehydrogenase1
dilutionantibodydilutionpre-treatmentsuppliercodeankyrin-g1:100h2
ds9800
er1
er2
e = 25 μm
figure 4a-b
figure 4d
figure 4e-f
figure 4g-h
figure 5c
figure 5d
f = 20 μm
h09
innogeneticsmn1020tdp43-p1:1500h1
kd1:500h1
king’s
labs610787tau
labs610833parvalbumin1:500h2
lki671:100h2
mab1572synaptophysin1:40h2
n1:2000h1
neuromab75-146app1:7500h2
nf200
novocastrancl-calretinincd31:50h2
novocastrancl-chrom-430gfap1:1000h1
probesa-21271idh11:50h1
r132h
segment = ais
sigmac7354calretinin1:100h1
tip-ptd-p02pre-treatment
v600
zymed18-0171znf200
“specific
1,000-fold
21–5
47–72
74–110
acobalt92
chromium59
discussionhip
forties—a
molybdenum1
postoperatively4
revision6
arthritis—a
kyphosis—as
1,307
2a-c
discussionintrapelvic
known—but
pin—a
rare—complication
encouraged—unless
patients—like
patient—are
review—even
surgeons’
14–31
8–20
calcimagon-d3
imperfecta—a
responsible—as
+10
0-s
1-stage
12/14
28-mm
30-s
30×
38-min
42-min
5-degree
500×
52-mm
5µg/l
6726
8/10
hip—a
reaction”
ti-6al-7nb
ti6a/7nb
3-degree
43-a2
bmp-7
discussionbone
1172
amputation—mainly
tumor—with
years—a
008–0
181ta
2,000-fold
2006a
39-year
arthroplasty—
augment—as
fernández-fairen
formation”
orthopédie
ring—contour
ti6al4v
“hallo
“halo
25–1
2–13
9–38
air–bone
amadė®
db0
dbspl0
dbspl5
fmt–rw
introductionactive
noise s/n
noise train
quiet 60
score40
usefuluseful major
usefuluseful rub
usefuluseful sound
 70
 80
 s/n
000/year
0051
03diabetes0
06s
13total381714,50953
20-31
20vaccination1
2410
25s
27fig
2950
29varicella0
3/100
30pregnancy5
32age
381
3970
41hypertension0
48herpes
68herpes
7110
72gemelli94180,55752
7340
9590
abscess2
andrea125218,35757
body3
carlo65135,03848
deafness12
dyspnoea10
female1
filippo97180,55753
fractures27
gerd12
haemophtysis2
hypertension32
ingestion8
introductionbell’s
lymphadenopathy1
lymphoadenopathy2
mastoiditis3
media31
mellitus11
mononucleosis2
nosebleeding84
oedema1
otitis48
perichondritis3
pharyngitis11
pimple2
pimple3
plug12
pregnancy2
scialoadenitis2
sex44
shock2
simplex0
simplex32
sinusitis13
tonsillitis8
total82
trauma20
vaccination5
varicella67
zoster0
zoster8
1940s
4th-5th
co-60
hypo-vascularity6
introductionradiation
laryngectomy3
t3n0mx
33rd
acc6
follow-up17
~10
25x
mustardé
1-2/month
1/month
250-500
30-55
34-38
introductionmenière’s
menière
menière’s
minutes’
β2-glycoprotein
ct4n0m0
discussionif
pt4nxm0
10-68
14-17
18-30
19-29
36-38
62-70
alveolusdfm45fc
archfemurps34fc
archme32mc
archpp29ms
archtv35ms
boneacetabulumic43ms
bonevu52ms
discussionmandibular
floordcn10mc
fracturesaa30mc
id27mc
introductionmandibular
mm32ms
parotid……………………endoscopicwhen
patellasog68mc
discussionwarthin
introductionsalivary
11-27
discussiontdcs
n-10
p-13/n-19
10-18
3000-powered
bard®
tricut™
45db
20-35
23-67
30-96
40-90
introductionsubcutaneous
x250
introductiontype
the15th
**25-year-old
101951
111958no10
1995-1996
1diedgladkii
2003-2004
2003/2004
40,514
419305,5
52,000
52006not
61962yes
71985
81930yes
91947no15
days1
days1diedpilgramm
days3
days7diedalexander
operation5
stated18
3c-d
4a-b-c
50-74
discussionrecurrent
90-1
anti-β2
neoral®
α2-
■
●
14/36
ck14
discussionsalivary
dp/t2
hhf35
introductionsarcomas
kl1
ssx-1
ssx-2
syt/ssx1
x:18
59,238
+90
2/ae-1
ae1/
ck34be12
1/79
10-19
19/80
7×3
discussionretro-pharyngeal
introductiontrans-oesophageal
24190/μl
discussiondnsis
8y10
introductionhaemangiopericytoma
mitosis/10
12-21
1979n/asymptomaticsurgery*symptomatic
1984exostosisasymptomaticno
1984osteoman/an/asmelt
1988exostosissymptomaticsurgerybeale
1988n/asymptomaticsurgerynavrátil
1992osteoman/an/adoan
1993osteomasymptomaticsurgerysingh
1994n/asymptomaticsurgeryestrem
1994osteomasymptomaticsurgeryramsey
1996osteomasymptomaticsurgeryclerico
1996osteomasymptomaticsurgerycoakley
1997osteomasymptomaticno
1998osteoman/an/aboedts
2000osteomasymptomaticsurgerytorres-valenzuela
2000osteomasymptomaticsurgeryvrabec
2001osteomaasymptomaticno
2006exostosissymptomaticno
2008osteomasymptomaticsurgeryarnoldner
treatmentkovacić
-2-fluorodeoxyglucose-pet
10-16
91-11
ctv1
ctv2
introductionbasaloid
pt1n0m0
2-50
cd68-reactive
cd68/pgm1
discussiongcts
g0
ki67-
ki67-index
ki67-labelling
mitoses/10
ps100
s100-positive
14,934
discussiondisorders
25-45
31-
8-19
discussioncervical
introductionschwannomas
3-3'-diaminobenzidine-
5-fu-cisplatin-vinorelbine
6/mm2
66-year-old-woman
75/mm2
ypn0
yrpt4
1-2-3
866
discussionsyms
introductioncarotidynia
molecule-1
sicam-1
surface–antigen
133018131638serum
1396
1593
1638
1754
17541654780type
1813
29-33
31-33
34-35
39-months
483932follow-upradiographic
58-69
6-11
dtc‡improvement
hpt†
introductionbrown
††hyperparathyroidism
‡differentiated
ga-76
gallium-67
tc-99mdp
β-glucan
0-25
0-9
011494
011694
0n2o1ch0l0103828228
12-34
17ahi
18post-operative
18pre-operative
18vas
19post-operative
19pre-operative
1m4225
2021pre-operative
23vas
25-50
2n2o2ch0l01337262410144m6529
42-65
421793
5173m4329
5215
582823
5m
5n2o1ch0l01598282496median44
6-25
6n3o2ch0l01088080310252m4628
821595
introductionsnoring
pillar®
200253/mtinnitus
200267/ftinnitus
200672/f-leftrooftrans-canal
200845/f-right-endaural
201062/fbleeding
201159/mbleeding
250-2000
6-22
8000
nostrand198755/mblood-tinged
wall1
10combined
23400
8combined
9internal
findingsdiagnosis159maleyesswelling
introductionlaryngocele
laryngopyocele257femalenoa
laryngopyocele351maleyesdiffuse
laryngopyocele434malenoa
laryngopyocele561femaleyesa
3in
discussionwounds
granufoam™
pt2-
pt3n1mx
13-month
191100
20x
22-year
b45
cafè-au-lait
cd56/n-cam
introductionperivascular
mtor/p70s6k
mtorc1
tsc1
tsc2
60gy
cheek–
cheek–cervical
ii–v
introductionfree
quicker15
13/100,000
b-45
45°
ci512
discussiontraumatic
hörby
introductioncochlear
0oral
0tongue
10f46
11m303
12f312
13f452
14m492
15f391
16m183
17m232
18f92
19m71
1oral
20m92
21f355
22f300
23f24
24m331
2oral
2tongue
3m72
3oral
3tongue
4f264
5f374
5oral
6f191
6oral
6tongue
7f132
7oral
8f181
8oral
8tongue
9m121
9oral
baseabscesstransoral9
basebleedingtransoral3ying
basedysphagiatranshyoid23
basedysphoniatransoral6enoz
baselumptransoral17cinar
baselumptransoral63
basesnoretransoral60mevio
f121
f151
f321
f394
m182
m205
m240
m250
m333
m383
m450
m770
m91
painco2
tonguedysphagiatransoral12gupta
tonguelumptransoral12ferreti
tonguelumptransoral12sawhney
tonguelumptransoral13
tonguelumptransoral135
tonguelumptransoral136
tonguelumptransoral137
tonguelumptransoral203
tonguelumptransoral28
tonguelumptransoral36hwang
tonguelumptransoral56
tonguelumptransoral60ballesteros
tonguelumptransoral6nakasato
transoral3hsu
ct2n0m0
introductionintraoral
discussionmucoepidermoid
introductionmucoepidermoid
discussionexposure
t1n0
t1n1
t2n2b
84-yearold
discussionka
43-1
norian®
1_3385dupggaacaca
3379-
4i
a1555g
chd7
ci24re
discussionincreased
gusher-oozer2
discussionosteoma
iggλ
discussionintramuscular
introductionintramuscular
6-mv
introductionbasosquamous
rt4n1m0
discussionfour
hhv-4
26,550
3-ct
ct-64-channel
discussiongoldenhar
introductiongoldenhar
6°/sec
4810
8-13
discussionhyperacusis
introductionhyperacusis
pöschl
t2-mr
2236
9471
galectin-3
682–90
688
phosphorylation”
“celecoxib
710–6
714
domains”
“stereoselective
1691
3early
discussionbml
×20
≤8
535
discussionlymphatic
“lymphangioma”
“lymphatic
107–110
192–245
21–37
3000–5690/te
5°
report17-year-old
 2lateral
 3mr
 4mr
 5an
 6an
“osteochondritis”
10–30-month
25-mm
4-fr
discussionesophageal
rc2
 2case
 3case
μg/h
discussionpolyarteritis
t2-wi
 2initial
 4follow-up
182211
1×
2342
2s
674
6heart‡
8-channel
organ2007200820102011liver†
t2*
t2*-w
t2*-weighted
table 1time
table 2measurements
 3this
†iron
‡iron
4–14
038
070”
3selective
45–150
4selective
5implantation
6coronal
discussionpredictive
sandwich”
“gelfoam
2venographs
3venographs
4endoscopic
discussionbilateral
ml/min/100
3contrast-enhanced
s7
9–14
discussionmest
 1a–c
1603
1pelvic
3-fr
andré
 1e
26–53
48–49
 1b–e
19fr
23-mm
24fr
9–52
ct1bn0m0
off”
“roll
16-slice
50–90
discussionhepatosplenic
spleen”
 1abdominal
 2ct
 3ct
 4abdominal
“bright
18×20
discussionsft
“black-and-white”
”yin-yang”
3modified
antagonist-ii”
discussionacquired
“protein
3/30
3/50
8a
≥3mm
10/1
10/5
1172c
12d
1:507
23d
33d
39/0
43d
60ma
75–83
ala391glu
discussioncrouzon
fgfr2
kleeblatt-schädel
1excision
0anterior
100–120
1posterior
2medial
4-channel
5anterior
8anterior
componentshapeboundary14
discussionraml
hemorrhage2right
hemorrhage7right
kidneyyesirregularpoor55
kidneyyesirregularpoor65
kidneyyesirregularpoor77
kidneyyesirregularpoortable 4ct
kidneyyesroundpoor21
kidneyyesroundpoor33
kidneyyesroundpoor410
percussion5526-h
plus-4
raml3left
raml4right
raml5left
raml6left
results1left
side1+++++–+–+++–2+++++–++++++3+++++–+–++++4+++++–++++++5++++++++++++6++++++++++++7+++++–+–++++aps
signs1631-week
tables 1
tables 3
tenderness2561-day
tenderness652sudden
tendernesstable 2surgical
thickenedtable 3ct
tumefaction362sudden
tumefaction444sudden
tumefaction7322-day
2there
3for
discussionselective
tempo4
100–300
16300
207000/mm3
discussioncarcinoid
embosphere®
reﬂux
yttrium-90
 1ct
 2angiography
 3unenhanced
360°
gdc-18
1854
discussionleiomyoma
x40
 4pathology
 1axial
 2coronal
 3low-power
“signet
0-cm
12–16
c5-1
discussionlymphangiomas
table 1summary
x6-1
 2pet
 3axial
 4axial
 6h
10-mm-diameter
2,3,9,11
2,4,9
52not
8 × 11 mm
discussionnodular
f250
f38110
f411
f411a
f592
f75
introductionnodular
m404
–7
5iiiobliteration
75–85
arch59iiaberrant
artery39
botalli1
discussionangiogenesis
lusoria”
table 1edwards
 1maximum
 1–4
 2maximum
 3volume-rendering
 4kommerell
 5chest
 6classification
“dysphagia
260-cm-long
 2axial
 3coronal
 43d
0035-inch
014-inch
5/16
introductiontranssphenoidal
location”
 1preoperative
 2after
“high-risk
5-cm-diameter
gy/20
 2mri
 3both
 4pathological
1449
 1postmortem
 2gross
18–23
f18
gnas-1
 318f-fdg
 4mri
 5typical
1012/l1
1012/l4
1012/l4–40
1012/l5
1012/l6
109/l142
109/l150–450
109/l157
109/l174
109/l188
109/l24
109/l34
109/l44
109/l70
109/lbefore
10–5
procedure3
recipient–donor
table 1laboratory
values4
0 × 6
300 mgi/ml
30 ml
5 ml/s
introductionleiomyosarcoma
11,14,20
5,6,11,19
introductionwandering
–18
–6,10
22 mmhg
27 mmhg
32 mmhg
9–18 mmhg
pa-1
pryce’s
introductionunlike
100 bpm
132 meq/l
2530 u/l
360 mg/dl
69,000
90 mg/dl
9 meq/l
introductionrecent
neut = 44
discussionradiation
introductionradiation-induced
12,14–17
14-year
141/74 mmhg
293,000
2 × 4 mm
39,000
90 min
“uneventful”
0 t
3-tesla
6 × 7 × 8 cm
8 × 5 × 4 cm
cells/mm3on
discussionangioleiomyomas
dog1
introductionangioleiomyomas
soft-tissue–attenuated
39th
500–550 ml
60–66 g
75 mg/day
introductionmarchiafava-bignami
10–15 mm
20 × magnification
24–26
65 mm
8,12
8,13
discussionimt
t1-hypointensity
t2-hyperintensity
“pseudotumor”
23 ml
4,5,7–10
50-min
70 min
75 ml
7 ml
discussionpercutaneous
introductionballoon-occluded
3000 v
introductionirreversible
114 ui/l
128 × 103/µl
165 ms
17 ms
241 mg/dl
41℃
485
490 mg/dl
64 ms
6 g/dl
73 g/dl
75 mm/h
80 mg/kg
90 mg/kg/day
90 mm/h
introductionanaplasma
radiologist’s
“edema-like
“geographic”
28–30℃
79 mg/dl
bodies”
discussionlymphangitis
“fish
“rice
“sporothricoid”
“swimming
“tubular-like”
16 -
1879
1–5 cm
2–14
5,10
5,8,19
5/mm3
50–65
5–15 cm
9,10,14–18
disease’s
n = 18
n =  2
“cystic”
3 t
4 ml/s
5 ml
70 ml
attinà
discussiontheoretically
f-18-fdg
introductionintimal
“pseudo-clot”
1450
0 × 5
0 × 9
2,9,10
39–79
ce-t1w
discussionaggressive
introductionaggressive
5-inch
5-inch-diameter
discussionmpnst
0/6
10 s
10 w/cm
110 s
12,000 j
126 min
13 ms
140 ms
14 ms
15 min
160 × 160
177lu-dotatate
192 × 192
1 mmol/kg
1 × 1 × 1 cm
200 s
21,600 j
23 t
24 s
25/100,000
256 × 216
2 ms
2 × 2 × 2 cm
324 × 270
33 s
350 × 350 mm
360 × 300 mm
360 × 309 mm
380 × 380
400 µm
46–93
5,22
5-hydroxyindoleacetic
500 ms
54,000
5hiaa
5 min 40 s
60 s
6 × 2
7/7 mm
7/8 mm
72 h
75–99
7 ms
8,11,22,25
80 min
8 ms
8 × 2
90y-dotatate
90y-dotatoc
b-ffe3d
discussiontreatment
fe3d
nürnberg
131i-labeled
21-gauge
7230
128 × 128
22 gy
240 mm
5 s
arms × 512
discussionconsistent
11–16
3,9,11,14,15
308,000 cells/mm3
4,360,000 cells/mm3
7040 cells/mm3
discussionxgpn
gerota’s
introductionxanthogranulomatous
“bear
“clear
“foam
8 cm
blalock–taussig
discussiontof
1000 u/h
12 h
15,000 u/day
15-month
3 min
5000-u
83 mmhg
90 mmhg
introductionblunt
p2-3
30–64
5 × 6 cm
architecture”
between collagen
discussionparapharyngeal
t1-signal
t2-signal
year’s
 100×
“hemangiopericytoma-like”
“patternless
“pepper”
“salt”
0 ml/s
1,4–7
120 kv
14,600
164/95
21 mmol/l
25 cm
3°f
4,6–13
41 mmol/l
4–55
5–4
625 mm
64 × 0
70 s
72–182
90 ml
ct750
introductionsmall
xenetix300
0131
0right
1246
1448
1arteries
1 day
1 ms
1–446
2396
256 × 128
28°
28 mm2
2ba
31234
31236
3154
3pca
3–81
41022
4371
4ss344
4 ml/min
51501
5 ms
5–344
6281
6375
669
6cerebral
6 ml/min
7228
7541
7993
7sss446
7 ml/min
80 cm/s
8120
8552
8570
8ba428
8 ml/min
91047
a235
c1–2
cbf = cpp/resistance
cpp = mean
day1
discussiondsa
excelsior-1018
icac1–2950
icamba1151
icv138
iss + icv
ml/minbefore1
pca328
pca + sca
pressure–icp
sca113
sigmoid–transverse–straight-sinuses
ts1061
vac1–2389
5–10 mm
discussiontms
schilder’s
18 ± 16gy
2g/dl
2 × 103/µl
3-64gy
40gy
65–75
89srcl2
ca15–3
strontium-89
β-rays
05–2
0 g/l
135 u/l
150–440 g/l
16 g
218 u/l
250 u/l
256 u/l
55 u/l
596 g/l
65 mmol/l
76 mmol/l
85 mm2/s
8 ml
926 u/l
b = 800 s/mm2
high–intermediate
1,20
14–19
7–16
8,11,17
8,24,25
936
discussionmeningioma
l-5
t-11
04–0
4 a
4 c
discussionbreast
discussionaberrant
introductionunderdevelopment
13–26
discussionmeningiomas
introductionmeningiomas
20–23
5 ml/min
99m-technetium
discussionhemorrhage
01 mg/dl
13–17
160–170
30–120
40 mg/dl
43 ml/min/1
73 m2
7–7
80–10
85–90
87–94
90 ml/min
discussiongout
edge”
introductiongout
l4/l5
–19
“overhanging
“punch-out”
“punched-out”
“uncommon”
0-tesla
04 × 10−3 mm2/s
18–38
19 × 19-mm
2 mmol/kg
500 mg/day
6 × 6 × 6 mm
8–49
99mtco4
factor = 1000
introductionof
warthin’s
2-f
250 µm
5-ml
6-ml
900 µm
9f
1/1900
1/2675
1886
35°
44–50
discussionthyroid
nodule”
pax-8
tc-99 m
ttf-2
“hot
discussionisolated
introductionherein
10 mm × 4 cm
40 gy
45 cm
48 h
70/40 mmhg
discussionggs
introductiongorlin-goltz
lucencies”
“flame-shaped
discussionbrain
100 ms
13a–c
15a–c
18a–c
2,32
2008:303
2010:122–243
250 ms
28,29
3,5–8
37,38
6–11 mm
7a
7b
8a–c
9–9
gray’s
introductionsubstantial
/af14188
/af141888
10 days
11,12,15
11,16,17
14,25-27
15 l/min
167 iu/kg
215–315
2–10 cm
3unrooted
3 days
4 g/l
5-40°c
52 μmol/l
560 kg
75 mmhg
7 mg/kg
8-4
847
85–97
88–145
8 h
ahv-4
ahv-5
ahv-5/fj798319
ahv-5/fj98319
authors´
butador®
case–control
cepesedan®
dexadreson®
ehv-2
ehv-2/hq247790
ehv-5
ehv-5/gq325597
ehv-7
ehv-7/eu165547
ehv-9
geepenil®
gq325597
herpesvirus/af141889
herpesvirus/eu17156
herpesvirus/eu717156
masson´s
mhv68
splitstree4
splittree4
ventoline®
“poor
-114
-600
13,14,20
1whole
8 sec
figures 2a
figures 2c
masson’s
pattern’
‘ground-glass’
‘honeycombing’
‘interstitial
‘interstitial’
‘pseudodiaphragm’
−600
0t
1t2-weighted
3spair
4dura
5higher
d-22335
dog´s
figures 1
figures 4
l1/l2
t3-l3
th13
032
1,12,14
1,4,14
11 × 7 × 4
2,4,5,7,12
20×35
3,14
30’000
4radiologic
5-39
5-½-month-old
6,12
92×10e9/l
animal’s
bar = 20
ct’s
cyst’s
dräger
germanyrkatheter-rüsch
gümligen
netherlandsc7500
pfäffikon
q24h
q2h
switzerlanddmorphasol®-10
switzerlandhfabius®-ce
switzerlando24ch
switzerlandtadvocid®
switzerlanduflunixine®
tierärtzte
“bichsel”
021
037
1002
16°c
1:6
2,8,9,15
20°c
2effect
3,16,17
388
3d-f
3effect
4-μl
515–560
788
cx31
d0
d7
db2
discussionprrsv
dri-block®
eu-1
evo®
grödig
invitrogen™
leja-4
minitüb
münster
na2hpo4
nah2po4
nucleospin®
q2
q3
q4
r123
r123-solution
r123/pi
r8004
rhodamine123/propidium
schönow
spermvision™
taqman®
trt1
trt2
μm/s
“leja-4“
0,01m
0311 1:20020
0334 1:50010
0760d331:300microwave
0873bbs/nc/vi-h141:1003
0a
0mouse
0polyclonalrabbit
0rabbit
10-13,18,26,33
12,14-16
12,18,19
12,19
13,26,27,30
13,26-28
15,27
1bovine
23x20x11
3marked
3x
3´3-diaminobenzene
400x
4moderate
5focal
5min,0,01m
7,17,19,29,30
700w
9,0rabbit
anti-s100
anti-s100az
anti-vimentinb180052v91:2003
bar = 100
bar = 50
bar = 60
bar = 70
bar = 90
cytokeratinam3515ae1/ae31:803
dako®
factoraa0082 1:8003
figure 1a
figure 1b
figure 1c
figure 1d
figure 2d
figure 4
figure 5
min/100°c
min/125°c
min/37°c
neurofilamentcahp245 1:50010
pnst’s
table 1
0×
1000 ×
10l/l
10–36
11–111
12-week-old
12 week
132–19
15 sec
1hematology
1–2 μm
2,8,9
200nm
2120
23 × 109/l
25 μl
2giemsa
2×
30 sec
316 bp
335–363
337 bp
38-0
3reticulocytes271×
40 × 95°c
5,6,11,12
5′agg-gag-cct-gag-aga-cgg-cta-cc3′and
5′tta-aat-acg-aat-gcc-ccc-aac3′
6-14
60°c
64–74
6 mg/kg
7×
8-16
8×
9×
c4000
concentration298g/l
concentration31g/l
düren
eosinophils0
figures 
hematocrit0
intervalerythrocytes1
jx454779
leukocytes20
lymphocytes4
monocytes1
neutrophils1
neutrophils12
piroa1
puppy’s
volume87fl
width25
10,11,15
2photomicrographs
40×30×30
90×70×60
discussionbeside
henson’s
3a-f
3g-l
3transversal
4,25
4longitudinal
5,23
6,16
6-kg
7,20
c1-t2
c3-c5
figures 2a-b
figures 2c-d
metaplasia”
pachymeningitis”
“osseous
“ossifying
-/6/11
-/7/-
/-39
/96fetus
1/439
12,16,17
13/-/2313/18/28
16/19
19,20,22
19/176
1:384
1schematic
2/239
20/28/-
2number
3,6,27
3/19
3duration
4-fold
4/338
4/54
4/8pcre
5/10/17
55/71
6,26,27
8/439
9/-/19-/7/-
9/339
a2254/n752
animaloxjarowolewaclduhodapuage/gendera10/f4/g4/f4/g16/f10/f4/f4/g5/f9/f11/fvaccination+
baden-württemberg
barns165sh
bladder”
c-/-/1-/9/-
culture/pcrg+/+   +/+-/+-/+ +/++/+ agender
d12-/-/
d12/d28384/19264/4832/6432/128128/12848/9616/128128/19248/12896/128n
d752
ehv-1-positive
ehv-1-specific
flunixin-meglumined,1
foalyes8100bsno9-11901
g2254/d752
horses’
horse’s
infection”
orf30
vhyes286sh
vhyes3128sh
vhyes42014sh
vhyes51210sh
vhyes6108sh
vhyes71110bm
“ehv-1
“index”
“multi”
“neuropathogenic”
“umn
≥38
**30
0*nd60**53475600+
00nd0
00neutrophils
05nd0
0ndhemoglobin
100nd00030
101thrombocytes
120125nd9780594080
120139packed
1300180nd1514323200
1401-
140 19 -
140 4-
140  -
14nd7
17nd0
1:256discussionalthough
1:64-
1morulae
1rectal
2-day-old
2563-
262
37eosinophils
40nd0
40red
442
52segmented
5lymphocytes
5nd40
72monocytes
76reticulocytes
774
800323white
81nd0
839
87nd0
88band
9-42502-04-09/1799
9nd1
birth0012344time 02:0019:3008:3008:3008:3011:00 ndrectal
birthcalfdam0-
iv  -
kc776917
kc776921
m73220
mother reference
negative -
negative  -
niedersächsisches
smear 2-
smear  -
wüppenhorst
  -
+8°c
1-39
11,29
120–150
154att
154attfragment
15 s
200 μl
28 cycles
2–5 days
2’
3170xl
35 cycles
3629 msd
364
3–5 days
4090461msd
426
45 s
45 μ
45°c
461 bp
4799 
4–16 days
4–5 days
50 μl
50°c
5 cycles
68°c
7-40
7–10 day
93°c
a72
ah4efgccggtgcaggacaagtaf27482051
ah ng6aaatagagcattgggcttaccaccatttttf
cpv2
cpv2a
cpv2b
cpv2c
fj005198
fj005233
fj222821
gu362935
js2
label’
mid-1980s
name5′
non-154att
pcr1
pcr4
practice’
sizereference3ng5attcctgttttacctccaattggatctgttr
suppliers’
vaccines’
vp2
 js2rccacccacaccataacaacar
‘good
‘off
‘puppy
‘type
0321
0n
0 1reference
0 325
1803138n
1photographic
1post-mortem
1rbc
2193149125157178120
2femalemix-bred426
2hematology
2histological
2n
2 basophils
2 neutrophils
3,10-12
393
3n
4,6,7
4-dogs
40n
45 hemoglobin
46 wbc
4day
4left
4 eosinophils
510040on
5530
5n
5ventrodorsal
5 35
632
676
6control
6 monocytes
7100703femalemix-bred427
71n
7control
7n
8-dogs
830
8lymphocytes
a140164159 hct
api20strep
biomérieux®
cav-1
cav-2
cdv/cav-2
cough”
croup”
figures 2
figures 4
rate/min1malemix-bred323
science’s
tissue”
Øk
β-haemolytic
 gram-positive
 the
 there
“kennel
“scar
11,14,38
11,26
11-months-old
13 × 103/μl
16,23,26,53-55
19,26,35,55
2 day
3,6,41
32,41-44
34,51
3microphotograph
4,27,56,57
42 kg
4 × 2 cm
5microphotograph
5 × 103/μl
6,14,16,19
9,21,23,32,33,35-37,39,40
9-12
bar = 1000 μm
cyst’
dogiiia°
huskyiia°
iia°
iiia°
regionborboeliia°
regionboxeriva°
retrieveric°
retrieveriia°
ridgebackia°
ridgebackiia°
ridgebackiva°
ridgebackvia°
shih-tzuic°
shih-tzuiva°
spanielic°
spanielivc°
spanielvia°
terrieric°
terrieriva°
‘dermoid
“a”
“b”
0-12 μmol/l
0-132 iu/l
0-78 iu/l
01-5
10,12
13-5 mhz
1812 iu/l
2-13
2-27
282 iu/l
2 mmol/l
3two
3 hours
7 μmol/l
8-54
9 mhz
hco3− 15
01 μg kg−1 min−1
08 mmol/l
0 mmol/l
100 bpm
100 mg/ml
100 μg
105 mmhg
107 mmhg
10 minutes
10 μg kg−1
10 μg kg−1 min−1
10–20 ml kg−1 h−1
12*this
12l-
15 minutes
18 mmol/l
196 mmhg
1details
1inhalation
1romifidine
1twenty-five
1 mmol/l
1¥14 year
200 kgelective
200 mmhg
20 minutes
22butorphanol2
2550 ml
25 μg kg−1 min−1
265 kgelective
28 mmol/l
2butorphanol
2cardiovascular
2thirty
2 l
2 mg kg−1ivisoflurane
2 ml kg−1 h−1
2 mmhg
2 μg kg−1
2¥12 year
3*6 month
30 bpm
30 μg
30 μg kg−1
30 μg kg−1 min−1
34 bpm
350 kgemergency
35 bpm
38 bpm
3ketamine
3twenty
3 mmhg
4*4 month
40 bpm
40 mmhg
40 μg kg−1
40 μg kg−1 at
40 μg kg−1 h−1
42 bpm
45 minutes
45 mmhg
46 bpm
48 bpm
4diazepam
4fifteen
4 mg−1 kg−1 min−1
4 mmhg
50/2
50 mmhg
50 μg
50 μg kg−1
55 mmhg
57 bpm
5at
5butorphanol2
5fifteen
5guaifenesine
5 mg kg−1lidocaine
5 ml kg−1
5 mmhg
5 μg kg−1
5 μg kg−1 min−1
5†10 year
60 minutes
60 mm
60 mmhg
60 μg kg−1
60 μg kg−1diazepam4
670 kgemergency
69 bpm
6acetilpromazine
6butorphanol2
6l-
6romifidine1
6 mmhg
6 μg kg−1 min−1
70 mmhg
72 bpm
72 mmhg
75guaifenesine
760 kgemergency
78 mmhg
79 mmhg
7 l-methadone/fenpipramide
80 bpm
80 μg kg−1
8romifidine1
8 mmhg
90 mmhg
96 mmhg
97 mmhg
9kpa = 284 mmhg
=20
=25
=30
=5
=5600 mlt0 = 85et
arthroscopyromifidine1
castrationacepromazine6
cmh20
cmh20t0 = 35et
cmh20t0 = 55et
cmh20t1 = 45et
cmh2ot0 = 45et
crit0 = 55 maximum
crit1 = 35maximum
crit1 = 40 maximum
crit1 = 70 maximum
fio2 = 0
fr = 5 min−1
fr = 6 min−1
fr = 7 min−1
fr = 8–10 min−1
guafenesin5
hr = heart
ibp = invasive
imketamine3
ivdiazepam4
ivketamine3
ivt1 = 28 maximum
iv at
ketamine3
kg-1 
kpa = 107 mmhg
kpa = 159 mmhg
kpa = 40 mmhg
kpa = 52
kpa = 63
kpa = 67
laparotomyromifidine1
methadone7
minimum0
min−1case
paco2 = 7
paco2 = 8
s/5
surgivet®
t0
tv = 10 ml kg−1
tv = 11
tv = 13 ml kg−1
tv = 15 ml kg−1
tv = 2200 ml
törneke
valium®
ventolin®
®10 mg/ml
α-1
β-adrenoreceptor
β1
β1-adrenoreptors
β2–selectivity
†
0 mg/l
1500 rpm
16-20 days
18°c
1fine
20 μl
22°c
28-30°c
2fine
300 × 6-7 μm
360 μm
3microfilaria
45 sec
4 cm
5-ataagtacgagtatcaatatc-3
5-tgattggtggttttggtaa-3
6-7 μm
630×
650 bp
7,29
8-10 days
90 sec
9 ml
advocate®
diseases”
figures 1
hema-tek®2000
jf461458
knott’s
profiles”
profile”
profile”in
wright’s
 blood
 typical
“standard”
“travel
-value0
/1
/18
/19
/2
0026
0035
0088
172a
1antibodies
1serum
1  
20 kg
25105
2527
2histomorphometric
2myocarditis
2  
30 hours
3myocarditis
4a-d
4myophagocytosis
5030
5dpe
=25 μm
a24
actinacta-1lifespan
analysis large
bars = 10 μm
bars = 25 μm
cd163+
cd172a
cd172a+
cd172a + and
cd44
cd44+
cd8+/cd3-/cd21
cd8+/cd3-/cd21-
cells¥
copies/μl
cs6
figures 2a-c
figure 1b-c
figure 2d-f
figure 3a-b
figure 3c-d
figure 4a-d
granulocytescd44p-bag40awasington
macrophagescd172a74-22-15awasington
nk-cellscd3sp7abcam/ab16669rabbitt-cellscd21lt21abcam/ab1090igg1b-cellstable
o1
pigs’
rabbitactincd1632a10-11serotec/mca2311gaigg1monocytes
university/pbov2037igg3leukocytescd8αmil-12serotec/mca1223igg2actls
university/pg2031igg2bmonocytes
vp1
vp110ga4in-houseigg3fmdv
vp16hc4in-houseigg2bfmdv
αvβ6
–phenotype
←
+2endoscopic
0rumen
0total
0–
103γ-gt
10410410696
105calcium
10 cm
10 l
110 cm
144142144145
155potassium
1680 mm
1abnormal
1cow
1haematological
2525259
25 cm
26104
29333530
2cow
2oesophagoscopy
2venous
30cnbc
30cnbccnbc15
30sodium
30 mmol/l
35total
3832
3perioesophageal
3 min
408625620
427
436
4abscess
4magnesium
592
5asat
5carcinoma
5chloride
6histological
6inorg
70969060
7urea
7’800
80fibrinogen
8 cm
8–
8’500 kg
9 g
calcamyl-40mp®
clamoxyl®
contractions/3 min
fluniximin®
pcf-q-180al
rangeph7
+2 mmol/l
+7
03 mmol/l
105 mmol/l
106 g/l
10’000
120 μmol/l
130 mmol/l
155 mmol/l
16’900
2’226 μmol/l
3,4,7,8
40-head
46 mmol/l
57 mmol/l
5 g/l
5 mmol/
5 mmol/l
5’000
7’042 μmol/l
80 g/l
8 g/l
authors‘
leukocytes/μl
1/1000
1146212190146298234246280309182/164/212/190/154/310/250/266/284/309/184clone
1164216190146282262250276301180/164/216/192/150/286/262/250/276/301/184oocyte
135 ± 10
15 μs
1microsatellite
1phenotypes
2,520 g
2146212190146298234246280309182/164/212/190/154/310/250/266/284/309/184the
2164212190146300246246272301178/168/212/190/154/304/254/266/284/305/182clone
2cleft
2 mg/kg
2’s
30 mg/kg
320 g
35 kg
4,23
60 days
60 ± 7
640 g
710 g
72 h
72 v
amoxicillin–clavamox
donor146212190146298234246280309182/164/212/190/154/310/250/266/284/309/184oocyte
idmarkerfhfhfhfhfhfhfhfhfhfh2537302731163372338133991014209725842712cell
nahco3
schilbach‒rott
snu-121123-13
tcm-199
0-39
0 mmhg
10dorsal
13,17
185 cm/s
1dorsoventral
20–24 mmol/l
2right
350-7
559 cm/s
565 cm/s
5 cm/s
6sagittal
75–100 mmhg
7sagittal
9cross
discussiontetralogy
figure 10
jag1
nkx2-5
pa02
pac02
vsd’s
zfpm2
“blown-off”
100–120/60–70 mm hg
113 beats/min
11improvement
120/70 mm hg
12reduction
13improvement
14prevention
15–18in
160+80 mg
200 joule
2amiodarone
3 months
40×57 mm
49 mm
52 beats/min
60 mm
80 mg
9stabilisation
condition,12
discussionacupuncture
figure 1ecg
figure 2ecg
gb20ear
ht6-pc6promote
inflammation14
ki3-bl23
lr3-li4
lr8
lu7regulate
sacs’
sp6-bl17disperse
systems9–11
‘big
00×109/l
0 g
10conclusionthis
127/79 mm hg
150×109–400×109/l
17 years
1 week
295×109/l
39 mg/dl
3 days
40×109–11
4 h
4 years
50 mg/dl
8 h
93×109/l
9previous
9 g/dl
discussionisi
figure 1axial
figure 2axial
figure 3axial
introductioninfectious
knee,5
structures,3
0 cun
0 mm
10 years
10–20 s
11 mmol/l
120–160
125–135 mm hg
128/85 mm hg
12 weeks
130/80 mm hg
140/85 mm hg
140/95 mm hg
140 mm hg
140–145 mm hg
146/95 mm hg
150/99 mm hg
150 mg
160/100 mm hg
160/95 mm hg
165 cm
1 min
24 h
25×40 mm
2 h
2 weeks
3 mm
3 mm hg
4 mm hg
5resultsafter
5 days
5 mg
5 min
5 mm hg
75 kg
75–85 mm hg
7 mm
80–90 mm hg
88 mmol/l
8 mm hg
90 mm hg
9 mm
=112 g/m2
blood’
changes1
cv4
cv6
discussionhypertension
e/a=0
e/a=1
figure 1changes
figure 2changes
gb20
hypertension’
ivstd=10
li11
li4
lr3
lvmi=109 g/m2
lvpwd=10
pressure 
rwt=0
sp6
st36
st9
‘reconcile
‘white
1although
1due
9another
9on
discussionmethylphenidate
edema5
emphysema6
introductionmethylphenidate
ritalin4
2lycanthropy
5-methoxy
7classic
8this
animals2–5
discussionlycanthropy
introductionlycanthropy
report6
“human”
“wolf”
10there
12according
12yates
30-50mg
400mg
5tramadol
introductiontramadol
low,3
noticed12
opioids5
serotonin2
trema,13
1,2drug
1,2its
crystal’s
introductionfetishism
‘flash’
‘methamphetamine’
‘rush’
6,7in
8diagnosis
8enucleation
children,5
discussiongiven
discussionpsychotic
introductionenucleation
-1,000/μlp-anca
-1,100/μl
-1,400/μlp-anca
-1,800/μl
-1,900/μl
-1,900/μlnot
-2,000/μl
-2,300/μlp-anca
-2,400/μl
-2,600/μl
-2,700/μl
-2,900/μl
-2400/μlp-anca
-270/μlnot
-3,200/μl
-3,300/μl
-3,500/μl
-3,700/μl
-3,900/μl
-300/μlp-anca
-400/μlp-anca
-500/μlp-anca
-550/μlp-anca
-560/μlp-anca
-638/μlp-anca
-670/μlp-anca
-800/μl
-900/μlp-anca+
1purpuric
2002-2003
23-26
26,29
2purpuric
3,4,7-22
4leukocytoclastic
5necrotic
6recurrent
800/μlp-anca
acl22
acl37
acl42
acl46
acl49
acl = immunoglobulin-m
aka = above
ana29
ana50
ana55
ana59
ana = antinuclear
anc 
anc = absolute
anti-ds-dna42
anti-ds-dna = anti-double-stranded
anti-hne48
anti-hne49
anti-hne = anti-human
anti-rnp = anti-ribonucleoprotein
arthralgia29
back42
buttocks49
c-anca27
c-anca = cytoplasmic
chromatography–mass
cocaine27
discussionlevamisole
dose49
earlobes22
earlobes27
ears49
ears55
ears59
extremities37
extremities41
extremities42
extremities43
extremities46
extremities50
filgrastim22
follow-up37
follow-up46
f = female
grafts49
intervention42
iv = intravenous
lac43
lac = lupus
lesions48
lesions50
levamisole’s
month’s
m = male
p-anca = perinuclear
prednisone29
soles48
specified41
steroids55
superinfection42
use43
wbc = white
week59
years/fnop-anca41
 1,000/μlp-anca
“marker”
“signature”
12 mg/day
21 years
27 years
5-meo-dipt
5-methoxy-n
5me0
conclusion5-meo-dipt
trip”
wife’s
“bad
“foxy”
“gt
14 mg
14–20
225 mg
day + an
montréal
université
1nymph
2end
3membrane
4–59–10
introductionlinguatula
2ap
3ap
70-year
introductionmetastases
20–26
2945
30–58
33-year
70–140
chromosome13
kayser–fleischer
2paraosteal
3soft
introductionfibro-osseous
10to
1voiding
2lasix
3severe
4lasix
5-folds
5improved
75-3
hydronephrosis”
introductionureteropelvic
1/40
12000
wg5
20–70
3–19
introductionstuttering
vi-17
vi-7
1active
2dead
discussioninsertion
109/liter
182/105
190/120
2++
conclusion‘progression
introductionpre-eclampsia
occurrence’
‘due
‘generalized’
‘magnesium
‘oxygen
‘preservative-free’
‘she
‘spinal
‘this
1well-circumscribed
2well-circumscribed
3few
4round
5cmmicroscopic
discussionmyoepitheliomas
gray–white
introductionmyoepithelioma
0-7
1/200,000
10-15/min
100-130
110-150
32-40
789101112
9-15/min
discussioncraniotomy
joints’
2representative
31011
32-87
60-90
1790
1specimen
2cyst
34discussioncysts
41011
67-gallium
99m
introductionsplenic
3brain
4789
581011
5contrast-enhanced
120000
1234567
171819
1carcinoma
2526
2627
2hamartomatous
30000
3sex
4melanin
d19s886
discussionpeutz–jegher
introductionpeutz–jegher
peutz–jegher
peutz–jeghers
stk11/lkb1gene
1-a
1flair-weighted
2flair-weighted
37-years-old
discussionms
discussiongallbladder
introductionlaparoscopic
t1n0m0
4histopathology
5histopathology
discussionclear
72/min
count-1
creatinine-1
eosinophils-3
hb-9
index-2
introductionway
lymphocytes-26
monocytes-1
polymorphs-70
potassium-3
sodium-136
sugar-83
urea-22
wbc-5800
291011
4homogenous
discussioncolloid
haut”
introductioncolloid
“das
2axillary
4progressive
cutis’
introductionskeletal
ventosa”
‘tuberculosis
“spina
10121314
15161718192021
1711
1six
3-q22
3789
cpxcr1
dxs17
dxys12
introductioncleft
klhl4
tbx22
v-3
vi-4
xq21
1hyper-signal
2trans-cranial
t2-magnetic
3dense
71617
anti-bp180
introductionless
introductiondiazepam
1:1200
1:900
1multi-slice
20-second
pt2n0mx
13478
1grayish
2interlacing
introductionleiomyoma
meigs’
α-inhibin
α-sma
1high-resolution
anti-scl70
discussionsine
2topography
4-40
40-80
cd99discussionewing
ewing’
introductionewing
115/min
145/95
20500/cm
4chest
5fibrin
6adrenal
discussionstreptomyces
introductionstreptomyces
125/min
140/90mm/hg
40finally
70/hour
85/50mm/hg
discussionupper
introductionupper
121314
1t1w
3flair
4thoracic
5thoracic
6thoracic
7thoracic
discussionabnormal
007
1hypodense
239
2569
2911
2well
4anaplastic
5710
578
il1
ki-1
kp-1
”the
1reported
2signet
59-63
713
891011
30f
5-13
creatine-3
g4
k-5
l27
na-134
sugar-84
tlc-8800/cmm
urea-108
103/cmm
1discharging
2blood
3antibiotic
introductionstaphylococcus
75-85
anatomy”
introductionosteosarcoma
“laws
“location”
1large
4giant
5on
6in
introductionneurofibromas
sign’
‘giant
‘neurofibroma
‘solitary
‘split
1bone
2higher
3600/cu
esr-58
introductiongranulomas
122/72
13-17
14-year-male
1non-contrast
30-110
5,600/mm3
introductioninvolvement
million/mm3
2radiological
4clinical
5clinical
1thumb
2operated
10111213141516
1171819
130-201
1567-1308
222324
2228293031
4045
4142
7-20
82229323334353637383940
medicinal’
‘hirudo
‘leech’
1dorsal
2palmar
4photograph
123456
15-degree
1sonography
2uterus
4mixed
5uterine
6histopathology
introductionupon
≥6
-beta-carbomethoxy-3beta-
1/2bid
12131415
20p13
232425
250/25
2lab
3eye-of-the-tiger
3her
4-fluorophenyl
4eye
59fe
introductionhallervorden-spatz
pank2–
scanningiodine-123
t2drugs
1photomicrograph
4photomicrograph
65l30
count-9000
discussionrhinosporidium
e5
hb-10
introductionoculosporidiosis
vermicularis’
‘mesomycetazoa’
‘oculosporidiosis
109/lt
267
4/1
99–2
chemical”
discussionurothelial
2884
40-week
50/mm3
discussionmultifocal
introductionperinatal
all-l1/acute
aml-m0
discussionamkl
3′utr
5′utr
62°c
cd11
cd37
cd39
cd6
cl2mg
ivs-ii-1
ivsi-110
ivsi-6
ivsi-ii-745
patients2
ptc-100
t/−28
u01317
α-gene
β-thalassaemia
β-thalassaemias
γ-globin
–t
−158
−28
−α3
−α4
cd57+
cd8+cd28-cd57+
cd8+cd57+
discussioncd57+
inf-γ
t-helper-1
88-year-old
+44
3626
6163
adv3
adv31
adv5
adv7
adv8
cmx001
introductioninthe
/m²/day
109 l
11–29
12 mg/m²/day
36 gy
45 mg
58–60
apl91
apl93
bcr3
cd16-ve
cd33+ve
cd34-ve
cd45+ve
cd56-ve
discussionextramedullary
lap0389
pml/rarα
q21-q22
t7-t8
–8
0–27
0–76
100 g/l
100 umol/l
109 g/l
10 g/l
120 fl
121 fl
1225 ug/l
1293
135–180
141 umol/l
150–400
15–370
20 mg/kg/day
2197 ug/l
250 ug/l
34–37
3–24
45 g/l
50–60 g/l
5271
5–30 mg/kg/day
60 g/l
80 g/l
80–100
86 g/l
90 g/l
953 ug/l
96–144
intermediate-1
nf-κb
us03
 g/l
 iu/ml
 ug/l
18×109/l
350 μmol/l
47  ×
58  ×
5 g/kg
67  ×
18,000
18,000 mg/sq
18,750 mg/sq
18000
1 ppm
20,000 mg
20,000 mg/sq
20000 mg/sq
200 mg/sq
24,000
28,000 mg/sq
2 sq
32 mg/m3
40,000 mg
40 ppm
44–46
44–47
46,000 mg/sq
8,000 mg/sq
92,000 mg
discussionkyle
g2-m
o6-guanine
o6-methylguanine
o6–methylguanine-dna
106 u/day
1 kg
2 kg
300-fold
300 mg
447 × 109/l
69 × 109/l
discussioncml
f317l
g1p1
g3p3
introductioncml
12 mg/m2
1375 cgy
200 mg/m2
21,700/μl
2400 cgy
3000 cgy
600 cgy
introductionchloroma
“chloroma”
10,15–20
bore”
cohorts’
course”
discussionsthe
easy”
educator’s
forums”
institutions’
interesting”
is”
learning”
member”
mind”
name”
nexus”
quickly”
subjects”
supported”
“blended
“enthusiastic
“frequently
“his
“lecturer
“out
“overall
“principal
“put
“staff
“too
“unpick”
“well
“…once
1at
5simulation
6virtual
demonstrated,7
discussionfaculty
exercises”
haven’t
he’s
introductioninteractive
i’d
i’ve
learn™
life®
pharmacy’s
school’s
son’s
spaces”
that’s
“cause
“fixed”
“may
“public
“real-world
“resident”
“shortcut”
“shots
“student-centered”
“teacher-centered”
”10
”case
”since
0–135 degrees
16–19
discussionsleeve
introductionbilateral
“overloading”
95°
interface”
introductionslipped
“bone-screw
0 msec
300 mmhg
4 msec
4 mv
6 mv
discussioncompression
introductionboth
1869
20 minutes
6 hours
c3–c6
c5-th2
c6-t1
0/155
10/128
13/311
18 g
2/155
220 lbs
2900 ml
3/10
30 gy
4/58
4 u
5/128
70 gy
c0-5
nömayr
occipito-c2
36 mm
introductioninstability
precautions”
“hip
“run-away”
like”
“tail
0 nylon
12 cm
15/85 degrees
15 degrees
20/85 degrees
20 deg
20 degrees
35 degrees
40 degrees
45 degrees
5x
60 degrees
70 degrees
action”
discussionextensor
series3
wrist”
“impossible”
“mass
“nightstick”
“spaghetti
3,4-methlyenedioxymethamphetamine
5-ht
5-ht1c
5-ht1d
5-ht2c
ca2+
cb1
cb2
introductionpriapism
Δ9-tetrahydrocannabinol
classic”
“evil”
1/6th
128/83
138/77
16–31
29–54
4–15
90–95
pt3b
55–65
63-year
discussionintraurethral
introductioncancer
mg/80
“toomey”
discussionenterovesical
t2b
115 iu/l
11 cm
126 mm
15 aatt
15 cm
350 iu/l
883 iu/l
8 aatt
discussionadrenocortical
25 mm
30 fr
32 fr
introductionrare
compérat
ductules—is
introductionphysicians
rete—presumably
wt-1
discussioneggcts
introductionextragonadal
135–145
24/10/2007
49–92
chco3
055
106cfu/l
10–100
120/72
508
545
556
5711
5714
607
96/72
cd8+t
cytokines—biomultiplex
gr-1
interleukin-12
methods2
p70
proinflammatory-th1-like
rc-14
s4–s5
“alumni”
ca-25
introductiontumors
“intrascrotal”
“median
“scrotal”
100/72
“ambulatory”
“mood”
diversion”
diverticulum”
“meckel
“neobladder”
“outcome”
“urinary
1-0-6-1
introductionbladder
10 kg
18 kg
18 m2
20 kg
22 kg
30 cm
30 kg
31 cm
3990 ml
42 kg
66 m2
6 kg
6 lb
74–92
800 ml
et743
introductionliposarcoma
“giant
10 mg/kg
10 mg/m2
13,010
25 mg
3 mg/kg
50 mg
54,390
600,000 iu/kg
6th-line
90206
discussionuntil
flt3
hif-1
pdgfr-β
pik3ca/akt
reports2
0–37 u/ml
127 meq/l
14 mg/dl
33–48
58–75
94 u/ml
discussionperitoneal
1—severe
2009/2010
2010/11
2010/11”
2010/2011
2—inflation
c-5
discussionsevere
events”
introductionnever
urethra—need
“long
”severe
11c-epinephrine
11c-hydroxyephedrine
123i-mibg
18f-fda
18f-fdopa
3 × 2 cm
and  
introductionextra-adrenal
iodine-131-m–iodobenzylguanidine
60 mm
discussionuretero-iliac
discussiontesticular
pt1
104/μl
106/μl
12000 u/day
2190 g
discussionaps
introductionantiphospholipid
140-cm
140 cm
142-cm-long
95 cm
2 cc
“sentinel
022 kg × 3,000
14 × 1
160 cm
1890s
1 l
1 mg/1 ml
200 ml
212 ml
22-g
220 ml
240 ml
295 ml
2 ml
3,000 g
3½
50-ml
57 kg
5 kg/cm2
627 ml
628 ml
63 kg
701 cm3
876 cm3
972 ml
cet1
cs2
gel”
hartmann’s
sacrifice”
x50
 10highly
 1serial
 2magnetic
 3mammography
 4magnetic
 5sonography
 6magnetic
 7a–c
 7cell
 8morphologic
 9a
 9a–c
“bodily
“fat
10g/dl
450u/ml
45mm
4kg
500u/ml
60×45mm
90mm
discussiongenito-urinary
0–22
0–25
14 grams
15 days
1–26
1–40
20–66
2–73
30 days7/43
50–80 g
5–28
7–78
9–81
ago8/120
alcohol more
breslow–day
consumption number
introductionalcohol
table 1carbohydrate-deficient
university—johns
ush2/30
ush4/10
 total
 typical
 within
  16–304/10
  1–153/31
  1–403/30
  1–44/32
  ≥15,000
  ≥414/9
  ≥53/7
−70°c
*** χ2 = 1
** χ2 = 2
05of
16–26
all—meet
coming-out—suggests
discussionfirst
internet’s
many—but
n = 116
n = 141
n = 45
n = 50
n = 95
online—even
place online47
p’s 
sd = 2
sex”
status steady45
table 1meeting
 casual26
 offline53
 regular28
χ2 = 1
χ2 = 2
“meeting
circumcision’s
introductionbetween
men’s
place—individuals
prevention’
surgery—be
teams—is
them—the
ucla’s
“insufficient
049
05** not
09number
12 month
15,00024
20–0
29–0
35–1
41–1
445
45–1
51* high
52 1–585
56–2
75,00014
85 in
90 days
90 days 07
94* 31–4047
96* 15,000–44,99945
bachelor’s
b relative
client’s
color5
controlbaseline6
counselor’s
c personalized
degree16
degree3
degree55
diseases ever67
d usual
equivalent35
francisco’s
introductionpersonalized
months12
participant’s
reported**0
satisfied”
statistictotal109
table 1comparison
table 2mean
three months
whites3
year21
 19–3044
 1trial
–* p 
–age
–annual
–education no
–history
– 
– 25+2
– 41–6017
– 45,000–74,99926
– 60+1
– 6–2415
– associate
– master’s
– not
‘booster’
“boyfriend
“excellent”
“high”
“self-justifications”
014 no1duration
020 ≥24 months1art
025 primary
030 no1family
06–2
095 
0–4 
1,578
11–18 
12–41
13–21 
217 13–24 months0
2–5 
2–7 
32–46
36–46 
40 years1sex male0
41 
491 female1educational
4–9 
51–61 
52–1
5–11 
7–13 
94–2
adherence17 
adherence missing
art*17 
art 0–12 months0
arvs14 
attainment secondary
belief56 
beliefs—e
effect2 
effects41 
effects pastors
health4 
herbs10 
herbs—are
higher1
hiv”—it
home yes0
interval* questions
introductionwith
legs*14 
life6 
lower1electricity
prayer17 
progression*8 
question—for
retention17 
retention you
soon3 
support yes2
symptoms”
table 1art
table 2multivariable
valueage ≥40 years1
 arvs
 hiv
 if
 there
 you
  patients
“cure”
“elimination
01  female2
01  no33
01  no41
01  ≤weekly14
01  ≤weekly31
02  no20
03  no34
06–14
07–4
12–0
14  ≤weekly41
160,000
23  no34
25–4
303
33–5
34–48 years
38 years
48–26
49–1
50–1
52  no31
59–2
62  no12
65–2
75–3
82  
87  no31
asia–pacific
drugs”
hcv”
incarcerated  yes35
introductionthailand
n = 350
old23
old24
or = 0
or = 2
or = 6
services  yes14
table 1bivariate
test”
use  yes16
variables ever
variables gender  male45
variables heroin
weekly16
weekly33
weekly6
x2
 = 6
 age  ≥38 years
 binge
 ever
 methamphetamine
 midazolam
 noticed
 syringe
 unprotected
  yes12
  yes13
  yes16
  yes27
  yes6
“ever
“have
“war
“yes”
≤weekly
≥38 years
-t1
1/mlproteins
113/μlvl
2-gp
2-gp anti
2002headache
2008blurred
2008headache
2008left
2008persistence
2008vertigo
2008worsening
260/μl
260/μlvl
270,000
355/μl
3tc
3tc lamivudine
5/mlproteins
52intrathecal
536/μlvl
abv abacavir
acv aciclovir
aep auditory
atv atazanavir
c-anca cytoplasmic
cartworseningcd4+
cart combination
changescd4+
csf cerebrospinal
fo fundus
ftc emtricitabine
gcv ganciclovir
gd-enhancement cart
gd-t1
gd gadolinium
hsv-1/2
ig intravenous
introductionsusac’s
iris”
la lupus
mep methylprednisolone
mri magnetic
p-anca perinuclear
pdn prednisone
pp65
q5h
relapse april
relapse november
resolutioncd4+:355/μlvl
rfa retinal
stabilizationcd4+
susac’s
symptomscsf  cart
tdf tenofovir
tpha treponema
v-gcv valganciclovir
vdrl venereal
vep visual
vertigobloodt2-hyperintense
vl hiv-rna
 cart
“autoimmune
-860c 
0 μg/ml
2c19
3a4
4 mg/kg/12 h
cut-off = 5
cyp2c19*17
histamine-2
rs12248560
strategy”
“boosting
245 mg/emtricitabin
28 hours
28 days
400 mg/ritonavir
4 g/l
56 years
5 mg
alpha-1-globulin
alpha-2-globulin
10–60
11 mmol/l
130–700
200/ritonavir
300/3tc
46 years
47,500
5-4 μm
53 g/l
557
5 μm
cd16+56+
cd4+/cd8+
combivir®
d4t
discussionmicrosporidia
ebv–ebna-1
hhv-6/7-8
kaletra®
205 g/dl
45 g/dl
511,000 c/ml
cd20−
discussionkaposi
hhv8+
mum1/irf4+
“extracavitary”
“solid”
14–22
19/28
191–448 cells/μl
19–53
205 copies/ml
2437
29 cells/μl
29–89 cells/μl
59 cells/μl
5 cells/μl
750,000 copies/ml
89 cells/μl
8–33
984 copies/ml
discussionautoimmunity
hiv-1-positive
i-123
i-131
ifnα
1/9
10q26
3a–c
3 × 4
64-mb
7-deoxycholesterol
a–
coexistence”
compression”
“simple
130/0
14,15although
15-gauge
17,23
1930s16
20indications
30-minute
3980
co-fact®
ddavp®
emergencies,17,18,19
given,7
methergin®
nalador®
pph,10
pph,10,13
prostin®
syntocinon®
~18
1390
1550
1btwo
2btwo
4700
4900
5,6,7polyhydramnios
5690
6320
7/9
fgf10
fgf10/fgfr2b
fgfr2b
peel”
“apple
“double-bubble”
∼72
12-day
13some
3,4,8,9,10,11,12
7 × 109/l
8,10
count = 14
discussionb
gni + card
post–lung
quinolones10,14,16
survanta®
11 × 9 × 17
19 + 4
25-μg
27 × 30 × 38-mm
3,4,7
35,000
3870-g
3900-g
5,6case
96 × 72 × 64
discussionone
dystocia4
norcuron®
11 × 13
11 × 1311 × 1312 × 1312 × 13neck
15myocardial
1av/lv
3,4,5,6an
5777volume
6av/lv
9a
etiologies1
ga32-wk
gabirth3
index0
measurements28-wk
volume0
102715hydropscalcifications
44116anemia
8there
928unknownhydrops
934unknownanemia
abughali3
ascitesechocardiogram3
b19-associated
b19-specific
cellsigm + 
count0
dilationigm + 
igm−
karyotype46xyfish
pcr + 
pcr−survivedthis
polymicrogyriaigm + 
polymicrogyriandigm−
report39unknownanemia
ventricleigm + 
02391diaphragmatic
1-ml
12102800ph
12p50vd3711
1350tetrasomy
1afi
26-gauge
2800-g
32002852ph
44251jejunal
66002926ph
72503320ph
73340left
atresia27vd377
complications,1
discussionamniotomy
hernia31vd377
palate28ve3811
speculum,7
11-
11-month
1206
13-cm
1365
9-cm
anemia5
birth—occurring
cases—are
discussionttts
inter–twin
ttts—defined
twin—occurs
twin”
weeks,7
~50
~68
“stuck
1,2,3,4,5
1323
134 × 109/l
1shortly
2301
276/7
284/7
3-0-0-3
3720
3 + protein
3 × 109/l
72 × 109/l
8 × 109/l
anti–nuclear
anti–smooth
cell–mediated/
g/24
g4p3
variant—hellp
“cured”
“hellp-like”
1170
23030
2424
2727
2n/anon/a281170neonatal
2nono3933701
3093 ± 805
3232
33mild
34290
3434
3770
37mild
3dilv
3 ± 3
47nono403380central
4dilv
5250
538200
56mild
56nono3833001
5dilv
6200
623
6nono3835201
7280
7 ± 5
8 ± 3
arch20
atresia29
death20–24
death24av
dilated22
discussiondilv
gestation,6
l-tga20
mean ± standard
mo3232
outcomesurvivalprenatalpostnatalprenatalpostnatal1340
valve3931601
valve3937701
valveno383080glenn
10*46xx
10abnormalities
18p11
20+5
21+1
21+3
3080
3there
40+3
446xyi
546xxi
646xxi
746xx
8mosaic
946xx
bifidag7
bottom”
bulbsg5
case11
cases4,5,6,7,8,9,10
feetg1
handsg1
hpe4
kidneyg1
ovariesg1
p021de
p025van
p026graf
p027froster-iskenius
p031spinner
p11,3
p137*froster-iskenius
p237present
p427levy-mozziconacci
proboscisg1
uterusg2
 + dic
“rocker
0 × 9
114/60
157/114
194,000/mm3
2-1-0-1
213/7
2595-g
363/7
3 × 4-cm
arf,2
capacity = 505
ci = 77
co2 = 37
ferritin = 9
gastroendoscopy,1
haas7
k = 3
na = 135
pregnancies3
was533,000/mm3
weight = 433
“conception
“presumptive
”7
1,6,7,8,9,10,11,12,13,14,15
11,510
1340
14,16
152739fcsf
153030fbloodbradycardia
15317nacsfpoor
15324nacsf
15325nacsf
15343fcsf
15350mcsf
15355nacsf
15360
15364fserology
15366mcsfrdaf
15415nacsffever
15full
15na6mblood
15na8mblood
15na8mnasopharynx
241,000
3164
32 × 
38in
409
4 × 
5bauer
5fblood
5fstool
5′-triphosphate
8870
anti-sjögren
b3-induced
block,3
cvb1
cvb2
cvb3
cvb4
discussionviral
fetal–neonatal
feversvtseveredicnonesequelae4bauer
irritabilitysvtseveredicivigdied12nathan
jetmildnoneiviggood14simpson
jetmildnoneivigsequelae15simpson
meningitisnonesequelae13simpson
meningitispleconarilgood7bendig
neonates,17
pleconarildied8bryant
pleconarildied9bryant
pleconarilsequelae10lu
pleconarilsequelae6bauer
rdsvtseveremeningitisnonedied2shah
report,1
tachycardiasvtseverenonenonesequelae18freund
term0
term3mblood
thrombocytopeniaiviggood17freund
thrombocytopenianonegood3hoi-shan
treatmentoutcome1goren
vfseveremeningitisnonegood11krogstad
vtseveremeningitisivigsequelae19this
vt—liver
1-day-old
22-day-old
28 × 109/l
2neurologically
3animal
4liver
547 × 109/l
60,000
60/mm3
78/36
carbon-14
discussiongalactosemia
galactose-1-phosphate
galactose + phosphate
galactose–glucose
n314d
q188r
s135l
“herniated”
/45
/46xyspeech
0075
13/21
14/22
16caseadult
16p11
29,857,066
3,4,5,6,7,8,9,10,11
31,840,925
44bx4
:p13
:q13
a_14_p103755
a_14_p125420
aquarius™
cornersna7246
cornersna8346
cornersna9546
fetal–maternal
findingsinheritancereference146
leukemiana5*double-size
lost6
novo10646
novo11846
novo3746
novo6446
origin4946
telomere–telomere
xy/18
 + r
 × 3
 − 16/*growth
 − 16growth
 − r
“artemisia”
∼22
0–637
1000/μl
100781009898zinc
105k
10we
1133025fibrinogen
11:30
11:57
120/40
165/59168/6267/5238/42tsh
1hgb
1pod
200j × 2
20–200
21,000
2131
214529581100pt
22creatinine
23–36
2pod
314ckmb
356d-dimer
360/7
3802
3bun
3hct
3ph6
3troponin
45–4
48base
4–24
50,000/ml
5 × 5-cm
612
637
6711
71–1
7platelets
7ptt
7–13
80–105
8101627ast/alt
arrest14
cesarean–hysterectomy
discussionafe
level = 40
ph = 6
pressure = 110
ventricle4
 21
 × two
“jumbo”
∼27
∼35
∼45
1,10,11,12
291/7
292/7
7,8we
al,5
∼11
∼9
1310
1snippv
2,3,4
20,21,22
al17
gastritis”
h2-blocker
nelson18
obstruction,11,12,13
stenosis,1,8,9,10
“emphysematous
10-μg
103,000/ml
133/83
13patients
232,000/ml
2 × 3
392/7
4reversible
4table
5-minute
50739
55/25
5although
70/45
705,183
:391–397
bp b
following a
fulfilled:1
h2-antagonists
h2-blockers
hg + 
report—second
se,8
 c
 d
”4
∼20
0-degree
1/8000
1/81
10 × 6 × 13
14-cm
149,000
16-cm
6at
dollars,7
patient,1
“minimal
10three
125/79
176/7
2700
3,4,5
4as
6infections
8°f
9 × 103/μl
abortion,1
al4
amniocentesis,3,4,5
chamberlain5
galask6
hall2
wine”
“foul-sweet”
“port
∼19
∼38
1,2,3clinical
1/2a
1/2b
1000 × 
10l
11,13the
16when
18l
19,20,21finally
4135
6discussionl
775
7l
dissemination9
examination—a
labor10
miscarriages,5
β-hemolytic
“granulomatosis
”after
1,3,4,5,6,7case
1,7,10
15although
2,10,11polymyxin
2,3,10
5,6,12,13,14
535-g
5dosing
discussionmdr-ab
reported8,9
0estimated
18baskett
19in
1predelivery
2gravidity3
2pph
2u-type1040138c/srepeat
2u-type838036c/stwins2u-type939042c/sprolonged
3postdelivery
3 ± 1
3 ± 5
4u-type432138c/stwins2u-type
5,12,14,15,16
5,17
5,6uterine
5u-type
7u-typebicor
7 ± 2
8nullipara
8table
9u-type1132141c/sprolonged
al23
al24
b-lynch11
b-lynch1241237c/srepeat
c/s0
c/s1
cho12
delivery,3
forceps520
hysterectomy13
hysterectomy333037c/stwins1
labor1
lig532038c/stwins22
lig740036c/stwins1
patients,10
prbcu-type232039c/sfailed
prbcu-type647036c/stwins32
procedures130035c/striples/bicor
section6
sherman25
ut34
yeh21,22
∼3500
≥ 1000
≥ 500
,6
1,15
2088
20in
3,23
30,000/μl
49th
8850/μl
colitis”
day7
discussiongenerally
fpies,18
hypersensitivity,21
mechanisms,19
mucosa,1,2
non–immunoglobulin
patients,17
stools,5
tests,3,4
tgf-β/tnf-α
β-lactoglobulin
“neonatal
04 × 109/l
1,2,3,4,5,6,7we
101/62
10cen–10q11
17unrecognized
18a
18most
1 × 1
1 × 2
2603
2870
2920
2 × 1
2 × 2
3097
4 × 3
6 × 2
6 × 3
7recently
8 × 1
9,10,11,12
al,7
choice”
discussiondespite
investigation”
was − 0
α-blockade
α-receptor
β-blockade
“medullary
“multiple
“pregnancy
“sipple
“technique
“ultrasound”
∼10 × 5
16 mm
19 mm
3807-g
defects,3
dextrocardia,2
discussionprenatal
0-mm
1,2,15,16,17
1,2,3,4,5,6our
12/70
128 × 320
12mriin
18management
18–20 wk28 wk
1prospective
1u/s
2,3,6fetal
25–26 wk36 wk
2u/s
2 mm19 wk
31–32 wkno
3euapostnatal
3u/s
4u/s
5u/s
6mri
6retinoblastoma
conclusion both
dacryocystocele2mos
dacryocystocele36 wk
done17 wk
done22 wk
done24 wk
done2mother+15 wk
done37 wk
done38 wk
done39 wk
done4father
done5sister
done6brother
factor = 2
fov = 22
gap = 0
matrix = 232 × 192
matrix = 256 × 160
matrix = 256 × 192
matrix = 320 × 160
matrix = 328
methods fetuses
micro28 wk
micro33 wk
micro37 wk
mri16–20++24+28++32+34+36++38+40+mri
mri1mother−18 wk
nex = 1
nex = 2
purpose our
results of
te = 120
te = 488
te = 650
te = 85
te = min
thickness = 3
ti = 22,000
ti = 750
tr = 12500
tr = 2100
tr = 2300
tr = 4000
tr = 6000
tr = 725
tr = 9000
tumor19 wk
tumor20 wk
tumor22 wk
tumor25 wk
tumor27 wk
tumor28 wk
tumor31 wk
tumor33 wk
tumor34 wk
tumor35 wk
tumor36 wk
tumor37 wk
tumor3half-sister
tumornanana22 wk
utero10,11
~67
 = 22
“dismal
”1
2-0-2-2
3135 g
443 g
discussionsimilar
isovue®-300
“abdominal
“balloon”
12,16,17we
145-day-old
17our
2994
34-weeks
4 ± 0
8discussionbarotrauma
a–a
streptococcus–induced
“black
”figure
477
527
722
819
apob100
discussionhomozygous
patient,11
pcsk9
100,000s
155/109
160/113
25,0003
76,000/μl
96,000/μl
adamts-13-deficient
adamts-136
background thrombotic
conclusion concurrent
discussionlaboratory
evidence5
g6
p1041
12,17,27placental
15,21
16,18traditionally
19the
19we
2,3,4,5,6transplacental
2,6,7
2,7the
22-week
26our
2771
3,4,6in
3,5,7
30-week
3572
4,19
55mg/100
6-day-old
7-week-old
9,28
a9
anomalies,17
coagulopathy,2,6,8,11
culture6,7
delays,16
delivery2,6,9
diabetes,14,15
g3p1
g3p1sa1
h2011:051
hepatitis,2,6,8,10,11
meningoencephalitis,2,6,7,9,10,13
myocarditis,2,6,10,11,12
~120
~17
“coxsackie
044588445351055all
15case
31-week-estimated
4050/mm3
4aseptic
6379632111255717triplet
64410219773206020triplet
9figure
a98
b100
c101
discussionaseptic
myocarditis,6
rarely,20
syndrome,5
1/ul
104/100
10some
13,14when
1335
14,19,37,38
14in
14neonatal
14the
18given
19,20,21
1948,1
1:1146
1:2813
23fmh
35,36
41if
48,49
54since
55given
6,28,29
6/1000
7/1000
79,000/ul
8/1000
abruption,32
calculate”
chorioangiomas,6,30,31
fetalis43
meanbp = 28
monochorionic–monoamnionic
outcome”
placenta,27
rate = 145
rate = 40
spo2 = 92
temperature = 97
twins33
version,26
~190cc
 = 42/21
“anemia
“likely
“massive
“to
”14
09/pco2
14/pco2
140 seconds
18-week
180 beats/min
1847
25-week
25 μg
2620 g
2650 g
2:50
30 seconds
31/pco2
3282 g
3:23
430-g
47/po2
491-g
65/po2
79/po2
conclusion patients
design two
discussionimprovements
efw = 2524 g
results in
041 sdrr
04 mssd
1,2heart
1000 hz
13411684293 psd
1342
1343 d
1480 g
16 psd
18711154 relative
191173147 rr
1 hz
3,4we
313
3133
3140
322218 d
3460
3850
38 vi
38 mm
3 power
409 sdrr
42 mm
4 edv
50 mm
6112 total
624
7252 power
733heart
75 pi1
7 d
8110
8191
8390
8 relative
931
961 ratio
9 ri1
conclusion results
design the
examination psv
hf/lf5
ms2
ms2/hz
results before
started—bradycardia
variability heart
110/70 mm
120 seconds
162,000
2669
4,5intracranial
49 seconds
65 seconds
risk”
~72
“high-embolic
“intracranial
“pregnancy”
“prosthetic
“safe”
≤35
10neonatal
195/minutes
3280-gram
3during
7high-output
81 × 1
discussionvgm
“including
1,2,3,4,5,6,7,8,9
1,2,3,4,5,6,7,8,9the
5pulling
6-french
6the
angulation’s
discussionneonatal
stylet’s
ventilation,3
~5-cm
“amplatz”
11we
1368
14f311368nonehydrops43
1m393328nonepleural
2072
21pleural
3328
63m372898trisomy
72m342072trisomy
9,10despite
91bcase
95m342620nonehydrops22
days4mct
described3
effusion29
effusion62
effusion78
enterocolitis8
formula2
hypothyroidism,7
imbalance,1
institution1acase
malnutrition,5
minomycin®
patient12
removaloutcome1mct
ssa + hdc30μg/kg/day8
ssa + pdn8μg/kg/day4
survive2mct
survive3mct
survive5mct
used4
used8
used8mg/kg
12/30
16-week
16q24
17–24
1a4
2174-g
2comparative
2we
6 ± 22
8 g
8–16
alveoli•
arterioles•
bed•
birth•
brother1
brotherhoursdavidson41998fnoneoligohydramnios1
casespathology•
cd31/endothelial
circumferencenone20
conclusion there
cyanosis•
cystsnormal1
dal-senan62003fnonemild
developed•
development•
diedrutledge11986fnonenot
difficulty•
discussed7 hchambers31991fovarian
disorders10
distress•
dmoerman51998fnonemild
done1
exam•
features•
fibers•
g1
hypertension•
jc/70a
jensen1
lung•
lymphatics•
misalignment•
mogillespie72004mnone
oligohydramnios1
platesetiology•
polyhydramniosnone4 hcurrent
report2010mnonemild
reportedmoerman51998fnonemild
results congenital
retardation1
tissue•
ventilator2
“glandlike”
13,000/μl
1311c 
17α-hydroxyprogesterone
2,14,15
2906
3267
5 × 3 × 3
871g 
bilirubin 
deficiency,5
hyperbilirubinemia,1,6,7
ivs11 + 93t 
method8
phototherapy3
pit-250icr
population,5,6,10
transfusion4
unevenly,8
v291m
 17
 c
11,15
11,16
11,18,19
1182
13 g
14patients
150/100 mm
2,11this
200 mg
250 × 109/l
2818 g
3,24
36+5
40 × 109/l
5 × plasma
6 × 109/l
8,9,10
81 mg
9,10,15
9,15
9,26
activity 
adamt-13
approach2,8,9
count 
protease”
thrombospondin1–like
ttp,11,18,19
 10
 200 × 109/l
“tea-colored”
“von
000gestational
101prior
1082membrane
13,14,15,16,17,18
13,14,15,16,17,18whereas
14/20
14it
1572
1572 ± 415 g
15in
1646
1membrane
1use
2,3,4,5,6,7
20/26
220gynecologic
220of
25 ± 30
2pregnancy
2 ± 5
326/7
3 ± 1
480 g
520 g
6 ± 2
7 ± 2
8,13,14an
8 ± 0
at ≥ 30
at ≥ 32
cerclage1
discussionpainless
sptb 
± 0
± 1
± 113
± 187
± 2
± 21
± 3
± 30
± 31
± 4
± 415
± 5
± 7
 28
“conventional”
151 mm
1highest
3outside
5129/67151/61131/60
85 mm
activity1112/62142/78149/75
al,4
cd134/91
cd190/115
conclusion gestational
discussionmore
ed4130/67142/85144/90
icd-9
nsvd130/80
nsvd160/100
nsvd160/90
pnc132/79155/92
results among
-1a
152/70
1a/1b
1b/1b
287
400,000
440,000
5/36
8fetuses
9 × 109/l
anemia ± hydrops
anti-hpa-1a
a–containing
discussionfetal/neonatal
f–positive
gonadotropin–induced
hpa-1a
t3/t4
11blood
1414 g
2003,4
2502
2944
3,5,6
942 g
anti-müllerian
discussionmonochorionic
hypothesis”
osunkoya,3
twins,13
 × 400
“chance
10 g
11/17
12postpartum
14regional
17a
1 seconds
2/13
249 × 109
267 × 109
3/87
32 seconds
4 g
4 × 109
5 seconds
72-hour
7we
8-hour
8 × 109
are 
dl−1
fviii 
levels 
post–dental
post–first
 50
1,6,8
181/7
192/7
19302729gestational
194/7
1ultrasound
1–4case
2,500/y
2-vessel
204/7
204/7220/7192/7181/7pregnancy
211/7
220/7
2”
3,500
3-vessel
3nearly
6,300
analysis69
equinovarus2,3
extremities3,4
foot3,4
g2p1001
historyg1g2p1001g2p1001g2p1001reason
kalousek6
xxx69
xxy69
11although
13,14,15,16,17
33,113 ± 32,503
4fig
60,500
7675
81-kg
9452 ± 12,610
cyst—cystic
helwig12
signs5
11these
11 wk
1344 g
1640 g
16 y
1918
1 mm
1 y
2340
2420
2670
28 wk
292na112
2indomethacin
2 wk
2 y
33 wk
35 db
35 wk
3 wk
4,5,6,7here
41/16 mm
5 y
65/29
700 g
8/8
935
95 × 106/μlpco256
adachi41st
age2nd
agedane51st
ageernst111st
calcification,5
cd34-positive
del1100t
dosagenephrocalcinosisnakagawa101st
fluidwbc5900/μlph7
g/dlpo234
hco326
hgcl106
hgk5
indomethacin1st
mentionedkonrad61st
meq/lca7
meq/lcl106
meq/lcr1
meq/lhb15
meq/lht43
meq/lk4
meq/lna131
meq/losm229
meq/lp6
meq/lrbc3
mg/dladh1
mg/dlaldosterone2020
mg/dlbun4
mg/dlca6
mg/dlcl96
mg/dlcr0
mg/dlcrp0
mg/dlk3
mg/dlna130
mg/dlp3
mg/dlplt168 × 103/μlbe−1
mg/kg/d1st
mg/kg/d2nd
mosmcr0
mosmosm257
nkcc2
pg/mlglu55
pg/mlica1
pg/mllactate24
pge2
r471x
slc12a1
~22
μg/kg/d
074x
129ck220
1480
1810 g
215 × 103/μl
23 × 106/μlt-bil2
5,6,7,9
6-thioguanine
6tgn
7500/μl
8-
ast24
be−12
birthwbc8100/μlrbc2
flalt2
g/dld-bil0
g/dltp4
g/dl at-ly5
g/dl lymph8
hb10
hct30
hgbun23
iu/l baso0
iu/l eosi0
iu/l mono13
iu/l myelo0
k4
mch47
mchc35
mcv135
meq/lcre2
meq/lcrp0
meq/ligg760
mercaptopurine,6
mg/dlerb/100
mg/dlglu93
mg/dl blast1
mg/dl meta1
mg/dl promyelo1
mg/dl seg71
mg/dl stab0
na132
pco249
pgldh377
ph7
plt293 × 103/μlalb2
pmol/8 × 108
r2 = 0
risk,5
wbc168cl107
wbc3022/μlica1
y = 1659e−0
004abreast
012cautopsy
1/7
100 ×
10 minextreme
1182bnewborns
11a
122voided
2,3patients
200 ×
2528preterm
25 g
3/509
375 g
3summery
509
543aoutpatient
590 g
600 ×
6our
7/33
baumannii”
findings123289
infected 
likely”
milkpostpartum40term
not329catheter
not424breast
not527voided
n = 16
n = 21
n = 33
results during
tip1037term
urine24
urine3239term
urine4040term
vessels221
vessels3150
yes234voided
yes630voided
 750-g
“acinetobacter
“pan-resistant”
“probably
”newborn
0 × 0
106–50morning
11-deoxycortisol
11-β
13530–235
17-hydroxypregnenolone
17-hydroxyprogestoerone
17-oh
17-α
1861–124
19378–457
1hormonal
1shbg
1 × 1
20340–325
21-hydroxylase
2differential
3-β-hydroxysteroid
3–22
452–45
4serum
5×
5 × 2
6–5
7 × 2
905
cah,8
conclusion we
crown–rump
dyspareunia—in
hemangiomas luteomadiverticuli hyperreactio
metastatic placental
methods case
objective acquired
pregnancy11-deoxycortisol
pregnancy17-oh
results we
staining,3,4
tissue,2
“primed”
1,220-g
220-v
25-ma
3,120
380-v
4in
55-hz
arrhythmias,5
electricity,2
nodes,7
parameters,4
“gatekeeper”
∼10
144,000/mm3
1and
2,560
23,600/mm3
259
67conclusionwe
endocarditis—high-flow
112reported
183,000/μl
192021
1perinatal
240-degree
242/7
24sonographic
25,600
3,353
362/7
376/7
390/7
3a”
3volvulus
51st
57-cm
60th
8fig
age1molvarec
al137vaginalun/ano
al1534cesareanf2,180dilated
al1534cesareanf2,190dilated
al1539cesareanf2,660dilated
al1734vaginalf3,000ascites
al1834undocumentedm2,170dilated
al1836cesareanm2,860unknownanastomosis2
al1934cesareanun/aunknownileostomy
al2137undocumentedf2,900polyhydramnios
al2332cesareanf2,150dilated
al2336cesareanm2,350dilated
al531cesareanm1,860dilated
al733vaginalm2,790dilated
anastomosis24
anastomosis28
aperistalticanastomosis18
ascitesanastomosis1
bean”
bowelsileoileostomy16
bowelunknown10
bowelunknown15
bowelunknown5
case37cesareanm3,353dilated
colostomy2
cost-effectiveness—there
d13park
fibrosis—characterized
g4p2103
gunay2034vaginalm2,000polyhydramnios
kenigsberg429-30vaginalf1,200polyhydramniosbowel
mo10black
mo12has
mo14noreldeen
mo16current
mo2molvarec
mo3durand
mo5durand
mo6leung
mo7crisera
peritonitisunknown1
polyhydramniosjejunoileostomy28
polyhydramniosjejunostomy9
pregnancies—especially
resection36
resection7
scan—we
signanastomosis4
wbc/μl
wk8usmani
y1092x
y11black
y15yu
y4durand
y9samuel
Δf508
“coffee
“target-like”
“whirlpool
1,353
37-week
discussionpancreatic
diseases,6
gata6
pdx1
ptf1a
1,014
1011infants
12due
147,000
19,000
19although
2,204
23this
2table
332/7
b19indeterminate
baby”
disease,14
hand-schüller-christian
lch,20
muffin”
trials,2122
v600e-positive
1996,1
27/10
32/12
36/20
40/10
43rd
47/20
70/34
7women
80/30
8although
bédard
i2
1,943
10dol
10poor
11dol
12dol
13838
13dol
14382451212638262abbreviations
15dol
1613138791363creatinine
16dol
190171137127231307d
20dol
215hct
29dol
36ast
36neonatal
3diagnosis
3platelet
461
4851
49519647492824271423344162344133alt
49wbc
5inr11
61929
629
840
93bun
9861578973721459359115301113ggt
discussionhsv
103/µl
1d-f
2/8
2470-g
p2-0-0-0-2
“fifth
05:47
1/8,000
29-week
2:40
3:30
4:57
5:20
g20010
status,6
“before-and-after”
00-1
00positive
031
04life
05ga
060
08-1
09ga
1,127
14abbreviations
150-5,500
17-1
180,000
1studies
2demographic
3-38
34previous
3perinatal
4-42
4-foldabbreviations
41postpartum
499 34-37
4risk
567table
567these
61-2
65-3,000
700 sepsis6522abbreviations
712
8-44
81-4
81313 
85859birth
8gestational
94-1
96-1
97-1
98-1
al52010180,940
al61991121
al72003114
analysisbor95
birth0
birth312633 1-7
birth5400neonatal
birth6500 
birth 
death1
death antepartum221977 during
gbs2017abbreviations
labor141200 within
máxima
orbidity rds121022 ivh6511 nec21
parity nulliparity6353 multiparity5547singleton
pprom21
pprom 
pregnancies1
pregnancies twins1210 triplets10
pregnancy10589multiple
studies67
valueor95
wk001313gestational
wk001313 34-37
wk10
wk11810099 27-34
wk141244 30-34
wk43
wk988399 27-30
1-l
215/7
223/7
225/7
231/7
235/7
gestations,3
1,878
1214
19despite
2290
272/7
6551
67891011121314
discussionfulminant
11it
1immunologic
20ro2123la4363sm171118323rnp9685856ana
22igg4
24complement
25igm0
3abbreviations
5ds
8echocardiography
90igg
9iga
c31
c40
hep2
investigations3
p200
postnatal1
postnatal25
postnatal3
ro52
2second
3,430
391/7
discussionvisceroatrial
isomerism,3
morphology,2
108/70 mm
78/51 mm
air–fluid
al22
anomaly,13
delivery,21
pregnancy,11
pregnancy,9
rare,4
uterus,4
1,038 g
12 mg
case201335–32nocesarean
cases6
conclusion if
delivery1,0001,1401,000salpingectomy9199831cesarean
delivery1,000hysterectomy14201327cesarean
delivery1,038expectant
delivery1,430cornual
delivery1,682cornual
delivery2,100subtotal
delivery2,786supracervical
delivery2,800supracervical
delivery3,010subtotal
delivery3,110supracervical
delivery32nocesarean
delivery37nocesarean
delivery–methotrexate12201036–39nocesarean
hysterectomy10199926–30yescesarean
hysterectomy71997–myomectomy33yescesarean
hysterectomy8199724–30
objective the
patient,13
results a
salpingectomy11200725–38nocesarean
salpingo-oophorectomy13201230–28nocesarean
salpingo-oophorectomy6198934–39nocesarean
treatment5198829myomectomy38yescesarean
2,755 g
conclusion while
objective cases
results the
834
834 g
acid–schiff
albicans—positive
×109/l
× 200
discussionganglioneuromas
discussion a
fénart
introduction most
stain × 400
twenty-four–hour
091
1,840 g
17–22
17–222524–3218 + 1–27 + 6cumulative
1fetal
1 mm303
2,340 g
21-day
25 + 1
28 + 4
2biometric
2 mm224
320/nl
33 + 2
35 + 0
38-year
4-weekly
4/nl
4 mm273
4 × 6
5 × 3
5 × 3-cm
6 mm261
6 mm60
710 g1,084 g1,846 g
85/nl
8 mm52
9/10/10
al32
al33
al34
available22
breast,2
brst-2
cancers—platinum
circumference204
circumference221
circumference31
ck7-positive
cm41
cm45
cm63
cm69
d1 + 8
decades,11
dose5
fl2d
gemcitabine—are
gestation25 + 129 + 034 + 6head
glypican-3
length42
literature,28
mo12
ovarian,4
ovarian4
pregnancies,1
q3w
q3wgemcitabine
q3w–pancreaticoduodenectomysacral
ratio1
region,21
s1/s2
studies16
study,18
study17
trial,19
washout,20
weight2,340 g6,410 g8,250 g
1,300 g
1,745 g
14 + 5
1outline
2,200 g
2,600 g
2treatment
34 + 6
3sutured
4double
5presentothercomplete530/0/0unknown24acute
5sutured
6continuously
7,400/µl
81/42 mm
abdomenabsent1,300anterior3continuouslybeneathcomplete233/1/0previous
abdomenpresent2,200fundal
abdomenpresent3,000fundal
abdomenpresent–anterior5continuouslybeneathincomplete431/1/0unknown21acute
abdomen–presentfundal3presentothercompleteabbreviations
abdomen––right
al,11
al,13
al,9
al8
anterior0
case2sutured
catgut37cesarean2,842–roeters
cesarean14acute
cesarean19acute
cesarean20acute
discussionrupture
goretex33cesarean2,2208/9martin
lateral2presentbeneathcomplete335/3/2previous
mesh34cesarean1,7007/9palacios-jaraquemada
ozeki10
posterior3continuouslybeneathcomplete629/0/0unknown26acute
reports,9
rupture128/3/2previous
scoresauthors1sutured
tachocomb34cesarean2,6008/9present
tachocomb35cesarean2,6128/9shirata
vicryl33cesarean2,3456/8/9wang
“repair”
“second
“uterine
1,530
10th–50th
lis1
lis1-
miller–dieker
α1-anti
22 + 2
29 + 6
3,350 g
background left
conclusion 
defects,6
discussionnoncompaction
layer”
life3
of 
shelf”
transplantation,8
“noncompacted
“spongy”
10,200
126 × 97 × 124 mm
1items
1 g
2,800 g
2 × 2 × 3
500–700
9,400/mm3
900–1,200
conclusion depending
mccaul7
objective we
results attempting
tubes1
years,13
0flow
1,020
170–350
1targeted
25–55
270170–350lv
29/12
31/17
3418atrial
35/18
464225–55lv
4septal
4 mm
5:1rv
6pdatransductal
8 mm
ao1
cm/s0
diameter2
ml/kg/min140
mm4
ms424035–55e
paat43
pda9
ratio0
2,010
2,310
abnormalities3
biochemistry13
cases,4
cloaca2
conclusions the
fluid,12
gamma–glutamyl
normal,1
orifice2
postfertilization15
processes7
results cloaca
suggested9
value 
“urethra
“urethra”
”anorectal
32-week-gestation
4,980 g
4/7
4/7weeks
case this
conclusion emergent
fibrinolytics—generally
rt-pa—in
1,390 g
177,000/mm3
19-week
2,700/mm3
2 seconds
31 seconds
al,3
al-matary4
al6
 in
 purpura
 we
1,496 g
103 mm
173,000
43/26
44 mm
648
9,800
cc5
fluid2
of − 7
tlr4
tlr416
t = 0
conclusion congenital
introduction temporary
patients,4
sympathetic–parasympathetic
37+2
approach3
constipation,7
constipation6
females4
ipp,1
remarks this
report two
review a
shape,3
therapy,10
tip1
1,975
30-day-old
always 
disorders”
myo5b
volume 
×16,700
×7,750
 400
 6
“congenital
1,000,000/ml
background breast
conclusions pink
prodigiosin1
with 
 1,000
12 mm × 16 mm
23 week
5q15
803 kb
conclusion antenatal
description a
dichorionic–diamniotic
discussionantenatal
introduction prenatal
points,7
polarity,2
processes,8
riko2
riok2
rp11–194d10
tube,6
weeksʼ
“split
3410 g
37th
discussion although
introduction encephalomalacia
β-hydroxybutyrate
“brain
13–54
17cm2
25-dihydroxyvitamin
25–0
45th
5°c/h
9–2
discussionscfn
mg/l—normal
“flu-phase”
−17
1865
1996rcarv20 wkchf3 mm1
1showing
2000ladrv30 wkasymptomaticn/an/an/an/an/anonenonespontaneous
2002lcxra23 wkasymptomaticn/a2
2003rcara22 wkchf4 mmn/an/a3:1n/a3
2006rcarv20 wkchf3
2008rcarv33 wkchf6 mmn/an/a3
2010rcarv23 wkchf6 mmn/an/an/an/a4
2012rcarv33 wkchf4 mm3
2012rcarv37 wkchf5 mm2
2:1n/a1
56:1map
5 mm × 4
65/35
68/38
8 mmn/an/an/an/a12
966
day–6
decades studyorigindraingaclinical
devicekaragöz
krause1
m/s2 mmn/an/a9
m/s4 mmn/a85/475
m/s5 mm1
m/s9 mmn/amap
st—t
10+
1review
44,000/mm3
5 × 0
76 kg
8 mhz
93,000/mm3
abnormality32/39management fasciotomy7 late
al14
asphyxia2 maternal
background neonatal
birth2
birth skin
cm–sized
comorbidity preterm9 maternal
conclusion necrotic
debridement4 no
diabetes-a2
dm7 oligohydraminos6 difficult
extraction5 abnormal
findings contractures38/45 radiologic
gain2
gain2 neonatal
kasabach–merritt
microsomal2 excessive
necrosis44 escher4 cyanosis1 erythema
only1long-term
pregnancy4 prom3 fetal
presentation5 twin
procedure20 surgical
seizures2 neonatal
sepsis1 neonatal
surgery19abbreviations
syndrome—88
varicella2clinical
context uterine
1,9,24
1/2010
10/2004
16,34
16–52
2/2002-8/2002
20mg/l
24mm
2initial
2 case
3000/mm3
32,33
37–50
3–32
4/2003
4/2010
53-years
620w
63u/ml
75u/ml
8/2007
8/2008
86-89
99u/ml
cyclophosphamide2001-2002
discussioneleven
mtx4/2007
ptpn22
ra‐associated
rs3087243
vasculitis”
“idiopathic
+5310
0,250,340,430
0platelet
104323020430–400triglycerides
10^6/l
15,1013,1011,94
1500250n
1fibrinogen
1β
2-6 mg/kg/d
200il2r
27 year-old
28-day-cultured
2routine
2 weeksafter
3flow
3 weeks
4,8n
54white-cell
587519235150–350ferritin
5pche
5table
5 mg/kg
5 monthsnormal
68127208
7200
72002000690223–710il6
7crp
918321894955320–12920prothombin
cd3+/cd56+
figure1a
figure1c
figure2
figure3
hlh-2004
il-1ß
interleukin-18
interleukin-1α
introductionmacrophage
ki-67+/cd68+
ki-67-positive
lineshaemoglobin 
scd25
sil-2
sil-2r
t-cell–derived
table1
table2
th3-th4
virus-1/2
   0
 2500
 500 μg1043 μg/l
 9
‘immature
/ml0enoxaparin
/ml3nadroparin
/ml3pentosan
/ml4dalteparin
/ml6
0sodium
136mporcine
230fdalteparinurticaria
352mheparinhypotension
3enoxaparin
3published
442fnadroparingeneralised
518fenoxaparinerythematous
5enoxaparin
627fenoxaparinerythematous
6enoxaparin
759fdalteparinblood
852freviparindyspnea
967fheparincardiac
arixtra™
c3a
c5a
clexane™
fibrezym™
fragmin™
fraxiparin™
mg/ml0fondaparinux
mg/ml4sodium
mg/ml5reading
mg/ml7reading
orgaran™
solution0histamine
ants”
discussionfire
epipen®
investigator’s
medicalert®
017
10–15 minutes
10–20 minutes
15 minutes
280-290 mosm
28 year
2 hours
3-o-methyl-glucose
3-omg
3-omg/rhamnose
30 minutes
32 year
340 mosm
3 months
50 km
5 months
60 minutes
90 minute
90 minutes
vo2max
Ω-5
109/l0
109/l4
109/lcd19
109/lcd8+0
109/liga3
asacol®
cd4+0
g/l0
g/l6
g/ligg12
g/ligm1
gp91-
p22
p22-
p47
p47-
rangewbc7
1-antitrypsin
2capsule
2new
3igg
5-21
adults❖
antibiotics❖
antibodies0
cd19+cd27+igd-
controls❖
criteria ❖
cytometry❖
defect❖
disease❖
disorder❖
g/liga0
g/ligm0
gut❖
igg3
intervalcd4498 × 106/l500-1650 × 106/lcd8271 × 106/l210-1200 × 106/lcd3794 × 106/l780-2600 × 106/lcd19122 × 106/l80-600 × 106/lcd5624 × 106/l40-600 × 106/lswitched
intervaligg1
introductionpatients
iu/mlisohemagglutininspresent cell
liver❖
msh5
pneumonitis❖
test❖
understanding”
 ❖
μg/g
μg/mldiphtheria
“pre-med”
“sharpened
❖
1cf
2naïve
4 l/min
9,25
anti-cd28
chronically 
f508del
figures 1b
foxp3
lag-3
 30
2-isopropyl-5-methyl
35 mm
3–4 hours
cow’s
w0f0
w10/f25
w25/f50
w3f25
***p 
-cy7-conjugated
002
01767
03457
06594
07112
12-myristate
12 ± 1
13-acetate
1394
155 mm
17/170/17total
1atopy
1 second
2***278
200-μg
24 hours
2 ± 105
35 ± 3
38atopy
4-color
425
6/117/10age
6857
6fev1
77***96
8224
8803
89 ± 14
anti-cd177
anti-cd4
anti-cd8
anti-il-5rα
cd11b/cd18
cd177
cd177+
cd177+crtam+
cd3+cd4+crtam+
cd3+cd8+
cd3+cd8+crtam+
cd355
cd3 + cd4+
cd3 + cd8+
cd4+crtam+
cd66
cd67
cd69
cd69+
cd8+crtam+t
crtam + eosinophils
crtam + neutrophils
crtam + subpopulation
crtam + t
discussionasthma
friedman’s
ifnγ
ifnγ-secretion
il5rα
il5rα+
il5rα+crtam+
khco3
mac-1
mean ± standard
necl-2
nelc-2
nh4c1
n°
ph 7
β2-agonists
 ± 0
 ± 1
 ± 2
 ± 4
 ± 5
 ± 6
*p ≤ 0
097/11
anti-cd16/32
anti-cd19
anti-cd40
c57bl/6
discussionby
fcγriib
figures 1b-c
igm + b
igm + cells
pbs +
were 
 ± sem
0-1200
039
045act
16/12bmi25 ± 3
18 ± 0
1rhinitis25/28gastroesophageal
1 ± 8
20-29
22duration
25/28
26 ± 9
27i
2at
2atopy25/28duration
2 ± 2
34±7
34 ± 7
3±9
3 ± 21
3 ± 4
3 ± 5
3 ± 9
470 ± 341
4 ± 10
4 ± 3
55 ± 0
57 ± 8
5act
5 ± 15
65-84sex
6 ± 0
6 ± 5
6 ± 8
718 ± 314
719 ± 5
7±23
7 ± 7
7 ± 9
8 ± 2
8 ± 9
92bmi-0
9±17
9 ± 1
9 ± 6
act 
act = 17 ± 1
act ≤ 19
act≤19
alpha = 
antagonist13/28act
asthma0
asthma’s
baseline = 620 ± 263
bronchodilators19/28leukotriene
disease2/28inhaled
disease7/28osteoporosis2/28heart
fef25-75
fev1 
mcg/day134 ± 107-26
mcg/day687 ± 248-22
m = 1/f = 5
nct01730976
n = 19
resultstable 1
r = -0
r = 0
score22
subjects’
valueage-0
 19
 70
≤19-17 ± 1
≤400
≥10
≥100
25-yr-old
5,7,8
allergy,9
asthma,1
discussionbovine
mean±3
4×3/16×15
6×4/20×19
discussionallergic
h-lase®
introductionhyaluronidase
mevan®
surgery4,6
triam®
,12
14-
16-kda
33-kda
4,9
discussionor
ingestion16
intensity,19
interleukin-5,18
introductionrice
previously5
α-amylase/trypsin
10,21
10,300/µl
112/70
12,24
121/minute
18although
19,400/µl
2-12
24/minute
241,000/µl
280/µl
37-54
4,10,20
4,12,19
4,6,12-17
5,10although
5,500/µl
6,25
60-125
644
allen2
badesch1
löffler
löffler7
≥25
0-314
0/+
1-g
115/minute
16,17ige-mediated
182/µl
29-4
5,350/µl
80-200
81/minute
85/50
9,10yacon
introductionyacon
02-0
1,225
227,000×103/µl
4direct
7,500×103/µl
8,9cutaneous
henoch-schönlein
myambutol®
pyrazinamid®
reported,17
1,2we
anti-cd123
anti-cd203c
discussionbeef
fcεri
interleukin-3
introductionbeef
1,262
1,3,5
1,335
1,612
11×103/µl
1recurrent
3,060
4although
albendazole,1,3
countries,1
introductiontoxocariasis
toxocariasis,5,6
18×14/50×44
18×9/46×46
antibiotics5,6
asthma,3
discussionantibiotics
korea,2
555
875
introductionwhile
1,5-11
1,9,12,13
2-guanidinothiazole
4apart
9direct
curan®
gaster®
introductionh2-receptor
zantac®
1,450
11psoriasiform
13in
14our
3low-level
42×103/µl
520×103/µl
5we
6,7the
60×103/µl
lad-1
β-subunit
β2-integrin
β2-integrins
1,11autoimmune
11,17in
13the
3-25
505,000/µl
690/µl
7,890/µl
chun3
géber1
mechanisms,9
progesterone®
warin14
22,890×103
30-min
7×6
discussionantihistamine
h1r
introductionhistamine
rare,7,8
1978,3
2,11,13
220/µl
3/35
3bs
4/31
6b
discussionpositive
groups,9
hapten1
introductionreactive
-20℃
1,8a
125/75
5allergic
c4h10
discussionlocal
52-year-old-female
discussioncorticosteroid
introductionvarious
reported,6,7
7there
985
cyp2c9
discussionnecrosis
nsaids8,9
≤600
1-3gonzalo-garijo
214,000/µl
29-31
4,730/µl
5-200
50-200
6+
6,600
724
lo1
pollen,7
pollen,8
powder,6
13,14although
16,17in
1:20,000
2,6-diisopropylphenol
2-5propofol
9,10the
introductionpropofol
smoflipid®
0-30
0-54
0-72
10-75
11,096
150,000-450,000
2,023
2,927
21,100/mm3
30-180
33,221
37,492
4,000-10,000
5,248
5-40
65-125
8,740
8-40
98,000/mm3
korea,1
mppdc-e2-related
narita7
tco2
,2
11there
3antihistamines
3approximately
5-7this
fcεria
h1/h2-antihistamines
stallergènes
14,000/µl
14,300/µl
17-month-old
2,3aip
21,900/µl
35-month-old
9,300/µl
adults,1
1003
7neuropeptides
activity14
discussionoccupational
introductioncapsaicin
permeability,3,6
response,8
trpv1
trpv1-independent
116/min
15several
17,460/ml
2-acylbonds
22-40
3-3
30,010/ml
3bee
504/455
68,000
6most
nossel16
pla2
survey5
66/minute
antibodies,3
diseases,5,6
igg4
introductionginseng
11,13hae
15,16to
2,13the
3,4,10
3,4,10approaches
3,4,8-10
4,9,10,17
6there
c1-inh
c1-inhibitor
clinic,3,4,8-10
discussionlanderman
hae,2
11,430/µl
13corticosteroids
16in
17-20in
2,296
2,550/µl
30,000/µl
39,000/µl
48,000/µl
anti-il-5
inf-α
3,4-d
3h-thymidine
4-hydroxypyrazolol
discussionallopurinol
respectively10
0-170
1,418
10,760/mm3
2,3,5,9
-25
11,820/mm3
13-35
404,000/mm3
48-72
5-9,16
50/µl
7-14
77-195
ch50/ml
discussionangioedema
introductionangioedema
pruritus,2
unicap®
0-20
6,520/mm3
discussionaep
interleukin-5
1,337
1,500-2,000
145/87
20-minute
47/µl
4here
9,400/µl
iu/l,10
≤100
1,2despite
10,13,14
discussionfusidic
fucidin®
introductionfusidic
,10
10:00
11during
15-120
313,000/µl
67/45
698
7,070/µl
868
discussionanaphylactic
introductionlevofloxacin
12topical
250/50
asthma,2
discussiontomioka
diskus®
1,048
1,500-ml
12we
23,740/µl
734
anti-hhv-6
cells/106
ifn-γ-releasing
ifn-γ-secreting
introductiondrug-induced
12-year
121℃
2-4,10
5,6in
7-9the
discussionfdes
fdes,1
reports18,19
10-14our
163/91
187/200
22,580/µl
26,000/µl
939
anti-cd52
anti-il5
2,9-13
2-4case
3,7,8
95/minute
beta2-agonist
cyp2d6*1/*10
cyp2d6,19
introductioncodeine
methods,5
se/cypalleles/cyp2d6
1/200,000-250,000
1133
1133a
129/min
14a
200,000-250,000
24we
27,28in
28/min
2nadph
3,380/mm3
378
95/55
asp378gly
b558
mutations19,21
ncf1
p22-phox
p40-phox
paasp378gly
rac-2
6wheat
7am
8pm
discussionfood
hwp1
introductionwheat-dependent
mm×12
mm×9
omega-5
-46
11in
2,340
3,15,16treatment
3,5,9
4,880
5,6,9
8,090
9,17,18
edema7
present,5,6
100/µl
10however
11namisato
132/min
1however
22±1
230,000/µl
2×22
3here
7,800/µl
closerin®
disturbance,7
hepatitis,8
levofexin®
mean±sd
neuropathy9
solondo®
tambutol®
yuhanizid®
1,630
10,11,12,13
3-76
38,300
4,213
5,9,13
6,000-15,000
8,9,10,11,12,13
discussiondress
introductiondrug
pocral®
2-2
25-years-old
30-93
47-years-old
children6
cpt-2
introductionasthma-like
s113l
synthase=1
test,1
1951,1
described,3,4
discussionmunchausen
professionals,7
wong2
1,2achalasia
139/93
14,440/mm3
1achalasia
200/mm3
5,6cough
9,150/mm3
93/min
discussioncough
elderly,14
patients,7,8
reports,5,6,10
,11
12,13a
19,20in
2so4
4,5we
allergen,11
allergy1
asthma14,15
beer,18
flour,2,3,8
flour2,3
immunocap®
ingestion,1
ingestion1,10
inhibitor7
ltp1
m14
mino™
pollen,4,5,7
pr-3
test6
urticaria,9
worker2
α-amylase
β-expansin
2it
6flare-up
beta1a
betalactams7
heparin9
interferon-β1
interferon-β1a
introductionga
neomycin,8
1-72
293,000/µl
4,5,6,7the
4-methylthio-3-butenyl
6,780/µl
80/35
hypersensitivity,15,16
system,10
1,2,3,7,8
1,3-galac-
3-galac
3-galactose
70/30
bites,7
encephalitis9
galactose-α-1
galactose-α-1,3-galactose
sdp6845
~2-3
10use
14milgrom
17inhaled
1synthetic
27–33
500/50
9evaluation
assessed—via
asthma,9
care”
up”
μg/puff
“step
“stepping
14irrespective
1876
18conclusionsozena
2,12
2surgical
4-mm-diameter
4–11
8,9,12
“stench
1–4of
7,8case
8conclusiontemporal
1s
1spirometry
3testing
41–8
9reactions
postbronchodilatorfev1
post–mint
pre–
r5
recognized,1,2
§x5hz
“right
*\,1
046
046^
0 km2
10 040
12 960
13 700
1660–2000
190 000
1935
1969–2011
1988–2011
1992–1996
1\documentclass
2010–2100
2019
2065
2068
22 550
22°e
24°e
2573\quad
2820
2\documentclass
30 730
3329\quad
33 800
350 years
38 740
3\documentclass
420 seals
523t_
55 200
565t_
59°n
5\documentclass
6040
60 years
64°n
6 years
800-m-wide
801t_
865\quad
90 years
a1b_1
bäcklin
forms”
heide-jørgensen
härkönen
introductionglobal
jüssi
kjellström
matlab®
matrix:4\documentclass
n = 579
rca3-model
rca3-scenario
sipilä
 1regions
 1–3
 2january
 3population
 5mean
±1 °c
λ
“dwarf
“ice-loving”
…at
/rf w kg−1
00°n
08 × 10−7 w kg−1
0 g m−2 year−1
0 ± 7
100 μw m−2
10 000 m3 s−1
10 mw m−2
12 m
14 150 km2
150–300 km3
17\documentclass
1919–1939
1969–1991
1970schanging
1970–1979
1987a
1987b
1 ml ≈ 44
1 − rf
2000–2009
200 km3
2010the
20\documentclass
21°n
25 km3 year−1
25 × 10−7 m2 s−2
25°e
25°n
28 g c m−2 year−1
29 m
2 g m−2 year−1
2 ml l−1
2 ml o2 l−1
2 × 10−6880
2 × 10−8
30 μw m−2
33°e
352
38°n
3 mw m−2
3 ± 0
3 × 10−750 ± 4085the
4 ± 0
4 × 10−41
50–70 m
57 μw m−2
59 m
5 ± 3
5 × 10−41
5 × 10−7
5–1 m
65 m
6 × 10−6350
6 μmol
70 m
75 ml o2 l−1
75°e
7 × 10−6121
800 m3 s−1
85 m
8 × 10−774 ± 4211754
90 m
98°e
9 × 10−777 ± 6131858
a0 = 1
a0 = 2
a0 ≈ 1
advection–diffusion
by19\documentclass
by1\documentclass
by4
b = κn2
consumptionhκno
current:12\documentclass
c m−2 year−1
equals15\documentclass
equals16\documentclass
equals18\documentclass
equals21\documentclass
e = 0
g/ρ0
g m−2 year−1
g′ = gρ′/ρ0
håkansson
jets:13\documentclass
l − 1
m2 s−1
m2 s−2
matthäus
ml l−1
n2 = −
n − 1
o2652
o2 
o2 m−2 year−1
obtains11\documentclass
obtains3\documentclass
operations6\documentclass
q0
q = 0
q = 800 m3 s−1
q = q
reads8\documentclass
relationship:22\documentclass
rf = 0
sandén
seawater5\documentclass
s 
s = s
s′
table 1averages
that2\documentclass
thus14\documentclass
w = 0
w = pb/a
w kg−1
w m−2
w′
z = d
z = h
z = h:10\documentclass
z = l
z = u
z = u:9\documentclass
z − 1
z − 2
 1left
 2isopleth
 2 ml l−1
 4upper
 5evolution
 6computed
 = a
 = pb/a
 × 10−7
 α 
 ρ
± 0
·
·Δz
Öland
Öresund
Δt
Δz
Φ
α = 10
α = 10discussionthe
κwa0o2
κ = a0n−1
ρ
ρ0
ρ0α
ρ0β
ρp
ρ′
∂o2/∂t 
∂s/∂t 
∂ρ/∂z
−q
+106
+316
+33
03 × 0
046 × 1012 kg
0imo-specifiedgaseous
106 kg
10 000 tons
11713
1278
1309
1310 5897311
138123121110co47
144132132124co51
14 000
14 70014 60015 00013 700nox
14 7008 3102 73015 66010 7807 71012 440avg
14 knots
15 60015 90016 60015 900nox
15 km
16 56027 3804 68020 77015 01025 80018 440average
16–25 
171 966 00093
18 
18 knots
1990–1999
1 785
2-stroke
2005/33/ec
2006200720082009all
2006–2008
2006–2009
2006–2009the
2008—on
2009results
2009selected
2011 6067422
2012b
2015
210 345 00097
220 million
247 793 00096
25 000 tons
260 million
261 088 00099
2800 tons
2971
2ec2
2 281
2–3 
300 gross
321345345318sox
3278
32–average
336369377360sox
3681606851
3all
3fig
3 29047 1406 39024 0609 03044 6002 110payload
3 the
4184
45 000
4ash1
4avg
5000 kw
500 gross
5130
61312
626
6 × 109 kg
6–co2
7so4
84 
8imo-specifiedpm2
8–14 
9093267355
90 l
915common
93 
age19
average2009ropaxtankergeneral
design4-stroke2-stroke4-strokeboth4-stroke2-stroke4-stroketotal
discussionoverview
dwt0
eca’s
gton−1 km−1
gt 
january–april
jan–april
number”
oc5
pays”
pm2
pollutantsco2
shipspm2
ships”
so4
standards—adopted
steam1
steam2
table 1most
table 2the
table 3predicted
table 4selected
 1seasonal
 2predicted
 3predicted
 4a–d
 4predicted
 50 000 tons
 5fractions
 6relative
±1 
“all
“ships
−15
−19
−68
1007/s13280-013-0432-4
128 km
14–26 × 109
1980 km2
1pathway
1tp
235 kb
264 675 m3 day−1
500 000
commons”
detroit’s’
ecosystems’
freshwater—drinking
generations’
growth’
knowledge”
lakes’
lakes”
lake’s
l’anse
r1,2
replace”
table 1four
 4details
‘limits
“avert
“casual
“r”
0314 m2
05 ng dm−3
0 g hg km−2 year−1
0 ng dm−3
1000 m
10 ng dm−3
10–60 ng dm−3
1157 ng m−2
1500 m
1631
16–110 ng dm−3
1706 ng m−2
1742 ng m−2
1784
18°32′28″e
1 m s−1 ≤ vw 
1 ng dm−3
1 ng m−2
20-cm
2008–2009
2008–may
25 ng dm−3
2600
2 mm season−1
2–19 ng dm−3
30–40 
3 ng m−2
3 ng m−2 season−1
3 sd
3–30 ng dm−3
42 
472 ng m−2
4 ng dm−3
500 m
54°30′34″n
5 ng dm−3
5 ng m−2 season−1
6 ng dm−3
70–80 
7 ng dm−3
800 m
8 ng dm−3
8 ng m−2
98–99 
9 mm season−1
9 μg m−2
9–41
amount—r
august–december
bcr-579—coastal
bełdowska
direction—wd
discussionhg
distinguished—heating
fluxes:1\documentclass
humidity—rh
hławiczka
introductionmercury
january–may
may–september
miętus
mm = dm3 m−2
model-based—and
ng dm−3
ng m−2
october–april
period—in
pressure—pa
r = −0
råö
similar—when
speed—vw
temperature—ta
vw 
wängberg
 1sampling
 2statistical
 3statistical
 3 m s−1
 4mercury
 4 m s−1
 5influence
++++ha-18m
++++ha-3f
++++ha-7f
0-10*holt
00 ± 1
00–3
02 range0
02 ± 0
02–5
03–12
03–5
044
04 ± 0
04 ± 1
050
05 mg kg−1
05 ± 0
06–1
071
080
084
08vzach
0917
09 ± 0
09 ± 1
09–0
0dittmann
0med
0 mg kg−1
0 poland
0–53
0–60
10/22
106*koeman
10med
10 mg kg−1
10 msvzach
10–224
11med
11 poland
11–1
11–8
12 mg kg−1
13 ± 0
14med
14 mg kg−1 dw
14 ± 1
14–0
1515151515151210 med2
15 am ± sd0
15 ± 0
15–0
15–2
15–4
15–47
15–6
15–8
16no
16 mgthg kg−1
16 ± 9
16–445
17med
17–1
18 msvzach
18 range0
1960–1980s
1965–1969un
1965–1976un
1969ad
196–480
1970–1972nestl
1972–1977un
1980–1990s
1982un
1982–2012
1984im
1986–1987ad
1987ad
1991–1995im-ad
1993–2000im-ad
1994–2001im-ad
1995–2012im
1996eagle
1996unknown++++ha-2m
1996unknown+++ha-11f
1997–2000juv-ad
1998unknown+++±ha-12f
19 range0
19 ± 0
19 ± 1
1med
1 mg kg−1
1 poland
1–2 months
2*falandysz
2003trauma++++fig
2003–2006im
2005train
2005trauma
2005–2007ad
2006shot
2007ad
2007juv-ad
2007shot
2007unknown++++ha-14f
2007unknown+++ha-16f
2008drowning
2008unknown
2009/147/ec
2009electric
2009trauma
2009unknown++++ha-8f
2009unknown+++ha-19f
2010electric
2011disease
2011disease++++ha-6m
2011unknown++++ha-21f
2012across
2012unknown
20–2
21 am ± sd1
21 range0
21 range3
21 ± 0
21 ± 1
21 ± 4
222222221614 med1
2222222222221614 med1
22222222 med5
222222 med0
23 1976–1978
23 am ± sd0
23 ± 0
24–1224med
25vwar-maz
25 ± 0
25–2
25–3
26 ± 1
26–0
26–2
28 greenland
29–1
29–4
2med
2–220
3*henriksson
3*norheim
303med
30 ± 0
30 ± 1
30–1
30–7
31 ± 0
32vzach
32 mg kg−1
32 ± 1
32–1
33333333 med0
33333333 med2
333333 med1
33 am ± sd1
33 mghg kg−1
33 ± 4
33–0
33–3
34vzach
34 am ± sd1
34–2
34–47
35 am ± sd3
36–1
36–2
37 range0
37–1
37–3
38 ± 0
38 ± 2
3komosa
3med
3 mghg kg−1
3 mgthg kg−1
3 norway
3 ppm
3–12*norheim
3–144*kenntner
3–211*krone
3–28
3–48
3–4 years
40–2
40–9
40–90
41 ± 0
41–3
43 range0
43 ± 0
44444443 med2
44444444 med0
44 range0
45 ± 0
45–0
462 sweden
46 am ± sd5
46–3
47 ± 0
47 ± 1
481
48 ± 0
48–59
49 am ± sd2
49 ± 0
49–0
4med
4 finland
4–180
4–220
5*holt
5* original
5/10
5/30
5000–6600
50 mghg kg−1
50 ± 0
50–4
50–60 mg kg−1
522
52am
52 ± 0
53all
53 range0
53 ± 1
53–64 
54 
54–1
54–13
551
55 ± 0
55°c
56vlodz
56vwar-maz
56 range0
57–6
57–9
5kitowski
5 finland
5 mgthg kg−1
5 poland
5–70*jensen
5–87
60vwar-maz
61table 3indices
61vzach
61 ± 0
621
62 ± 0
63 ± 0
643
64vzach
651
65 ± 0
65–7
67 ± 0
683
68 ± 3
69 ± 0
69–1
6falandysz
6med
6osprey
6this
6 mgthg kg−1
6 mg kg−1
6 poland
6–14*krone
6–180
6–21
6–30
701
70 ± 1
70–90 
71 ± 0
71–3
72 ± 2
72 ± 3
72–2
733
73 ± 0
73–0
74–1
75 mg kg−1 dw
75 ± 0
75 ± 1
75–5
7600–11
765
76 ± 4
76–81
771
781
78 
792
7med
7 mghg kg−1
7 mgmehg kg−1
7 mg kg−1
7 norway
7 ± 26
7–0
7–60
80 ± 0
81 ± 0
81–1
81–47
82 ± 0
84 ± 0
85–92 
86 am ± sd1
87*falandysz
871
87–3
880
88888854 med2
88 am ± sd2
88 ± 0
891
8am
8falandysz
8 germany
8 mg kg−1
8–6
8–7
901
903
90 ± 0
91 ± 1
91 ± 3
921
926
92 ± 0
934
93 ± 0
94–97 
951
96 ± 1
982
98 ± 1
991
99 
99–3
9häkkinen
9med
9–110
9–19
ad n
ad n = 17
attack++++ha-10m
brain–blood
brandenburg++++ha-5m
brandenburg++++ha-9m
collision+++ha-20m
dl-13
dl-220
dl-25
dl-53
dl-54*lemarchand
dl-57med
dorm-2
emaciated++++ha-22m
food—mehg
frøslie
f = 48
germany+++±ha-4f
gun++++ph-2f
gun+++ha-13f
gun+++ha-15m
ha-1f
h = 16
h = 20
h = 6
häsänen
im + ad n
im + subad + ad n
im n
im n = 13
k 
k–b
k–m
k–w
l 
l–b
ma-3000
mehgk/mehgl = 1
mehg = mehg/thg × 100
mg kg−1
m–w
n = 102
n = 11
n = 14
n = 150
n = 16
n = 180
n = 22
n = 23
n = 24
n = 5
n = 57
n = 6
n = 7
n = 85
n = 9
oc/rv = 97
osprey’s
ph-1f
poland++++ha-17m
polish–german
resident’
subad n
table 1origin
table 2concentration
table 4concentration
thgk/thgl = 1
thgk/thgl ≤ 1
u = 8
vzach + vwar-maz + vlodz n
~48
~60 
~7 mghg kg−1
 1967–1976
 1location
 2percentage
 b 
 finland
 france
 germany
 k
 l 
 m 
 n
 norway
 n = 10
 poland
‘mainly
‘resident’
−20 °c
,1
0000000 international0000000
0000000 international0000000neutral
0000000 international0000000positive
0050
00500
0050nature
005other
006
0090
0090reindeer
010other
0110nature
0120
01400
0160
0180
0190
01900
0190reindeer
0210
021forestry
02400
024other
0250other
0260
03000
0310
03300
03500
0360
0370
03700
0380
03900
04000positive
0430
0460
0470
0480
048forestry
049infrastructure
04 national0
0510
0580
0660
0690
06900
07000
0720
07800
07 local
080 national1
0900
0900 international01
090 external
0911
093
0930
094tourism
101tourism
1101
111infrastructure
1319914238reindeer
1380
1870
1local
20000000 regional00
20000000 regional01
20000000 regional1
213
21 
23001
230 regional03
249367tourism
28002
2regionalnationalexternal
3030
340 external
36001
391
3950
400 local
431
47 local
497373forestry
4 local
51 local
52004
5200 regional4
531
5514
5602
561
563
60 000
6400 external
6697109nature
6802
7100 external
73100 regional0
7600 national1
7700000 national1
81 local
8200 external
841
8500 national0
860 national1
861
92003
9311
953
9600 external
973
9902
99 local
actors—leads
collaboration”
conservation19126interactions
development”
df = 4
forestry”
globalization—for
international—approximately
interviewees’
introductionnorthern
levels—as
levels—aside
levels—have
logging”
may—in
mechanisms—to
müller
other—from
positive”
public–private
regulation”
reviewed—may
rights—can
sandström
scale00
scale0000000 local
scales—from
sweden’s
söderholm
tables 4
table 1number
table 2storuman
table 4frequency
table 5observed/expected
tengö
their…needs”
they…
usetable 3vilhelmina
us”
well…the
well…they
with…
 2vilhelmina
 3effect
 no
—as
“consult
“macroculture”—disputed
“market-based
“nodes”
“strongly
“want
“weakly
“works
…
1008
104 km2
195 000
1985a
1985b
1994a
1994b
1999a
1999b
2004–2007
2008–2010
20–14
27 km2
2 km
2©
2–4 weeks
30 000
3–4 weeks
44 254
4 ha
4 km2
51 739
61 256
63 ha
69 000
6 km2
80 ha
81 500
april–may
df = 12
df = 193
droppings m−2
eythórsson
farmers’
nord-trøndelag
n = 106
n = 78
political–sociological
rs = 0
rs = −0
scheme”
sd = 3
sd = 4
shapiro–wilk
spearman’s
søreng
ten year
three years
t = 2
t = 7
vesterålen
 1study
 2pink-footed
 3cumulative
 4mean
±se
“environmental
,1\documentclass
1007/s13280-013-0441-3
10\documentclass
10^
112 500
11980s1
1438
15 μmol g−1
1606
1980–2005
2009a
2009b
20\
20\,000
20 750
20 cm
210025–000
21\,000
21\,000\
21 000
288
2fs
2 g
2 ± 2
2·c
30 cm
386
3900
3·5h2o
400:1
40\,000
40 000 km2
450 × 109
48\,000
48\,000\
48 000
50 g p m−2
52000s1
550 000
5800
5 g
5 mmol
5 ± 0
60 m
61990s1
65\
65 g cm−3
6 ± 1
700 000
7163
7253
75 m
7 g
81970s1
8 g
8 ± 0
9112
9132
93 750
97\
are3\documentclass
basin”
dose–response
do”
estimates1960s0
extsink = 7000
extsink = 9000
extsource = 35 000
extsource = 60 000
fe4
fick’s
follows6\documentclass
fs = 2
gächter
hypoxia–anoxia
introductionalready
intsink1
intsink2
intsink = intsink1 + intsink2
intsink − intsource
intsource = 45 750
intsource = 91 500
kalén
mn-oxides’
m year−1
m−3
oxic–anoxic
p-paradigm—anoxic
paper’s
proper”
q1 + qe
q1 ≈ qf
respectively,9\documentclass
sources”
table 1flux
thus,2\documentclass
thus5\documentclass
thus8\documentclass
v = v1 + v2
 2phosphorus
 3content
 4phosphorus
 = 1
 = 5000
 = 5000 km2
±20 
‘return’
“estimation
“estuaries
“excess”
“phosphorus
03 n-no3
0 mg l−1
1007/s13280-013-0461-z
100 
102 kg n ha−1
104 ha
107 m
10 ha
11 kg
127sewage
12 kg
1436 kb
15annual
15 kg n ha−1 year−1
168 p-po4
1984–2013
1991–2010
1993–2001the
1998–2002
1998–2006
20-year-long
2003–2006
2035
2035–2064
2050s
2050sscenario
2050type
2070–2099
20–60
22 
234 m
23−12n-no3
24 n-no3
24–31 
28 n-no3
29 soluble
2—coefficient
32 
34 
36 mg n l−1
37 kg n ha−1
3organic
3 n-no3
40 kg
41 organic
44 kg n ha−1 year−1
44 n-no3
482 km2
49 
50-by-50 km
524 organic
53 kg
53−6−1
58100
62 
62−40
65 
66 
6 + sd
76 
77 
78−18sediment
793 mm
79−80
7 kg
7–15
82 
833p-po4
86 
8 km
909 ha
92 
950 m3
96 
9 mio
a1b
aquifer250 actual
area—the
area”
baseflow1
baseline4
bau-2050
bau-20505
bau-cc-2050
bau-cc-20507
bau-cc-2050 + all 2050
bau-cc-2050 + bz9
bau-cc-2050 + ra10
bau-cc-2050 + vc8
bański
best—combination
bz—buffer
cc-2050
cc-2050 2050
cw—constructed
density0
discharge0
drainage14 baseflow206 total
echam5-rca3-a1b
echam5-rca3-sresa1b
eu-27
evapotranspiration455 pet684area-specific
fall—fallow
farm’s
featurebau-2050msa-2050population
follows:1\documentclass
follows:2\documentclass
follows:3\documentclass
forcesclimatecurrent2050
frse—forests
giełczewski
gioŚ
go2–go9
groundwater29
ha−1
introductionaquatic
kamin´ska
kg ha−1 year−1
km2
krzymin´ski
kämäri
load0
loads2
lsu ha−1
measuresfigure 7
msa-2050
msa-20506
msa-cc-2050
msa-cc-205011
msa-cc-2050 + allfor
msa-cc-2050 + bz13
msa-cc-2050 + cw15
msa-cc-2050 + ra14
msa-cc-2050 + vc12
n-nh4
n-no3
nash–sutcliffe
nse—nash–sutcliffe
n ha−1
p-po4
p0
pbias—percent
poland’s
puławy
p ha−1
r2 = 0
ra—avoiding
reda-Łeba
runoff0
runoff2
runoff25 subsurface
runoff299 percolation
runoff44 tile
s1–s4
scenario—hereafter
sector’s
sufi-2
swat2009
table 1calibration
table 2comparison
table 3model
table 4average
today’s
t year−1
urld—urban
urmd—urban
use current1
uz2–uz3—grassland
vc + bz + ra
vc + bz + ra + cw
vc—vegetative
watr—water
 + adaptation
 2annual
 3basin-averaged
 4foreign
 5percent
 6spatial
 7simulated
 8percent
 m3
 precipitation793 snowmelt58 surface
 sediment
 tss2
Δx1
Δx2
Δx3
—assumes
“risk
+95 
009
025–0
04 day−1
073 km3
0 sd
0–10 m
1007/s13280-014-0524-9
10–16 m
10–20 m
12-
12 000 h
13-
13 m
15-m
15 km2
15 m
162 kb
16 m
16 × 24 cm2
16–22
16–22 m
1 m2
1 m3 s−1
1 sd
20-m
2000–2010
2009–2012
2009–2012in
20 m2009
20 mdeeper
22-m
2277294-byfjorden-ett-fiskeeldorado
22 m
25–40 days
2 m3 s−1
2 m day−1
2 m s−1
2–4 m
30-
30 m
32 m
35-m
35 m
38-
39-m
3 m
3 °c
40-m
41-m
5-m
5-year-long
50 000
5 m
5 m—see
5 × 106 m2
5 × 106 m3 day−1
6 m
79 
7 × 105 m3 day−1
8 m3 s−1
8–2
8–2012
9 months
9—nh4
b17
b18
b20
bäve
ctd—7
dgt—diffusive
doors”
fe2+
fjord—see
gc–fpd
gc–ms
h2s
introductioncoastal
iron’s
koljö
may2011
may2012
mn2+
nitrogen–phosphorus
no3
norén
oct2009
oxygenationsediment–water
pearson–rosenberg
period—during
s4
sar11
se/nyheter/uddevalla/1
sensors—were
strata”
ståhl
sup05
tonnes—most
x2 = 9
~50 × 106 m3
~58 × 106 m3
 2the
 3salinity
 4e
 4f
 4panels
 5the
 6sediment
 7b
 7the
 8abundances
§
µg l−1
×fig
×××
××××
“deep
“mud
“time”
0 µg/ml
1120 g
1600s
16 mg
20 µg/ml
271 mg
274 mg
296 mg
400 g
42 mg
68 mg/dl
80 g
8 mg
8–12 nm
discussionvp
patient’
reiter’s
vp”
“sporadic
∂
11,500
124/77
2°f
4,8,9
558,000
discussionmycobacterium
rgm’s
12,21,22
16,18,19,22
1915
1–14
2/5–3/5
22,24
6,15–19
64-306
9,10,13,14
t-2
term”
“brown
“is
1005
10–50
226–903
24-hr
25–125
400–300
40–220
423ng/ml
52/min
55/min
6–27
9,11,14
9:1
backgroundsjögren
discussionsjögren
sicca”
–a
“keratoconjunctivitis
3×9
5,10,17–19
5×103/ul
6×5
6–8,10,11,13
discussionrhodococcus
36-year-old-female
5×103
crescent”
“air
“halo”
1055
12×
1590
18-month
8/0
discussionintimal
iu/10
1,2,5
1,3–5
discussionpr
gs-5030
state-of–the-art
‘air
discussionzygomycosis
4+4=8
586
discussionprostate
12,25
22–24
shouldn’t
159/94
18–24
1980–1997
28–57
47/ul
4–3
97°
cxcl13
cxcrl12
cxcrl13
host’s
subject’s
titer…
tlr2
“almost
“enhancement
“legs
“ventriculomegaly
“wobbly
”hiv
1×2
392,000
4×4
7cm
discussiondistant
15–25
60–75
“dog-sheep”
437000
1/hpf
10–13
11/hpf
121/64
133/72
2/hpf
8–9
9°f
g3p0a2
2025
22–25
27,29
adnan’s
aged”
discussionabout
“sickness
7×2×3
athlete’s
traumeel®
16–7
discussionstrongyloidiasis
rodríguez
“crampy”
150/85
56–71
discussionextract
elaterium’s
hco2–
sato2
2,13
2,7,16
4,10,17
4,7,14
6,18
ewing’s
1,10
219
2376
3179
“mononucleosis-like”
bro-1
discussionmoraxella
for10
6·5
cytokeratin-8
discussioncombination
pt3apn0
1460
kcnj11
kir6
1/ml
bmi=41
discussionatelectasis
n2o/o2
n2o/oxygen
1,2,5,10
10,671
1ab
2,8,12–14
453,000
46-year
6,15
gagliardi’s
‘shaggy
0–480
0–6
10–35
17,19–23
3960×10
3–45
53–151
709
7–17
9/l
articles”
clinician’s
“related
10mg/day
2036
discussioncoumadin
fournier’s
16–38
39–24
59–90×109/l
60–100×109/l
79–152
12,900/ul
backgroundpott’s
diagnosespott’s
discussionpott’s
incidencepott’s
potts’s
pott’s
treatmentpott’s
tumor’
‘pott’s
“puffy”
discussionpseudallesheria
103/min
198’000/ul
2/cumm
3/2
382
546/cumm
89,000
12,15–19
130/83
2,11,12
2,6–10
8f
masquerader”
virchow’s
130610
2738
38th
70×77×68
pringle’s
protocol-2
1,2,6
1/250,000
69/1000
discussionacheiropodia
extremities”
“dysostoses
18×4
20×2
21×4
21–23
22×4
2900
37,000
hgm11
q13-qter
q21-qter
rpmi-1640
td1
td2
1–3,11
2,3,6,7
100,000–150,000
140,000
14c-serotonin
1628
23,000
50–55
58,000
60–65
78,000
90,000
9–45
discussionhit
factor-4
fire”
heparin-pf4
hit-1
pf4
“adding
100–140
1015×103
130–430×103
1mg/dl
21–27
3×103
hyperkalemia”
v671f
“spurious
1,080
1–9
5,580
7,17,18
arst0332
discussionsynovial
0–35
125–243
13cm×11cm
21days
236u/l
241u/l
3-course
5×9
6-course
7–26
bc1-6
ca-199
discussioninvolvement
mum-1
than50
β2-microglobin
0–37
1,12,11
4500
bricker’s
1,2,7,8–10,11–24
1,8–10,11–14,17,19–21,23,24
10,12,13,17,20
10,15,16
11,12,17,21
12-years
13,16–20
13q-
13q34
1×1×0
2,7,8–10,15–24
8,11–13
discussional
ortner’s
37-year
756,000
leucocytes/mm3
platelets/mm3
35–40
8×103/mm3
sjrögen’s
stensen’s
1mm
100ml
104°f
13,16
18–56
5840
8,11
8500
discussionbiliary
22-year–old
6-months
1,7,9–13
14,15,20,21
14,19
179/64
3-view
39/40
4×103/ul
8×103/ul
discussionpyometra
‘pyometra’
0017
130/85
5,15
94×74
discussionatrial
rt-3d
1,3,6,7
1,6,11
1980’s
2,5–13
22–54
25–35
3,19
30-pound
70–86
75–80
85–95
11,200
148/96
154/64
6–12
96/min
discussionamiodarone
go”
line”
stand”
“front
“new”
“sit
3,14–16
discussionhyponatremia
mmol/24
mmol/l/24
7,520/mm3
78/59
discussionaeromonas
kl-6
1,14
154/84
16srrna
302/mm³
4,5,7,8
6,8–10
7,11,15,16
report:27
th/mm³
1,16
1,30
11,19
19–21
34,35
36,37
6x4
cd16
cd54
cox2
discussionextranodal
ki67-positive
lmp1
‘nasal-type’
8/4
hga1c
mic=0
mic=1
mic=2
mic=8
mic=8/4
∼6
131-hippuran
299
32200/l
91000
130/74
17,9,10
1–3,5,8,9
1–5,10
1–6,8,9
2,4–7
3,5,6,8,9
3,6,8
702
discussiontoluene
nh4+
2′,2′-difluorodeoxycytidine
cytarabine’s
11,13
2,20
8,21,22
“hobnail”
“indeterminate”
100000/mm3
220–496
3,4,8
45/min
5000/mm3
50–64
6-day
85/55
9,11,12
90–97
discussionp
14,15,18
14,17
16–53
17,19
1857
2,17
3,14,15
anti-s-100
breslow’s
discussionanorectal
mart-1
melanoma”
“melanocyte-specific”
49-case
epıydural
mahkam’s
spınal
2,3–6
discussionglass
1,2,8
3–27
discussionmulticystic
0–0
167/106
44×109/l
5–17
6–2
7–55
7–7×109/l
1256
1443
18/minute
86–88
backgroundcrohn’s
discussiongas
8×7
discussionschwannomas
discussionlaparoscopic
10×12
6,10,18,19
brca-1
brca1
ercc1
gpb6
her2/neu
k12/13-ras
k13-ras
rrm1
t4b
0–690
10–55
122–236
14–40
2220/l
2–20
3500–5500
3500–8500
35–125
35–143
4–23
5–27
5–35
7840/l
7–50
discussionmen
men1-related
men2a
men2b
1007
2,3,7
20–760
4–37
500–4000
cl/hco3
höglund
scl26a3
11-fold
20,000/year
9×104
discussionec
1173
17q25
1:40000
2–25
5th–10th
pompe’s
1mg/kg/day
discussionliterature
‘severe’
750,000
discussionblunt
1187
clinicians’
inflammation”
n°/mmc
“ascites
150/82
18–1
24–30
40–129
45–55
62–124
65–1
87–1
aho’s
discussionapproximately
3,8–10
32–36
8,078
8,273
90/53
979
v2–v6
0-i
0-iic+iii
10×20
1150
4,5,13–15
887
bauhin’s
dacruz’s
ly1
muc2
muc5ac
n0/52
n=54
polyps”
quantiferon®
sm2
v0
“adenomatous
“gastric-type”
“intestinal-type”
2-de
2±1
30–70
7,11–14
alpha-1-antitrypsin
apo-lipoprotein-a1
apolipoprotein-a1
cc10
pro-apolipoprotein-a1
pro-lipoprotein-a1
β2-inhalation
17°c
25×18×15
32°c
1,20,21
1,3,10,19
1,4,7
3,22
300/mm3
4,15
70–90
“dull”
100mg/kg/j
16550
24–48
272
520/ml
12-cm
9-mm
discussiontumors
⩽20
159/98
65–85
87/24
92/60
95/34
discussionpapillary
rv5
rv6
10,18,20,23
19,28
20×30
autotac®
discussionmembrane
extended®
gc®
“odontogenic”
“pseudo”
8–18
discussionmode
ft3
henning®
1809
200/120
3,9,10
cr=1
population’s
“linear”
10,23,27–31
10,30–31,36–38
11,15,33–35
17,25
18–21,32
1961
3,27
3,5,13,15,25
36,38
73–95
steal”
“stealing”
“steals”
“subclavian
1,11
1672
1731
bleichner’s
grynfeltt’s
“flank”
“meshplasty”
“routine”
175/77
antigens”
backgroundgoodpasture’s
goodpasture’s
o’donoghue
report:80
“hidden
12–17
1786
91/52
discussionnitrous
110bpm
2,4,5
5l
aetiology’
discussionatraumatic
gentleman’s
iv–v
i–v
kehr’s
rupture’
spleen’
‘non-traumatic
‘rupture
‘spontaneous
2,18
discussioncentral
28×11
28×13cm
arg899x
discussiontable
ift88
nphp2
nphp3
1,2,5,11
1:35,000–40,000
63,000
altman’s
cell”
discussionsacrococcygeal
hlxb9
operator’s
βhcg
“wandering
01:25
100/58
10:40
11:50
1979–2002
24/7
28°c
28–32°c
30°c
30–47
33–35°c
53–80
5:48
6:40
7:12
7:50
8:00
8:40
94/47
heart’
‘cold
“icy
−10°c
−6°c
13088
1751
201/74
3100/cmm
462
900/cmm
⩽10
115/73
1884
200cc
2cc
4–6,8–10
51-year
discussioncardiac
150/103
21,000/mcl
discussionpleural
130/81
bruch’s
coombs’
discussionhypercalcemia
111/min
365×104/mm3
discussionvod
pge1
20×15×8
discussionendobronchial
ewsfli1
086
110/68
29,30
32–34
35–37
39–43
97th
58final
arnold’s
discussionembryologically
jacobson’s
3,12,13
59final
cv2
cv2-ab
ma2
na=133
syndromes”
“classical
10–11
50final
—medication
3–72
4,6,8
64final
119/74
128-slice
40–80
57final
ct®
vital®
13-mm
5×4×3
discussionaccording
“chicken-wire”
144×109
17-month
28final
4×109/lpositioning
85×109
alarm”
discussionatls
kidney”
ullevål
“trauma
−33
15–49
18it
20pericardial
23the
34-year
38–56
decision–making
herpesvirus-8–related
rifafour®
tb–immune
virus–associated
“sc”
complications,2
t1-magnetic
t2-fluid
“elephantiasis”
“endemic
“mossy
sälgeback
süperficialis
31-day
33-day-old
5-8-mm
dağcınar
p1-p4
9-22
12/4,520
17/4,520
2/354
6-3
5-27
706
18-2
introductionanatomical
rodríguez-niedenführ
1,008
40°
adigüzel
discussionanatomical
gümusburun
discussionbasically
170°
12th-17th
discussionparts
9-15-mm
discussiondevelopmentally
introductionnumerous
discussioninstances
0±1
0±3
0±8
26±9
2±6
5002
5±5
63±9
932
5×40
6×36
8×3
8×5
a2-a5
introductionaneurysms
norrgård
discussionurinary
introductionureteric
mm×11
discussionpreviously
introductionomohyoid
introductionknowledge
t3-t4
270°
introductionvolvulus
discussiondouble
discussionhead
neutrin-1
neutrin-2
00605
22nd
t12-l1
discussionvariations
cm×0
cm×2
discussionganglion
introductionganglion
03-2
24-year-old-female
7-5
introductiontotal
29-65
6cm
855
discussionthough
0159
036 
078
0 mm2
1suprascapular
1width
1 and
1 mm2
2002—american
2003—turkish
2012—thai
2792
2bony
32-row
3suprascapular
3 mm2
4potential
4 mm2
4  middle
4–2 
4–38
5abb
5area
5 mm2
5–38
6123
6 mm2
6  distal
7–3
9area
9superior
9 mm
9 mm2
bayramoğlu
foramen—a
pap-159
rap-98
rnn/12/10/ke
table 1measurements
urgüden
use—an
 1schematic
 3structures
  proximal
—a
—the
“sling
101 mm
10–25 
1–5 
23–1
37 mm
40 days
43 mm
44 mm
45 years
4 × 2
7–12 mm
89 mm
artery”
britain66frmid-cervical
c5–6
c5–c6
ehlers–danlos
france18frc5epilepsydolichoarterial
france51mrnot
germany61frnot
japan37mrc4brain-stem
japan67mrc5temporal
japan70frc4occipital
lumen”
marfan’s
states49frnot
table 1reports
tk–64-row
turkey62mlc2vertigo
vasović
 2helical
 3three-dimensional
 5duplication
“duplication
“duplication”
“fenestration
“fenestration”
“structures
1accessory
1–2 
23 mm
25 
2accessory
3discussionthe
4proper
5gastroduodenal
8cystic
arha—arising
arteries—branches
calot’s
miyaki’s
table 1diameter
 1structures
introductiondashanga
1Āyurvedic
2Āyurvedic
3balance
4comparison
65-0
conclusionĀyurvedic
dhātuksaya
jatharāgni
jāgarana
kaphāvrta
mātrā
nidrā
nāśa
pañcakarma
rātri
sailor”
smṛtikṣaya
udāna
vyāna
vāha
vāk
vāta-pittaja
vātaroganut
Āvarana
Āyurveda
Āyurvedic
Śirobasti
Śirorogas
“drunken
1procedure
amaśaya
amāśaya
auṣdha
dhūmapana
doṣas
guṇa
guṇapacifies
introductionsadyo
kaphashāmaka
kaphavātashāmaka
kaṭuvipāka
lekhanakāri
mukhābhyaṅga
mṛidu
mṛudutva
paśchātkarma
pūrvakarma
rogādhiṣṭhāna
rūksha
rūkṣaguṇa
saindhavalavaṇam
sampraprtivighātana
shākhā
srotogāmi
srotośodhana
srotośuddhi
sūkshma
sūkshmamārgānusāri
tridoṣa
tridoṣaśāmaka
tīkṣṇaguna
ushṇavīrya
vatānulomana
vikriṛta
vikāra
viśodhana
vyavāyī
ūrdhvajatru
ūrdhvajatrugata
1medication
1timeline
brāhma
daśamūlaharītakī
dhānvantaram
introductionpontine
kasāyam
mṛdu
nimbāmrtādi
nimbāmṛtādi
pañcatiktakam
poṭṭali
poṭṭalī
rasāyanam
sindūram
varaṇādi
śopha
1before
actionmañjiṣṭhā
adhaṇkāyaja
attivivṛttavraṇa
balaguḍūcyādi
bīḍi
chikitsā
dhātugata
dośas
duṣṭa
dāha
dāhanāśaka
dīpanīya
hīkashāyam
introductionvenous
kapha-pitta-shāmaka
kaphadośa
kaś
kledāmshatā
kāla
kāyam
kṣīrapāka
manjishṭhā
manjishṭhādi
mañjiṣṭhādi
moses’
nimbamṛtadi
nimbāmr
nāśaka
raktavarṇa
shleshma-śotha
srāva
s’odhana
tikta-kashāya
tikta-kaśāya
tridośaśāmaka
tādi
vedanāhara
vraṇa
vātapradhānatridoshajavraṇa
vīrvya
yaṣṭhimadhu
yaṣṭimadhu
āsthāpana
āyam
īrapāka
Śotha
Śuntṇ
śothāvasthā
ūci
–mañjiṣṭhā
1bastitable
2basti
agnidīpti
aliptatā
anupāna
apāna
ashti-majjāgata
asthi-sandhānakara
asthidhātu
asthidhātukṣāya
aṅgagauravatā
basti-vaṅkṣaṇa-pārshwa-uru-parwa-asthi
bhedo-asthiparvaṇāṃ
bṛhmaṇa
cūrṇ
cūrṇa
dehalāghavatā
dhātvagni
dischargeamṛtottara
discussionavn
duṣṭ
dīpana
ghṛta
gomūtra
gṇa
harītakī
hingvaṣṭka
hiṅgu
hiṅgvaṣṭaka
introductionavascular
jaṭharāgni
jihvā
jihvāliptatā
jīraka
kaiśor
kalābasti
kaśāya
kaṣāaya
kledaguṇa
kṛṣṇa
kṣīra
kṣīrabasti
kṣīrrabasti
mahābhautika
mahābhuta
mahābhūta
mahāmañjiṣṭhādi
majjā
majjādhātukṣaya
majjāgata
malabaddhatā
marīca
māṃsabalakṣaya
nirāmāvasthā
pañcarasa
prasādana
pācana
pādaśotha
pādśotha
pāna
pṛthvī
rasadhātu
saghṛta
sahacaarādi
samprāpti
sandhishūla
sandhānakara
saṃskarāsya
scheduledīpana
tiktarasapradhānadravya
trikaṭu
ushṇa
vighaṭana
vikāras
vāta-pittashāmaka
vātavyādhi
vātānulomana
vātānuolamana
Ācāryas
Ākāśa
āma
āmapacana
śothahara
śuṇṭhi
śuṇṭhi-zingiber
‘9’
“10”
“9”
“vas”
“visual
ajagallikā
apāmarga
bhūtaghna
bilvādi
carmakīla
discussioncontemporary
dāhashamana
dūṣiviṣha
garaviṣa
granthināśaka
introductionmolluscum
kaphavāaja
kaphavātahara
kaphavātaja
kaṭurasa
kṇāra
kṣudra
kṣudraroga
kṣārakarma
lootāviṣa
māmsapradoṣaja
pratisaraṇīya
pīḍakas
sarpaviṣa
savarṇa
shūlaghna
viṣaghna
vraṇāropaka
“wait
1-tablet
15:200
1list
aragvāda
aragvādādi
bhallātaka
bhṛṅgarāja
candanāsava
daśāṅga
duṣṭavraṇa
ghṛtam
guḍuci
haridrāa
kaphadoṣa
kaphavikāra
kaṇḍu
kirātatikta
kuṣṭha
prakṛti
vibhītakī
viḍaṅga
viṣavikāṛa
Śatadhauta
Śatadhautaghṛtam
0mild
1-4moderate
10case
11case
1follow-up
2assessment
3action
3dried
4materials
5-7severe
5prepared
8case
9case
abhayāriṣṭa
agnimāndya
annapāna
arṣa
avyāyāma
bhaiṣaja
cūrna
dhūpa
discussionjīmūtaka
divā
i0
ii0
jīmūtaka
jīmūtakaconclusionjīmūtaka
nighaṇṭu
suśruta
takrāriṣṭa
viṣṭambi
vāgbhaṭa
Ādarsha
ṣaṣṭi
12’o
2fistulogram
3fistulogram
4during
5after
apāmārga
avagāha
aṣṭamahāgada
aṣṭamāhāgada
dāraṇā
hadn’t
introductionsuśruta
kṣārasūtra
māṁsa
nimbādi
pañcavalkala
pradeśa
prakṛiti
sannipāta
saṁhitā
āgantuja
śleṣma
1000 u/l
127 u/l
13 mg/dl
162,2 s
210 u/l
23,100/μl
317,000/μl
39 mg/dl
557 u/l
6 mg/dl
76 u/l
1,000 μg/l
100 μg/l
139 mg/l
13–150 μg/l
14 ug/dl
1 μg/l
211 g
215 μg/dl
26,387 μ/l
26,387 μg/l
272 k/ul
2 k/ul
3,000–30,000 μg/l
300–400 μg/l
306 ug/dl
325 mg
3 k/ul
49 μg/dl
50–80
5 ng/ml
5 μg/l
67 fl
70 fl
72 u/l
79 mm/hr
8–10 mg
discussionanemia
08 mmol/l
0–7 mg/l
109 cells/l
10–35 u/l
118 u/l
140/75 mmhg
150 beats/minute
159 u/l
173 u/l
20 mg/l
225 u/l
22 kpa
2 litres/min
30–95 u/l
32 m/s
333 mg/l
40 breaths/minute
4 mg/h
4 mg/kg
5000 ml
5 kpa
5–50 u/l
6 mmol/l
80/40 mmhg
8–45 u/l
− 4 mmol/l
000 iu/24 h
06 ng/ml
0–2
153 cm
18 l
1 
2/25
25–30 cmh2o
31 l
33–36
3 mbar
3 mmhg
450 ml
5 mg/die
5 mg/l
5 mmhg
600 mg/24 h
68 kg
8 mmhg
8 mmol/l
8–14
9 mmhg
aspiration1
burst”
cm0
co2-values
instability”
paco2-values
petco2
pn1b
pt1c
s4a
 3
 356
“severe
100/minute
106/67 mmhg
131/91
153/96 mmhg
160/102 mmhg
1 mmol/l
248 000/l
34 kg
3840 g
65/42 mmhg
6 gr/l
8 g/l
introductioncardiopulmonary
–10
–82
−12 mmol/l
19-gauge
1–3 mhz
2,400
2|d
2 hz
2–7 mhz
360-degree
3 ms
50-mm
5 ma
7-2
introductioncontinuous
iu-22
iu22
time—the
x7-2
“doughnut”
“flat”
57-year
patient′s
–41
“no-reflow”
discussionunder
100 mg
99m-hmpao
99m-tc-hexamethyl-propylene
introductioncomplex
05–0
08 μg·kg−1·min−1
08–0
107 mmhg
108-minute
109·l−1
10 cm h2o
10 μg·kg−1 min−1
10–12 cmh2o
110/56 mmhg
120/53 mmhg
125/80 mmhg
138/88 mmhg
13 g·dl−1
140/95 mmhg
149/71 mmhg
150/70 mmhg
1585 ng·ml−1
160 cm
162 cm
166 mmhg
170 mmhg
184 g·l−1
1 mmol·l−1
200 ml
21 ml
230 u·l−1
267 u·l−1
271 g·l−1
33-week
34 mmhg
36 mmhg
38 mmhg
3–5 mg
3–5 ml
400 ml
41 mmhg
45-minute
48 mm
4 ml·hour−1
4 μg·ml−1
52 g·dl−1
54 mm
550 ml
55 mm
5 g·dl−1
5 μg·kg−1·min−1
60 kg
61 mmhg
62 kg
6 g·dl−1
6 l·min−1
6 mg
79–120 beats·min−1
94–123/40–67 mmhg
96 g·dl−1
beats·min−1
breaths·min−1
discussionpregnancy-induced
hco3−
–50
–74
–76
–88
2issues
2scalp
5patient
μg/kg/hour
μg/kg/minute
“this
113/65
139/79
1cardiomegaly
2tricuspid
6-minute
70/minute
70–80
75/56
ventricular–pulmonary
1brainsuite
25–50
3intact
discussionbrainsuite
μg/hour
497×10
5-day-old-boy
85/40
e9/l
female=1
g7
kg-1
m-1
p6+1
“fighting
1a-p
‘b’
018
2follow
3enlargement
to1998
6913–16
6–13
flex-it®
gliderite®
glidescope®
spot”
“blind
26-g
88/minute
cm/m2
reserve”
“cardiac
introductionsymmetrical
jelco®
118/72
1wholebody
1×5
2scanned
3scanned
5–6/min
introductionhydatidosis
t9–t10
–16
–35
17-6
1993-2000
1air-fluid
2000-7000
20×10
2following
92–94
discussionmistaking
fluid”
introductiondiaphragmatic
level”
“fluid
“gas
“pleural
′regular′
22-times
90kg
160/96
164-cm-tall
164/94
1major
38-weeks
68-kg
discussionta
“pulseless
115/
18-kg
26/
80/
90/56
discussionfb
hco3-15
hco3-18
introductionforeign
pco2-29
pco2-39
po2-61
po2-72
so2-89
so2-97
1,455
1cervical
37-0
5-lead
62/
95-99
domínguez
drop’
t4-t8
‘hanging
211,903
244,796
63-kg
discussionon
gm\6
introductionleprosy
o2-carrying
patients′
110/
168/96
discussionbrachial
introductionperforming
t1-t4
100-150
124/76
14/
1subarachnoid
2accumulation
3l
40:60
70/
92/
97-99
introductionpneumocephalus
sheridan/spiral-flex®
μg/
14g
155/110
200/160
230/160
2complete
70/50
715
discussionadrenal
introductionadrenal
invasive”
“minimally
1823
75–230
introductionneuromuscular
α2-agonist
10h
1985-1987
2003-2005
37-years
3h
60/30
80/42
94/58
be/bd-12
be/bd–0
hco-3
introductionamniotic
po2162
1pre
70ml/kg
discussiondysmorphic
1acceptable
1history
2st
2typical
3no
4no
discussionbrugada
hh1
scn5a
tetrodotoxin-“insensitive”
v1–v2
v1–v3
—kerala
1congenital
2extend
3confirming
30–33
34–36°c
grade-2
introductionarthrogryposis
28g
2common
88-95
introductionbabies
‘football’
116/77
147/89
16g
5mcg/kg/min
600/mm3
60–80/min
6h
80–94
92/min
introductionebstein
α2
1cardiac
1differences
2etiopathology
3management
4diagnosis
53-year
80–82
introductionperioperative
v2-4
150/min
27-year
l2–l3
103/dl
25–100
2echocardiogram
3echocardiogram
49-year
4femoral
introductionpatent
patent”
“pencil
“probe
20–29
4910
891112
introductionsymptoms
nibp=112/65
nibp=70/42
“kounis
2l/min
3specimen
8-week-old
μgm/kg
2,30,000/mm3
2-4th
introductiondextrocardia
“stomach
1postmortem
192/110
36/min
1externally
2use
discussiondisrupted
intersurgical®
introductionfacial
1distinguishing
2121314
2indicators
3drugs
aetiologies’
introductionmyoclonus
lance–adams
–sensitive
17q21
discussionjobs
introductionjob
154/88
160/94
170-cm
2-3cm
4ct
76-kg
discussionvery
1level
discussionepidural
introductioncombined
“squeezing”
“volume
11/2
27g
introductionbyssinosis
resistance”
t6-t12
1trend
50000/μl
31/2
3landmarks
4500/cumm
86-90/50-60
95-100/65-70
chloride-97
144/90
144/92
1888
1cyanosisfigure
2clubbingfigure
93-94
1pet
introductionanesthetic
t7the
α-blocker
104/64
118/74
12-14/min
30-45
68/min/regular
72/min/s
89-92
92/45
hr100bpm
o2-0
rr10bpm
spo2-98-99
spo2-99-100
02/0
105/min
1:20000
2imaging
3electrocardiogram
4electrocardiogram
:30
introductionsitus
11,080
200-400
discussionbupivacaine-induced
introductionlocal
“lipid
1fusion
2fusion
discussionapert
introductionapert
1,00,000/cumm
106/79
1minimum
20,000/cumm
2guidelines
50,000/cumm
56,000
134/min
17,840/mm3
40,000/mm3
80,000/mm3
introductionhemolysis
oxide-oxygen–isoflurane
preeclampsia–eclampsia
0-8
1000u
312-lead
“tako-tsubo
108/78
introductionwolff-parkinson-white
waves”
wave”
wave”figure
“delta
“delta”
“kent”
116/minute
120/minute
16-20
200mlof
5months
800mlof
t6dermatomal
1polydactylyfigure
2mallampati
35°c
85th
discussionlaurence-moon
116/70
1child
51hla-b*51
discussionbd
introductionbehçet
120-200j
birefringence”
discussionamyloidosis
introductionamerican
kick”
“apple-green
“atrial
31/min
92/58
discussionicm
introductionischemic
2endotracheal
discussionairway
e2m4vt
“defatting”
11-19
127/98
148/70
15-46
15s
16-22
1changes
29-50
37/464
38,5
4/25/39
5/138/3
7/42
ml/100g/min
portex™
15-20°
1shortening
78-82
003-0
5-23
8-8
87-238
fraction-29
igf-1
introductionacromegalic
saccà
t4-
1submental
23456
hernández
discussioncauses
l2-interspace
“absent”
“collapses”
“dry
“give”
106/66
76/40
introductiondilated
/40
116/62
130/
1gangrenous
2mutilated
3gangrenous
80/46
μg/kg/hr
1direct
2direct
“sniff”
2intraoral
introductionranula
118/70
12q2
1polydactyly
2loss
abnormalities0
defect2
discussionholt-oram
examination1
life-threatening4
missing3
tbx5
thumb2
“heart-hand
“upper
110-120
12-24
introductionnegative
−50
110-130
1113
1l
35-45
55-70
discussionpseudo-pancreatic
introductionnon-obstetric
t10-11
129/84
134/90
6l/min
discussiontransient
infarction”
introductionintrathecal
126/74
1319
21,500
3-21
8-years-old
discussiontetanus
introductiontetanus
1,00,00
12-72
120/84
200/min
2517
4-16
abg-ph-7
bp-86/60
hr-140/min
hr-190/min
pco2-38
po2-103
spo2-100
spo2-92
spo2-99
t8-l1
wrong”
α-blocking
“going
“unexpected”
“unusual
“vagotonia”
1computerized
assisted”
discussioncoordination
drug”
e1v1m3
introductionterrorism
sighs”
study”
“assisted
“extended
“prospective
≤5
≥16
0400
104/47
1148
16-fold
2anesthetic
introductionanesthesiologists
“machinery”
düger
introductionadministration
t6-l2
t9-t10
wouldn’t
103/65
103/68
107/56
114/68
140/100
63/min
65/44
80-mm
anesthesiologists’
introductionopen
shot”
th7
th8
th9
2cuff
3technique
4technique
5technique
6schematic
discussionproblems
epifuse®
introductionone
portex®
1258
1carpal
2carpal
ca+2-
discussionanxiety
hco3−-14
na+-133
pco2-16
po2-30
po4−
spasms5
168/min
1tracheotome
26fr
30-37
3piece
48-55
70°
85-91
discussioninhaled
introductionasphyxiation
3spinal
anesthesia”
puncture”
“lumbosacral
“pokers
“tfs”
“transsacral
1engaging
2placement
conclusion“positioning”
firing”
introductionpositioning
position”
“hiring
“standing
128/74
1743
1arrow
21°c
34-35°c
68/min
a-vdo2
aa3
ceo2
discussioncarotid
do2
sjvo2
1general
2splenectomy
75-2
discussionhypersplenism
propofol-150
introductionhoarseness
1245
1palpable
2palpable
3:5
54/min
check”
discussioncolor
failure”
introductionmedication
“system
“triple
-96
-99
119/68
119/min
2resolving
94/56
94/min
discussionmassive
introductionpneumothorax
“lateral”
1-h
1vocal
2vocal
5-h
72-hdiscussionserious
introductionpotential
n2o+
7–14
mass2
ml/30
observer’s
ppp33
“anesthesia”
“modern”
1b+
2-needle
2c+
5-7/10
80°c
electrode’s
tests’
‘manual
1-ms
20-degree
atf3
axon’s
introductionphantom
ions’
point2
1/4
4balloon
5fluoroscopic
6ct
discussionkyphoplasty
heart’s
introductionprevalence
–40
introductionmigraine
100kgs
101kgs
1post-operative
400mls
500ml
c3-6
c4-5
c44
exposed3
factors:1
hours2
surgery5
introductiondegenerative
stageexplanation1minimal
135/90
pericardium3
90mcg/kg
feiba®
10ml
40mg
introductiondiagnostic
o2-air-sevoflurane
ºc
μgr
0,33
1,05
11/01/2012
18/11/2009
1week
1x5,3
203,4
25/01/2012
29/12/2010
30/10/2009
4,3x3
75mg
9,4
anymore”
broca’s
radiofrequency–4
1820s
discussionclostridium
introductionbotulinum
snap-25
1-α
102kg
10cm
11500
173cm
17q22-24
1985,1990
2p168
45-80
80mg
carney’s
discussioncarney’s
introductioncarney’s
jude’s
prkar1a
red/tan1
27-gauge
38–42
introductionoccipital
nerve2
discussionbupivacaine
10/20
235×10
40000
5-min
introductionpostoperative
nf-Ƙβ
poein®
0-600
0625
131i
3480
424
beta-1
discussionpheochromocytoma
endocrinologist’s
introductionpheochromocytoma
mg-2
mg-3
t8-t9
11table
d10w
g/q6h
introductioncitrullinemia
mg/q12h
mg/q8h
neurologists’
µg/kg
μmol/dl
5cc
90-92
appropri­ate
compli­cations
disloca­tion
2-26
5-19
5-26
vein3
alpha2-adrenoceptor
discussionxeroderma
introductionxeroderma
03-0
1/100/000
1/20,000
1/5000
136/75
fev1/fvc:82
no:35fr
35-years-old
42°c
5ml
picture”the
t11-t12
“christmas
“stunning”
1:100000
8:30
d’souza
introductionunilateral
n2o-
µg/kg/min
12-13
120-140
150-mm
34/min
introductiondespite
17-20
discussioninternational
introductioncluster
to15
-98
30-42
88-142
90-132/60-82
90/62
introductionone-lung
intubation3
o2/n2o
pharyngo–laryngo–oesophagectomy
–93
–98
discussionanesthesiologists
introductiontransnasal
lumen3
t2n0
1779
290/μl
4,10
4,9,10
4,900/μl
5,020
5tuberculous
67-year
6pulmonary
7macroscopic
800/μl
8macroscopic
acid‡negativenapositivecerebrospinal
culture†spinal
quantiferon®-tb
th3
th5
th6
β-trace-protein
†cultures
‡morning
0644248note
0 × 109/l
117 × 109/l
19≤0
229 × 109/l
3cm-long
3 × 109/l
516e
blactx-m-24
blakpc-2
discussionkpc-producing
hasn’t
imp ≥ 16
introductioncarbapenems
q12h
Özdemir
≤42≤1≤1≤10
≥128≥64≥6464≥1696≥8≥1680
100 mg/kg
11 weeks
1260
12 hours
16 days
19 days
1:8
258 mg/l
2brain
2cells/mm3
2 mg/l
3imaging
400 mg
48 × 73 mm
4 mg/l
8 mg/l
cell/μl
discussionsalthough
inshi’s
introductioncryptococcal
magnification × 40
magnification × 400
t2-flair
yeasts/μl
≥1:32
0 g
100 kg
10 years
11,12,19
117 cm
12,20
13 years
14,39
15 mg/kg/day
16-18 kda
178 cm
1980-1990s
2-yr
20 mg/day/kg
21 mm
26-28 kda
2thoracic
2 week-interruptions
30-yr
30 km-range
30 years
387
3positron
3 years
45 kg
45 mm
52-yr
6,22
6 years
7,36,37
7 kda
9 years
a10
a11
administration’
ae”
b13
b41
besançon
biomédicale
ccpprb/franche-comté
comité
dq3
dr13
em2
em2+
franche-comté
introductionalveolar
margin”
on”
risk’
surgery”
tapeworm”
‘at
‘cyclic
‘tolerance’
“cyclic”
“discontinuous”
“fox
“immunogenetics
“inactive”
“inactivity”
“multi-organ
“m”
“n”
“opportunistic
“pseudo-tumor”
“radical
“radically
“radical”
“security
“tumor-like”
“tumor”
2/μl
2zeil-nelson
4/μl
5/μl
95/50
ziehl–neelsen
μg/0
104536
108297
108541
15-locus
1tree
2177
3163
3320
3398
3416
37-year/old
4038
4093
4356
7,8,22,23
9,18
bact/alert®3d
discussionm
fr/recherche/genopole/pf8/mlst/myco-abscessus
inter-patients’
ionization–time
mlst2
münchausen
st1
tr109
tr116
tr150
tr155
tr172
tr45
vntr3
03 × 109/l
12 days
2-g
2 days
2–15
38 × 105 iu/l
5 mg/l
68 × 109/l
8-time
876
91 × 109/l
927
discussionparatyphoid
 ≥ 0
11-mm
12,250
1894
discussionstercoral
-120
-40
339,000/mm3
introductioncancers
10,800/mm3
11,900/mm3
111/75
12,300/mm3
t3n2m0
~7
125-mmhg
3-times
5-fluorouracyl
introductioninsufficiency
pt3n1m0
myod1
pms2
1,918
106/ml
13,960/µl
224,000/µl
67-years
4,020
7,316
t2n2bm0
10-46
18-fluorodeoxy-glucose-positron
discussionintramucosal
rpt3n1b
rpt4an0
sm1
236,000/mm3
5,900/mm3
8-cm
type-1
introductiondiverticular
1-cm-sized
13,300
309,000
5-mm-sized
discussioncomplications
113u/l
186/113
6,490
7/10
7-cm
27-month
4-gy
discussiondifferent
introductionperineal
parietex®
pt3n1am0
cox-1
discussioncancer
13,500/mm3
335,000/mm3
muc4
α1-antichymotrypsin
1916
28f
discussionetiology
124-meq/l
132-146
132-meq/l
289-308
3-22
300-900
5-50
5-g
532
55-4
89-1
9-23
1827
19,700
introductiontransrectal
ptisn0m1
tisn0m0
tisn0m1
3-cm-sized
7-cm-sized
0/20
discussioniscm
gr2
gr4
introductionintramedullary
28-fr
cm2-sized
introductionperianal
0×2
18,943
36-month
5,7-19
6~3
acid22
ahmed2
areas2,3
bccs2
costs22
dermatitis6
discussionchronic
disease2,23
months~20
neck1
world5
amlodipine8
bite4
case9,10
discussionga
exposure5
extremities2
ga1
infection7
observed2
photochemotherapy11,12
vaccination6
4-amino-4deoxy-10-methyl-pteroyl
72×103/mm3
99×103
discussionmtx
disease1,2
disease5-7
effects1,4
hla-b51
insufficiency3,4
introductionmethotrexate
reported3-6
synthesis1-3
turnover3
199613-16
28-year
30~35
50s
chondrosarcoma8
gene6
imaging11
layer3
lesions7,9
lipoblasts1
liposarcoma4
pleomorphic4,5
predominance2
prognosis10
retroperitoneum1,2
surgery12
1825
alternatives18,19
cause9,10
complete5
discussionprs
disease11-15
disorders7
introductionparry-romberg
involvement24-27
jablonska21
life3,4
nerve5
parry1
romberg2
scalp20
scalp6
stable11,16-18
unknown5,8
witman22
200210
activity3
apoptosis6
eyrthematosus8,9
modalities2
potential3,7
tnf-α3,5
weakness1
weakness4
1~4-mm
abdomen5
affected6,10
borders4
burgdorferi6
cases7,8
discussionatrophoderma
normal6
pasini1
rufli6
treatment6
vivoli2
yet11
4an
5-fluorouracil8
85-year-old
hands1
infundibulum6
intervals10
ka15
ka9
kas13
scar4,5
scc1
scc7
specificity7
successful10
weeks2,3
1798
contraceptives3
discussionerythema
equal4
gel®
levels6
malignancy1,4
nodosum4
nodosum5
nodosum7
panniculitis2
patients6
progesterone1
progesterone9
vagina10
women5
activities2,19
antibiotics2,17
borders11
capacity2
carcinoma3,12,14
colitis4-6
common8
cultured7
discussionblastomycosis-like
dysfunction8,9
follows13
greatly2
immunocompromised1
immunodeficiency3-5
infiltration11,12
introductionblastomycosis-like
laser15
microabscesses1
pyoderma2,18
theory8,10
47061
ab240943
america17,18
aquaspersa14
b1-3
cases9-13
discussionchromoblastomycosis
disease1-3,5
disease6
incidents1,2
introductionchromoblastomycosis
japan4-7
phialide2
plaque5
samples9,19
spinifera1-5
subjects16
verrucosa15
36~62
5:2
adenocarcinoma1-3
common2
diagnoses1
excluded1
far1-6
literature1-6
lung9
metastasis1-6
patient6
reticularis12
stomach1
subtypes11
vessels1,5
actin4
cooper2
discussiondfsp
history1
introductiondermatofibrosarcoma
myxofibrosarcoma6
neck3
neoplasms5
03×103/µl
094×103/µl
0~19
2-week-old
25-day-old
3,150
36-day-old
5×103/µl
626×103/µl
6~8
83×103/µl
complications20-23
discussionem
drugs10
examination9-12
infants3,4
infection12
literature3-7
longer17-19
nodosum13,14
protein9
reaction15,16
vaccination11
126-9
caseation18
cgpd3,13
dermatitis5
discussioncgpd
dyspnea15
edema16
girls6,7
introductionchildhood
irritants3
lesher5
solutions11,12
women17
colleagues9
lesion1-4
literature10
location8
ns5-8
4:17
approach18
cysts3-5
derivative3
explanation10
follicles7,9
origin1,4,5
origin3-5
regions4,8
respectively1
tree1
croatia1
croatia1,2
erythema5
introductionmal
mdm6
mdm7
needed9
ppk8
slurp-1
soles4
taiwan1,2
taiwan3
19947
allyn®
amof14
amof8
amplification13
area9
asians1
epidermis6
episcope™
inspection11
melanoma10
outcome3
phase13
skin12
3,960
65,960
bloom1
case4
cases2-8
foliaceus16
literature2-8
psoriasis15
report13
treatment9-12
carcinoma2,6
carcinoma3
carcinoma8
care7
contact4
digit3,4
digits3
discussionsubungual
graft7
injuries2
introductionsubungual
joint7
malignant7
pathologist7
patients3,9,10
predisposition5-7
type4
4×103/µl
6×109/l
enterococci2
mercury3,4
mrsa1
present5
1,023
11~13
124,000/mm3
2,221
30,110/mm3
6-phosphate
657
agarwalla3
aging1
agranulocytosis1
cases16
daponse1
dapsone1,3
dermatitis1,3
discussioneed
disease7,8
edema1,3
eed5,6
effectiveness1,3
effects1
erythematosus1,3
extremities4,5
features5,6
findings1,3
findings5,6
function2
g6pd-deficient
hemolysis1-3
hepatitis1,3
hours13
introductiondapsone
leukocytoclasis5,6
mediated4,5
methaemoglobinemia2
period14
sign9
syndrome1-3
therapy12
therapy14
toribio15
achieved6
dysraphism1-4
hemangiomas1
introductionfaun-tail
lasers9,10
techniques5,6
ablation4-8
elsewhere3,13
introductionpincer
methods4-9
nail1
pain2
pattern10
respectively4,12
severity7,11
shoes3
7~14
agents9
dermatosis10
discussionpsoriasis
disease3,8
koebner2,6
neurosurgery1
radiotherapy2
reaction7
state1,5
structures11
system1,5
t1n2
trunk4
arteries9
bellagen™
bellagen™-based
cultures3
departments5-7
discussionacellular
enhancement4
fascia3
function9
girth3
grafting3
introductionaesthetic
kmno4
media1
micheels11
rate4
surederm™
technique2
viability10
0~5
20~44
60~80
acantholysis1,3
affected5,6
cases1,3,4
cases4,11,12
dapsone19
disease9,10
disease9,13
dsg3
effect16,17
fatal1,2
gürcan
igg4,11
immunoglobulins3,15
keratinocytes1,2,4
lesions17,20
level19,20
manner17,19
plaques1,2
published8,16,18
pyoderma1,3
relapses4,7,8
reversible19
steroids1,16
subtypes1,3
tongue9,10
type2,7
uncertain13,14
vegetans1,2
vegetations4,5
vesiculation3,4
vulgaris3,11
agents3,5,12
anti-vegfr-2
arise3,4
available15
cancer10,19
cancers7,8
cancers9,10
cells7,8,15
changes9,19
d4200c00077
dermatitis1,2,14
discussiondrug-induced
docetaxel9,10
entity1,2
feature1,4,14
introductiondrug-related
keratinocytes3,14
kinase6,7
kinases6,7
light1,2
light2,3
nature1,11
pan-epidermal1,4
photoallergy3,4,12
photoreaction12,13
photosensitivity9,12,13
photosensitivy16
polymers9,10
predictable11,13
present2,14
prolongation6-8
reactions3-5
reactions9,10
receptor-2
spared1-4
t2n3m1
taxotere™
trial17
tumors15,16
tumors17,18
vandetanib20
vegfr-2
zactima™
zd6474
discussiongga
effective2,10
korea1,3,11
literature3
type2,10
vaccination2-5
vaccinations3-9
years1,2
19801
5-aminolevulanic
633±6
base12
cancers14
column13
discussionpeoddn
effects3
extremities3
forms5
introductionporokeratotic
invaginations10
levulan®
pathognomonic9
peoddn11
plugs3
porokeratosis15
porokeratosis5
revive™
skin2
up2
1,520/mm3
114~286
19421
1b~d
2,559
2~1
37~150
66~110
80~220
degeneration10
develop6
discussionae
elements4
infiltration3
keratinization9
methotrexate13
paronychia2
perform7
polymerase7
previously4,5
tissues7
vesicles3
vesiculation3,11
weeks7
zinc8
180®
allegra®
allergy15
cases6,11,12
discussionfexofenadine
h1-antihistamine-induced
hypersensitivity14
introductionh1
kit®
literature2-13
own2,4,9,13
rare1,2
reaction9,10
shock1
system7
tests4,12,13
xyzal®
1/100,0001
150~400×109/l
2a~d
3,400/mm3
4,500~1,0000/mm3
560/mm3
90~180
99×109/l
children8
discussionhematological
hyperemia7
incidence2
jsle10
jsle3
lesions4
mortalities9
severe3
sle1
sle6
years10
0~20
ankles2
autoantigens12
criteria6
dapsone6
discussionextra-intestinal
disorders4
erythema14
leukocytoclasis13
respectively15
symptoms1
dermoscopy8
role8
sh7
shaft9
size6
structures1-4
study10
0~41
17,500/mm3
3,600~10,200/mm3
3-hydroxy-3-methylglutaryl-coenzyme
aminopenicillin4
apoptosis4
database8
discussionsjs
epidermis4
indications8
introductionvandetanib
medication7
person-years4
sjs8
study2
syndrome6
targets5
vandetanib1
zactima®
cancer15
carcinoma6,7
cavity3
discussionverrucous
entities8
far9,10
hpv-11
hpv-6
hpv1,4,13
introductionpenile
metastasis4,10
sccs2
skin4
system14
tumor12
unclear10
used15
1,2,5-7
9-months
alopecia1
brittle2,3
decalvans11
degenerates6
differentiation3,8
discussionegfr
egfr1
follicle10
follicle6
follicles6
infiltrate11
jih9
monotherapy1,2
paronychia3
settings4
site6
tarceva®
19591
1:120
79~152
cases2-11
claim2
difficult14
discussionbullous
entities11
erythematosus3
factors2
hep-2
lsa19
morphea15
morphea16
obliterans13
occlusion3,12
skin20
uva1
dermatitis6-8
discussionimatinib
eruption11,12
gleevec™
helpful18
introductionimatinib
psoriasis9,10
pustulosis4,5
rash1,2
reaction13,14
reaction15
reaction2,16
reports11,12
sti571
successful19
syndrome3
transduction1
arteritis5
avulsion9
carcinomas4
cholangiocarcinoma8
conditions1
discussionscalp
dissemination2
gangrenosum6
mellitus10
osteomyelitis12
patients11
remission13
site2
ulcer3
77×109
acid5,6
administration1
dermatoses13
dermis12
eruptions1
ibuprofen3
leukocytosis1
levofloxacin10
neutrophils4
only6-9
prange5
process3
properties14
reported15
response2
woman11
contact11
discussionau
effective17
erythema8
formation2
formation6
histamine1
introductionaquagenic
later3,4
minutes2,9
proposed10
rawnsley1
reported3,5,6
response2,16
solvents13,14
stress2
symptoms8,15
temperatures9
test2,7
tkach12
urticaria2
urticaria6,8
urticaria9
vary2
wheals2
10~50
17-propionate
areas12,15
cancer4,5
circumstances9,13,15,17-19
corticosteroids6,7
cutis1,2
disease16
disorders9
dm9,10
dysfunction4
group6,7
hla-dq7
observed11,14
profunda1,21
reduction1,2
respectively11
sclerosis1,21,22
shoulders1-4
treatments12,18-20
17×103/µl
39×103/ml
agep5
amines5,6
antibiotics1
lacquer2,3
reported4-6
reported9
required1
ryan7
system2
1-3-maximal
1960s7,9
adnexes8,9
calmette-guérin
cellulitis14,15
derivative9
fde1-3
fde10-12
fde4,5
fde4,5,14
kidney8,9
l2-maximal
penis13
penis3
point7,8
presented6
route16,17
th6-th10
ureter8,9
vaccination4
venepuncture5
zones7,8
cgf®
cgf®3
discussionduoderm
dressing12
duoderm1
extrathin®
extrathin®2
healing1
introductionhydrocolloid
reported1,4-11
antibodies4
bp180
bp230
bp9
bullae6
conditions7
mds8
reports2,5
steroids2,11
therapy2,10
uncertain1,2
-1αβ
0-day-old
20~100
application8
births3
dressings4
eb9
epithelialization14-16
factor-αβ
factor7
healing5
k903
kaloderm®
membrane2
periphery12,13
resistance6
results11
12q23-24
2,8-11
abalation6,13
areas6
comedones13
familial1,2
introductiondarier
responsible12
serca2
trait7
1/10~1/2
alternative3
drug5
protocol4
1,017
43-9006
95~280
bleeding15
discussionten
disease5,6
introductionadverse
life-saving14
malignancy2
medication7,8
nexavar®
reactions17
role13
sjs-ten4
symptoms1,3
ten16
tissues10-12
weeks9
factors5
infection4
injection7,8
introductionlocalized
irradiation2,3
site9
stress1
19-month-old
21-month
adulthood13
deposition3
deposition9,10
discussioncalcinosis
forms5,6
introductionmilia-like
micc1,11
old2-4
patients3,7,8
scarring7
to21
years2-4
behavior6
cancers4
cases1,3
highlighted1
plane3
sccs1-6
subtypes3
theory5
conditions10
css6
described2-5
discussionws
disorders2
hyperpigmentation7
introductionwells
lesions8
presentation9
regimen5
systems10
ws5
1920s
20×14
canter7
damage3
develop4
introductionnicolau
recurrence1
report69-year-old
reports5-7
syphilis1,2
8-associated
carcinomas6
edema2
interferon-α16
ks15
ks15,18
ks7
lineage9,10
liver11
patient8
patients3,4
progression3
status12,13
tumors17
warranted14
5~30
absent6
bch13,14
bch17
cases15,16
cd1a12
cells8,9
disease6-9
disorder2
entity16,18
geh6,8
jxg12
lch9
literature2,4,5
mellitus10,11
neck2
present3
reported13,19
scars2
11~14
1919
5~6
8~24
decades18
described4-11
eyelids1-3
eyelids15
finger17
fuchs13
gestation14
introductionkissing
literature4-12
nevus16
outcomes10
penis4-11
prepuce4
reported1-12,14-17
0~9
5,7,15,16
amyloidosis5
cells4,7,12
degeneration3
deposits8,9
diameter3,10,11
discussionamyloid
keratinocytes1-6
predilection5,7
protein2
size1-3
skin1-3
2~8
2×3×1
9×10
ae1/3
carcinoma3-5
cm1
copeland3
empd1
empd4
gland6,7
homeobox-2
literature3-5
malignancy8
mnf116
mucin2
receptor2/neu
vimentin3
51-year-old-man
abnormalities7
anti-dsg-1
anti-dsg-3
folliculitis2-5
hairs2,3
lesions2,3
localized1
scalp2,3
stage9
state8
units6
antagonists5,6
antagonists9
aphthae2
bht3
discussionbht
effect2
kessler3
mice8
t4n2m1
tongue3
tongue4
200bp
5'-aag-tgt-tgt-tcc-act-gcc-aaa-3
5'-aca-cgg-cys-tgt-att-act-gt-3
5'-act-ctg-cag-cct-ctt-ggg-cac-tgc-tct-aaa-3
5'-agt-tac-tat-gac-cta-gtc-cc-3
5'-cac-tgc-agg-ctc-aag-att-gct-cag-gtg-gg-3
5'-ctc-tgc-aga-atc-cgc-agc-tcg-acg-cag-ca-3
5'-ctt-cct-gca-gat-gac-gtc-tcc-acc-gca-agg-gat-g-3
5'-ctt-cct-gca-gat-gac-tcc-tac-aac-tcc-aag-gtt
5'-ctt-cct-gca-gat-gac-tcc-tac-aac-tcc-agg-gtt-g-3
5'-ctt-cct-gca-gat-gac-tcc-tac-acc-tcc-agc-gtt-g-3
5'-ggn-act-gca-gga-aag-gaa-tct-ggc-att-ccg-3
5'-gtg-acc-agg-gtn-cct-tgg-ccc-cag-3
5'-tga-gga-gac-ggt-gac-c-3
5'-tgt-aat-gat-aag-ctt-tgt-tcc-3
5'-ttc-ctg-cag-atg-acg-tct-cca-act-caa-agg-atg-3
6/35
activation16,17
cd20+
cd202-10
cd8-cd30-
chemotherapy20
gene2-10
introductioncd20
jgt12
jgt3
jgt4
monoclonality18
patches11
positive19
recently2-10
reported11-15
specified11,21,22
transformation6
uchl-11
v10
v11
v12
v8
v9
vp-16
carcinoma6
cases9
detected9
discussionporokeratosis
dsap3-7
dsap3-7,10,11
introductiondisseminated
lesions6,7
porokeratosis8
ridges1,2
surfaces1,7
19883
3~32-years-of-age
5~67
adult1,2
arm8
discussionhobnail
introductionhobnail
literature7-16
persons3
proposed4-6
torrelo18
24-year
agent1
cases5
considered8
discussionvasculitis
exclusion6
extremities6
fluoxetine9
headache1
inhibitor1
injury4
introductionsibutramine
manifestation13
necrosis6
noradrenaline1
paroxetine10
potential2
pustulation6
rate2
rechallenge5
reductil®
reported11
response8
reuptake2
sibutramine3
vasculitis4
vasculitis7
vasculitis8
discussiongeographic
glossodynia1
immunodeficiency6
infiltration9
introductiongeographic
leukoplakia8
map1
mm1,4
pain7
severity3
symptoms5
unknown2
vit-b12
wear6
glaucoma1
infancy1
introductionsturge-weber
lesion4,5
prognosis4
symptoms6,7
active11
discussionlfe
elastin1,11
face9,10
keloid13
lesion2
literature6-8
sato14
sd3-5
sd4,12
staining1
tissues2
tissues4,5
benefit9
clinicians3
collagen3
cross-sections1
dermatofibroma6
fibers3
indicated1,3
introductionleiomyomas
locations1,2
piloleiomyomas1
piloleiomyomas1,3,4
stains1,3
subcutis1
success7,8
tumor1,2
unclear1
6×2
circumscribed4
degeneration7
differentiation6
gct1
gct1,4-6
gct4
immunohistochemistry1,4,6
introduced3
nik-c3
nn-gct1
reactivity9
scar8
trunk5
8×2
cells12,13
derivation13
described1-6,8,9
develop17
glands5
jordaan18
literature2-10
nevi1-6
nevi13
nevi8-10
nevi9
papules14,15
scap16
stroma11-13
taas1-11
tumors13,19
3×4
ae1/ae37,10
antigen7
cells7,8,12,13
desmin8
displayed2,6,9
heterogeneity3
lipids2
melanoma3
melanoma5
morphology11
myoglobin11
series6
11-20
40-years-old
5,7,9,10
96-years-old
assess1,5
dermis2,5,8
discussionesos
implantation11
introductionextraskeletal
months4
osteosarcoma1
osteosarcoma2,3
periosteum1
report11
sarcoma4
sites12,13
tissue7
wilson6
arthritis6,9
arthrosis10
cmsc6,11
cmsc8
nodules1,2,4,6,7
origin1-8
rare10
scar1-8
studies1-12
syndrome3,10,12
0~17
150~350×103
36~72
4,030
45ro
4b~d
53~334
555×103/mm3
5~17
5~8
614~1,295
79a
8±12
amyloidosis6
anti-il-6
areas13
attempted17,18
cases8-15
cd17
discussioncd
factor-β
factor11
females1,9
follicles9
hypoalbuminemia18
increased10
lymphoma10,15
multicentric2
patients21,22
pemphigus4
pericardium1,16
proliferation1,2
purpura5
results12,23,24
role10
sarcoma7
syndrome1,17
type18
type2,12
types17
vessels19
3×1
discussionscap
epithelioma3
fisher12
glands1,2
hamartoma15,16
ns4-10
reported2-10
unit14
winkelmann13
18f-labeled
6~12
cancer4
discussionlung
ercc-1
kanazawa10
katlic9
lower-grade5,6
months9,10
type3
5~3
concentration4,9
csa3
cysts2
factors1,2
fk506
keratinocytes7
masses1
phase3
rate2,3
remnants2
tacrolimus2,3,5
tacrolimus4
tsukubaensis1
8×1
discussionfsch
doesn't1,2
fsch3-6
introductionfolliculosebaceous
neurofibroma10,11
nodules9
scalp2
stf7
1285delc
1733insc
197416
4-14
ackerman18
acrochordon7
clinically13
conditions5
continuously4,23,24
decades10,11
disorder17
dubé1
fibrofolliculoma5,12
histologically7
mutations22
neoplasms9
nm_144997
patients21
pneumothorax3,8
protein10,21
stroma1,14
suggested2,3
syndrome1
trichodiscoma15
underdiagnosed7,20
429th
7-fold
acrochordons1
etc8
h429pfs*27
improvement9-11
indicated7
mutations1,4
preventive2
previously6
under-diagnosed2,5
unverified2-4
worldwide2
1,4-7
appearance6
clinically1
diameter2,3
discussiongves
p63+/sma+
present6
rosettes3
s-1008-10
secretion11
ulceration1,5,7
14-month
18936
2-fluoro-2-deoxy-d-glucose
20069
adenomatosis3-5
bcc11
dermis12,13
epidermis14
lesions15
metastasize3
now1,7
reason10
recommended3,16,19
sites16-18
spread5
0~1
0~27
0~3
110~200
14,053
3/0
cancers6
literature13-16
metastases2
metastases7
penis12
t2n1m0
weitzner17
carcinoma1
dvorszky4
joints3
organs1
proliferation6
schwartz2
schwartz3
surface1
tgf-α
1200l®
40c
570~730
ankilite®
discussiondsap
intermediates3
introductionphotodynamic
parameters4-6
porokeratosis2
1800s
2,490/µl
4,870/µl
age5
aml13
aml6
chemotherapy16
development8
diagnosis15
discussiongs
disorder7
green3
king2
leukemia17,18
lineage11
misdiagnosis8
proptosis4
rappaport3
rates14
remission1
reported17,18
seen9
survival14
tumors10
useful12
60~70
area12
fibers11
foci8
formation13
ganglia15
joint16
lining13
lotzbeck1
lymphatics9
men12
mucin10
mucin13,14
neurofibromatosis6,7
patient4
respectively3
sole17
structures5
texture13
vessels1
5-ac
7,8,11,12
cea11,12
discussionpresently
molecule8
muc-2
origin10
regions2
scrotum5,6
years1
years3,4
ck8
differentiation2
discussionclassic
disease2,3
reported2,7-9
nevus8
ns4
ns5
ns7
phenomenon8
time1,2
trichilemmoma6
trichoblastoma3,4
trichoblastomas8
vulgaris10
31×0
arthritis14
carcinoma12
cases1-7
cea2,7,14
pressure1-7
selye8
surgery9,10
syndrome13
tendon11
trauma1-7
vivo16
cd34-
cd68+
diagnosed2
discussionbased
fibrohistiocytomas3
introductionbased
leiomyosarcoma5-7
subtypes2
19217
collagen5
ctn14
discussionctn
fiber1
introductionconnective
lesions12
literature1,3-6
organs8
osteopoikilosis9,10
skin15
skin3,5,6
steiner3
synthesis11
t1-3
10×8
abnormality10
becker1
cells4,5
cutis4
dermatofibroma5
discussionbecker
hypoplasia3
koopman8
males6
morphea5
nasemann13
neoplasm5
people2
syringomas5,12
techniques11
adipocytes4,7
adipogenesis8
angiogenesis9
appearance3
cells5
discussionsinus
emphasized1,3
fgf-2
fletcher1
introductionsinusoidal
lesions1-3
miyachi2
response10
stroma1-3
tissue4
25~66
area1-4
associated1-4
cystadenoma11,12
discussionhidradenoma
glands5-7
good1-4
involved9
papilliferum1,5-9
papilliferum11
pattern2-5
region6-9
seen6
size9
cryotherapy1
discussionsm
excluded8
introductionsteatocystoma
junction1,2
material1,3,9
reported1,4-7
scalp1,4
scalp1,4-7
wall3
bochdalek2
calcification5,6
discussioncartilage
examination9
heteroplasia4
irreversible9,10
often7
otalgia8
relief11
wassmund3
11×9
antigen4
nerves1
neurofibroma5
aans3
body2
chevallier2
cyst1
discussionpseudocyst
introductionpseudocyst
literature4-7
mg/day1,4-7
occlusion1
scalp8
6·2×109
aml-m1
aml-m3
aml15,16
discussiongranulocytic
hypothesized7
introductiongranulocytic
leukemia6-11
sarcoma1,9
sarcoma17
syndromes1-5
10~35
7~6
alm8
introductionmelanoma
melanoma9,10
melanomas1
melanoma…
metastasize5
pigmentation7
years6
…regression
11,020
3,600~10,200
62-year
agent3
attack5,6
conjunctivitis2-4
drug1
feature6,7
itraconazole2,3,5
literature2-4,10
membranes2
mg2
performed3,8
performed6,8
petrolatum10
pigmentation2
prominent6,7
safe3,4
sites3
5-y
cd56+/-
cd56+5
cd7+/-
cd8+/-
cgd-tcl10
cgd-tcl8
dermatitis10
difference6
discussioncgd-tcl
epidermis5
f1-phenotype
fungoides10
lymphoma2
lymphoma3
present10
prognosis5,10
prognosis8
seen6,10
sub-type2
sub-type2,5
sub-type6
survival9
tcrγ
tcrδ
uvb12
βf1
γ/δ
angiomas4
canal6
condition2
date8-11
hemangiomas3
kidney7
proliferation8,9,11
unclear2
8×0
adults9
granuloma9
implicated4
membrane3
mucoceles2
options6-8
results10
trauma1,2
years1,5
60×109/l
arenas13
atkinson8
bed2
disorder10
floccosum10
hhv-8-specific
introductionproximal
matrix1
plates2
pso1
respectively5
species4
sporanox®
variants3
virus-8
χ2=11
3b-d
6×8
chronicity3
destruction12
factors3
keloids6
mechanisms11,12
results8
subtype2
thigh1-3
tumor4
1877
buttocks23
cheek8
cheek8-11
e13
equal16
eyelid9-11
face18
fingertips24
illness22,23
introductionsubepidermal
kellaway15
kim8
often17
period3,4
scn20
smooth1
staining12
staining18,19
surface9
tezuka19
thighs22
trauma2
winer14
years11,24
19682
19793
5~15
back1-3,5,6
bundles3,5,6
collagenomas3
discussionfcc
lenticularis7,8
macules6
nigricans2,4
osteopoikilosis9
patients10
quantity3
reasons11
sclerosis3
structures1,3
10~20
2~6
bsc5
cancers2
carcinomas4,5
cure6
dissection9
entity6
examination2
introductionlymphatic
life4,5
lymphadenopathy5
pathophysiology4,5
scc3
types3
types5
05~0
1,575,000
1,740
12/µl
3~4
3~8
4,000~10,000/µl
40~83
41,410/µl
70~100
715,000
annular8
birth1
common10
delivery1
lesions6
nations2
pregnancy1
pseudoparalysis5
syphilis3,4
1µm1
acid-fast17
actinomycosis9
cases19
difficult1
drainage3
genitalia5
granules16
granules9
hosts15
inadequate9
infections4
inflammation3
interest11-14
involvement20
life8
media18
negative17
observed10
recurrence9
region7
tracts2
12×9×9
6×5×3
cancer6
centimeters2
cysts10
epidermis2,5
juhász
masses6-8
other8
periods6
seen10
shah4
surgery7
szócska3
trunk1
0~7
125,000/mm3
40~74
cd1a/s-100
disseminatum9,10
ham56
hypothesis12
literature2,3
spectrum5-8
studies5,12,13
work2,3
year7
20-positive
8,457
associates2
bladder7
brain10,13
breasts4
cells2,12
cervix5
colon9
diagnosis14
discussionlcnec
gallbladder6
literature10,11
lungs3
metastasis9
microscopy1
ovaries8
reported4,10,11,17-19
350,000/µl
4,000/µl
a-68-year-old
blood5
developed9
diseases6
findings7,8
foodstuffs1
infections2,3
introductionaeromonas
literature11-13
patients14
researchers6,10
studies1
β-hemolysin
amlodipine2,3,5
blockers1-5
discussioniatrogenic
erythematosus5
introductioncalcium
isotretinoin6
reported1-5
telangiectasia2
urticaria1
verapamil8
52~23
angiography5,6
eruption2
iomeprol4
iomeron®
iopamidol7
iopamiro®
iopromide2
media2
media3,4
media4
medication1
omnipaque™
reactions2
structure2,6
tetracyclines1
ultravist®
value2
189410,11
196012
3-q31
35~50
9q23
bccs3,7
bccs6-8
cyanosis19
depth9
diagnosis13
diameter3,5,16
discussionbcns
expressivity1
gene4,5
korea5,9,16-18
korea9
lesions2
observed17
pinkus6-8
present14,15
scoliosis12
syndrome17
syndrome4,5
trait1
29-day-old
activation16
crusted7-9
discussioncshrh
granules13
histiocytes14
introductionlangerhans
involvement1
korea2,3
lch1
maturation17,18
underreported6
variant7,15
years19
19688
2,330
atresias6,7
correction11
eb1
eb5
itga6
itgb49
mucosa10
period4
sepsis4
sub-type2-4
α6β4
1+~5+
197911
2:11
5~3:17,11
areas1-7
college8
discussionchung
fibromatosis13
foot11
fts11
introductionfibroma
macrophages10,12
old1,2
q31-32
thumb1,2
years9
-δ
19798
199910
19999
authors2
cd45ro
cd45ro+
defined11
described4
detected16,17
disease3
erythematosus4-6
fungoides4
introductionpoikiloderma
malignancy16
mf3
origin1
predilection1
premycosis2
specific18
antaya5
congenital8,9
dermis3,4
discussionpe
entity2,9
females3,4
fibers9,12,13
fibrils8,9,12,13
fragmentation9
history5
inflammation1,2
introductionpapular
jirarattanapochai8
lesions15,19
nevi7,8
osteopoikilosis11
pe18
proteoglycan6
spectrum1,5,15
trait16
3d-crt
beam10
discussionfor
gy9
introductionmycosis
lesions10
margins1,2
mf5
radiotherapy6-10
therapies1,7
tissue10
uva-1
women1-4
11-years-old
19311
32-years-old
a698v
akv2,7
akv5,12
change12
discussionakv
disease5,9-12
finding6
introductionacrokeratosis
mckusick4
p602l
panja12
predilection2,3
reported3,6-11
round11,12
wilson5
areas12
extremities5
korea1
obstruction2,15
radiotherapy13,14
radiotherapy2,5
scalp3,4
scar6,7
site8
vesicles13
wall2
19481
alfa17
carcinoma18
carcinomas8,9
inflammation3,7
introductionverrucous
lip11
lip2
papillomatosis2
reconstruction10
reported4
warts11-16
28-years-of-age
4-month-old
adults2
cd344
cd347
childhood6
epidermis1,2
fat2
fibers5
hormones2,5
introductiondermatomyofibroma
nodules4
period1-6
surface8
150µm
4®
595
600µm4,5
8-week
capillaries14
change2
discussionpws
effective10-13
introductionport
perfecta®
photothermolysis1
sr®
treatment1
veins8,9
visible3
yag6,7
0~15
13,7-16
79×106
9×103
ck-719
ducts2
limbs2
mehregan1
reizner20
α-feto-protein
1848
anemia10
described1
discussionhed
finding5
g-6-pd
g-6-pd-deficient
g6pd11
glands4
hed6
introductionhypohidrotic
normal9
planning7
worldwide8
xq12-q13
xq2611
10/15
10/37
11/15
12/33
12/35
12/37
14/33
19683
28/37
30/37
32/37
5/37
9/14
antigen2
article2
cases2,4
cases6-16
channels1
child2
eah5
eruption8,16
mastocytosis2
n=6
n=9
reasons2
reports3
structures2,4
0~110
alopecia3
brandt1
danbolt2
discussionacrodermatitis
established9
level5
level6,7
normal8
occur8
activities15
ad1
challenges13,14
crucial8
discussionad
foods17,18
histamine7,8
hypersensitivities9,10
interleukin-31
intolerance11
intolerance12
involved2
protopic®
score5
symptoms3,4
5-aminolevulinic
5×6
7~0
activities1-4
appropriate5,13,15
cells5,15
dermatitis12
disease13
etiology2-4,6,7
lamp®
lesions14
locations2-4,6
neck2-4,6,7
rapidly1,8,9
sbcc6
subtypes2-4,7,9
treatment15
type1,6-8
30~40
both3
described9
eliminated6
interleukin-67
literature3,9,11,12
manifestations1
noted8
patients5
reticularis3
schwannomas10
women2
25-dihydroxycholecalciferol
2d3
2d316
50µg/ml
activity13
alopecia4,5
arm9
arthritis8
cells12
cycle3
cycling3
d-1a-hydroxylase
d3-resistant
discussionaa
dominance11
downregulation7
genes1
growth3
growth6
hormones1
il-1214
production10
production15
receptors7
self9
1α
azathioprine13
case7
discussionpityriasis
flora10
globasa1
il6
inadequate2
known11
melanocytes2
pathogens12
patients8
penis6,9
17th
changes3,8
chest1
extracts5
histopathologically8
introductionpigmentary
pregnancy3
progesterone4
suggested2
conservatively3
core2
diagnosis3,4
jadassohn1
lipomas2
rings11,12
valves9,10
veins8
30~60
4~7
9,000
adults6-8
age1,2
checklist16
discussionivig
elam-1
ivig17
kimata6
reported6-12
self-limiting15
study14
success3-5
suggested13
th118
trials6-12
abscess7
choice2,10
countries5,6
diagnosis11
focus2
involved2-4
obtained1,7
others2-4
phase2,10
possible4
skin2-4
structures2,9
suspected1,7
suspicion1
tissue3
treatment2,3
treatment7,8
tuberculosis5
tuberculosis7,8
0~10
0~22
2µg/ml
35~62
6µg/ml
arthritis7
discussioncoexistence
gli-1
immunoglobulin6
introductionnecrobiosis
reported3-5
sarcoidosis10
studies3-5
walls1
1,2,5-9
antigen1
discussionmcc
disease7,8,12
introductionmerkel
survival1,8
synchronously2,5-9
toker3
toker4
back2
clear2
content2
depressed3
increases2
introductionlinear
sd1,4
sd5
sd5-7
specimens1
adults10
bruner4
disappear9
discussionnevus
hypertension8
stimulation6,7
vörner3
women1,2
19-year
fashion3
form4
gvhd5
infection1
mosaicism2
180~210/beats/min
a16
cells14
color10
edema4-6
ev71
infection11-13
introductionhand
months16
mucosa3
triggered15
carcinoma9
children4
contagiosum6
dermatomyositis7
discussiongranular
infection8
men3
ostia1
parakeratosis10
processing5
sweating1
bones1
cross-over9
discussionmelorheostosis
form8
introductionmelorheostosis
joanny1
mccredie6
melorheostosis5
unt7,8
1~10
45~17
4~9
aj85377
culture3
definitive15
focus2,3
infection14
infections11,18
infections3-5
infections4,8
korea6,7
noted8,10
onychomycoses3-5
onychomycosis13
onychomycosis16
reporters3-5
response17
soil12
suppression5
surgery2,9,10
therapy6
therapy7
toenails6,7
000/µl
000~1,045
0436/µl
1,500×
1,500×109/l
11-kg
125~235u/l
166±20
25~30
502
50~150
69~179
73~143
circulation1-3
counts1-3
deaths1-3,8
et4,5
et6,7
et9
gangrene4,5
mean±standard
mplw515
necessary1,2
non-0
purpura1,6,7
tet2
years1,3
atopy7-10
diseases3
disorders1
effects4-6
examples11-13
noted2
seen2
burn2,7
detected1
discussionmorsicatio
disorders3,4
frequency4
glycogen1
identified5
inflammation6
introduction'morsicatio
labiorum'2
manipulation1,6
meet5
mucosa1,5
patients1-3
present4
sucking1,2
teeth4
warranted1,4
16888
ay373852
body16
cases13
cause4,8,11,14,15
conducted4,9-12
english21
fungi4
growth11
observed15,23
onychomycosis13,18
onychomycosis17,22
onychopathic1
piraccini13
rare19
reporter6-8
romano8
test13,17,23
treatment25
well19,20
worldwide6-8
0~14
3,890
7,8,10
accepted4,5
births2,3
clefts1
encephalocele4
eyebrow4
fras1
frem1
gene8,9
hairline1
ipl12
isolated7
now9-11
sporadically4,6
stenosis11
syndrome4,7,8
aks1
aks6
crust2,3
crusts2
diffusum4
discussionaks
introductionangiokeratomas
lacunae7
melanomas5
melanomas6
specificity2
view2
cea3,4
epc8
granules5
rate1,2
15-hydroxyprostaglandin
3~5
4q33-q34
blephroptosis10
complicated13
deformities15-17
degradation8
discussiontsg
erosion14
expectancy18
hormones7
introductiontouraine-soulente-golé
laxity4
sinuses4,11-13
spontaneously13
substance5,6
touraine-soulente-golé
β-tromboglobulin
198510
application3
copper7
discoloration1,2
discussionmetallic
information1
literature6
particles12
production7
rare9
reaction11
replacement4
silver8
surgery11
thallium9
ti-al6-v4
vanadium4
vessels11
biology17-19
cysts8,9
ddd10,11
ddd12-15
ddd8,9
discussionddd
feet16
findings4-7
gene10,11
gene11
groups20
introductiondowling-degos
k14
k5
scars1-3
tips8,9
anagen2,3,14,15
bites11
burn10
cast2,4,5,14,15
growth16
hirsutism1,2
insufficiency9
lines16
lymphadenectomy12
pick13
respectively6-8
sex1
trauma3-5
199715
19~77
58~62
89~100
abroad3
cultures8-10
glucantime®
introductionleishmaniasis
joints12
leishmaniasis14
major1,3
pentostam®
sandflies1,2
species1
species1,4
species11
specimens7
therapy13
ulcers5,6
17,100
29,200
40~80
894
agent14
fever1
g-csf15
hands6,7
hormone18
introductionsweet
malignancies4,5
manifestations10
mild6,7
neonate2
neutrophils6,7
ss16
ss3
therapy11,12
2+and
2c~f
3c~f
79-year
ck20-
ck7+
empd8,10-14
gcdfp-155-7
hmb-45-
keratinocytes8
p63-
theory2-4
woodruff1
area1
brownstein3
foot5
report2
182_183ins
4-methylumbelliferryl
cells10
difficult4
discussionfabry
exon1
female11
gl-3
gl-32
later8,9
life7recently
mutations5,6
pasp61glufsx32
report3
vasculopathy2
0/binet
0~37
125/85
125~243
12~64
5,400
76~86
7~9
86~100
adenocarcinoma3
agents9,10
cancers1-3
cases1,2
cholelithiasis3
ck-19
clear10
clear9
cll9
discussionherein
dissemination3
involved3,6
pn1
tumors3
discussionimmunity
diseases1,2
diseases8
marks3
planus5
reports1,2
vit17
-1α
apoptosis8
catecholamines7
death6
epidermis2
melanocytes9
populations3
process1
vitiligo1
alopecia3,4
anti-her2
antibodies2-4
breast3,5,6
differentiation7
dimers2
found3
her1
her2+
her2-directed
her2-positive
her3
her4
herceptin®
keratinocytes7,8
pathways4
prognosis1
survival2
toxicity2-4
1,817
6205
agents3
causes2,11-13
chaetomium16,17
cultures15
ef524036
fungi2
identifined4
onychomycosis4,7-10
paper9
specimens14
subjects4
treatment18
years7-10
50~75
discussionsuperficial
form6
helwig10
implications1
introductionleiomyosarcomas
itself9
leiomyosarcoma1
leiomyosarcoma6
location2
melanoma8
nodules3,5
noted1
space1
sunlight3,4
tissue9
3,13
cells1,2
dialysis3-8
discussionks
dysfunction15
groups14
immunosuppressed3-8
ks1,2
ks2,3,12
ks6
leukocytes7
patients9-11
processes3
properties11
reactions7
stress8
tumorigenesis2,3
cases4,7,8,10-15
continuation13
drugs3
exacerbation5
introductioninterferon
pathogenesis7
problem8,10-12
process6
sarcoidosis2
sites2
stability2
virus1
vitro9
14,12-18
1698c
176670
2095c
275-210
3,930
6q
9p4
chromosomes4,18
complications18
delivery13
discussionnls
disorder1-4
face1
families12,16
findings5
genes20
hypoplasia4
ichthyosis10,11
introductionneu
karyotype4
nls4,14,18
nls9
transglutaminase-1
turkey10,12-16
zmpste24
19551
773
a/h1n1
areas7
arthropathy1,3-5
cases7
cured16
discussioninfection
greenflu-s®
ingression12
psoriasis13
reported8-10
th1-dominant
vaccine1-6
virus14
weeks15
2,058
3,219
baraclude®
described8
discussionentecavir
dizziness4
entecavir3
igdr9-11
introductionentecavir
patients5,6
responses7
short1,2
vitro1,2
angiosarcomas2,10,11
color3,4,5
discussionangiosarcomas
prognosis3,4,5,6,7,8,12
radiation12
reported3,4,5,6
resectable1,2
sarcomas3
tissues3
tumors12
undefined3,4,5,6,7,8
warranted2,9,10,11
200812
256-person-study
acupuncture6
clarithromycin4
complex12
drugs12
group8,9
increased7,8,9
infections2
organisms1,3,4,5,6,7
patients1,2,3,4,5
patients1,7
patients12
procedures1,3,4,5,6,7
respectively12
species10,11
surgery1,3,4,5
3,4,5,6,7,8,9,10,11,12,13,14,15,16
5-ala19
5-aminolaevulinic
633±3
body1
bowen1
imperceptibility19
introductionbowen
mal20
minimal11,19
necrosis17
nsaids19
outcomes2
pain11,19
source19
tegaderm™
therapies2
treated2
5℃/axillary
bits2,3
cases9,10
colleagues2
diarrhea6,7,8
easy2
entity2
hours1,5
hyperpigmentation6
localization1
necrolysis4
patch12,13
psoriasis2,4,5
reactions1
surfaces5
14-day-old
19876
4,5,12
cells8,11
cshrh4,5,6,7,8,9,10
cshrh6
cshrh7,8
discussionlangerhans
diseases8,9,10
involvement7,8,9,10
lesions3,4,5,7,8,9,10,12
lymphocytes8,9
mm7,8
months8,9,10
nucleus8,9
performed8,11,13
pritzker1
reported3,4,5,7,8,9,10
solitary1,2,3,4,5,6,7,8,9,10,11
spontaneously8,9
ulceration7,8
-γ
3a~e
affected2
blood6
cases12
ccr7
cd11a
cd11a/cd18
cd11a/cd18-mediated
cd62l
cells16
clones13
date6
discussionivl
introductionintravascular
nodules6
overestimated7
phenotype4
sites7
tappeiner1
testis10
tia-1+
treatment11
vessels5
~100
443
abnormalities4
acne10
discussionen
disorders11
embryogenesis5
en14
en6
face7
kang12
kofmann8
köse
nc15
newborns1,2
rare13
scarring9
time3
19011
233-year-old
configuration8
described3,4,5,6
dhar17
discussionln
extremities1,2
factors12
flynn15
investigators1
ln1,2,7
lp9,10,11,12
ls20
mg·kg-1·day-1
nodosum10
obscure1
papillae8
papules1,16
patient7
patients9,10,11,12
reported16
simultaneously18,19
spinulosus14
vitiligo13
's100
7-×0
actin13
cells1,2,4,14
differentiation1,6,7,8,9,10,11
discussionneurothekeoma
excised1
extremities2,3,4,5
introductionneurothekeoma
ki-m1p
leu-7
literature16,17
neurothekeoma1,2,6,7,8,9,10,11
nki/c3
report2,4
schubert12
sheath1
stroma13
type5
women1
≤10
≤50
area1,2
discussiongreen
drugs8,9
follicles2
introductiongreen
methods9
organism1,2,3
organisms10
others7
psoriasis5
solution2,6
tobrex®
608
608t
area7
discussionepidermolysis
exon2
filaments6
friction4,5
krt-5
krt14
l608p
severity2,3
structure8
α-helical
17α-estradiol
5,040
5α-reductase
aromatase10
cancer11,12,13
hirsutism9
introductionchemotherapy-induced
level6
literature1,2,3,4,5
minoxidil5
pazzaglia7
therapy1,2
c-erbb2
dermis5,6
discussionpaget
eusebi1
hmb-454
introductionpigmented
melanocytes3
308-nm
appearance7
areas10
closure5
condition1
cost-effective7
fibrin4,14
fixation14,15
genitalia8,9
grafts4
healing4
hlsc9870
melanocytes7
months2
mölnlycke
plasma4,5,14
reported6
skin13
tearing13
tissue7,11,12
transmission4
treatment3
vitiligo2
~91
1,064-nm
1,444-nm
110°
15-mj
2,100
40-hz
5~0
6×3
osmidrosis1
osmidrosis2
~11
calcipotriol14
cream15
cryotherapy13-15
curettage14
discussionperforating
expressivity6,7
failure8,9
fibers7
gel14,15
ice8
imiquimod18
introductionelastosis
isotretinoin14,15
laser16
lesions15,18
patterns1
radiation14
scarring19
solution15
stripping8,13
tazarotene15
therapy14,17
therapy15,16
therapy15,20
therapy5,10-12
treatment16
tretinoin14,15,17
4×4×5
bump1
capillaries4
discussionsoft
16s~23s
5µg/ml
7h9
abscessus4,7
adékambi
clarithromycin3,4
concentration≤0
countries6,7
genes3
groups1
myco-id®
reported5
sequence3,4
calciphylaxis1,6,7
effective6
factors1
factors1-5
half-lives1-3
morbidity1,3
1,254
1,444
10×5
18-g
accusculpt™
coollipo®
cooltouch®
discussionsurgical
fat1
glands2-4
method3,4
mobility3
possible1,4
recurrence3
smartlipo®
wavelengths5
1,2,3,4,5,6,7,8,9,10,11,12,13
causes3
erythematosus5,8
fortifiers12
groove1,2
ineffective4,7,9
introductionpterygium
investigated1,2,10
leprosy13
neurofibromatosis5
patterson5
piu11
plate4
prandi3
stroke2,7
toes1,7,9
women11
advantages4,5,6,7,11,12
application5
contour12
defect7
expected3,8
flap10
flap7,11
flap9
ideal3,4,5,6,7,8,9,10,11
subunits1,2
support5,12
4,5,6,7,8,9,10,11,12,13
7×0
bart4
bp13
discussionbp
hpv-16
hpv-18
hpv-31
hpv-33
hpv-35
hpv-35-positive
hpv-42
hpv-45
hpv-51
hpv-52
hpv-56
introductionbowenoid
literature4,5,6,7,8,9,10,11,12,13
lloyd1
papillomavirus-16
reported14,15,16,17
rüdlinger
3,4,5,6,7,8,9,10
cases10,11,12,13
date2
diagnosis3
discussionfolliculotropic
eczema16,17
forms1
introductionfolliculotropic
mf13
mf14
mf19
mf20
respectively6
soles16
syndrome18
5-immunoreactive
amyloidosis2
astwazaturow1
discussionnp
region2
relaxants7
results6
stage2
authors16
colon2
diagnosis9
established18
factor12
gland1,2,3
immunity8
immunosuppression6,7
introductionsebaceous
malignancy1,2
margins16
neoplasms3,5
nodule10
prognosis2
retinoblastoma3,5
tgf-β1
therapy17
transplantation6,7
1~2-cm
anetoderma2,3
degeneration6,7
degeneration8,9
fibers10
introductionanetoderma
occurred4
plaque4
1,8,11,12,13,14,15,16
adenocarcinoma17
helwig1
msh-2
msh-2-positive
nodules1,2
nodules5,6,7,8
rapidly9,10
treatment19,20
units18
challenging1,9
dermis2
discussionhistopathologic
disease4
introductionmetastatic
lesions1,3
melanoma10,11
metastasis3,12,13,14
n2c
neoplasms1
others8
1-cm-thick
1on
6,7,8,9,10,11,12,13,14
7×1
animal2
discussionmyiasis
easier16
exposure15
flies2
hosts1
infection5
introductionmyiasis
needed5
pupate1
regions1
sweat4
techniques5
tissue1,2,3
tropics5
used17,18
blaschko10
disease2,10
fernández-torres
hypothesis8
literature1,2,3,4,5,6,7
remain2
1flat
×115
1,2,12
12,14
1esophageal
20-32
3,15
3,4,11,13,14
3esophagogram
4second
5esophagogram
7,9,10
7oc
bp=140/80
echography=40
hr=90/
lannier’s
rr=24/min
sao2=96
t=36
triangle’s
13,15,16
17-39
1842
1barium
20°-70°
2operative
3duodenojejunal
6°
in1861
introductionwilke’s
wilke’s
wilkie’s
1isolated
75-91
8-95
1217
64–306
1000-fold
102-128/100,000
157/100,000
1730g/dl
18mg/l
2,912
22-year-period
27-82
3,13,15
3,13-15
3,5,10,15
3,6,11
3,7,13
3,7-9,13
3,9,12,15
3-4,9,12,15
3-5,7,9-14
3-6,8-12,14
4,6,8,9,11,14
4-6,8,9
4-week-duration
5,7-8,10
52mm/h
7-8,10
7-8,14
700-1600
cirrhosis”
ki-67+
lymphoma”
mum1
sjögren’s
“biliary
“hd”
“hodgkin
“lymphoma”
“malignancy”
“nhl”
“non-hodgkin
“pbc”
+1cm
10,13
100-110
100-fold
12,22
13,17,19
22,25
38-40
3nd
6,14,15
dot”
γgt
“suspected”
0-40
20×103/μl
21×17
27/0
2contrast
4surgical
4’0
70/3
7×103/μl
callot’s
ggt:872
introductionaneurysmal
protein/albumin:5
quincke’s
sgot:149
sgpt:203u/l
total/conjugated:1
1intra-operative
40mm
introductionlower
ec-3890li
endoscopy’s
1,2,4,5
2signet-ring
signet–ring
1slit
2slit
758
atp7b
discussionalso
introductiongalactorrhea
wilson’s
0/2
110,000
1×105
discussionadequate
medical®
20-45
introductionincisional
1/128
1/64
25-75
2spiral
3mild
pneumonias”
receptor-d4
1ercp
2,013
3plain
45-50mm
4follow
1diffuse
2superficial
1exogastric
5/50
9×8
1giant
grynfeltt-lesshaft’s
petit’s
valsalva’s
13-20
1recipient’s
21-29
2270
23,25-29
2580
26-29
2recipient
33,34,37
33-35
3serological
5histopathological
c4d
introductionclassically
recipient’s
1230
5–26
cm×10
cm×9
discussionalonso-lej
todani’s
2gastroduodenoscopy
3wedge
1circumferential
29-10
barrett’s
2inferior
10-french
15-40
1massive
2bile
57-yearold
4large
5endoscopic
discussionpet-ct
introductionampullary
wilson−cook
winston−salem
‘positive’
13-55
16–30
cd25+
cd7−
cd8−
factor-κb
pao2/
‘flower
1,8-11
2transrectal
discussionrlp
introductionlinitis
plastica”
“linitis
1spurting
endoscopist´s
13000/mm3
2cannulation
2pre-contrast
87-100
2perioperative
childhood”
month-6
n=3
pyloroplasty”
“heineke-mikulicz
“jodhpur
150-400
3surgical
d=0
tübingen
“intussesception”
2small
7-7
introductionstrongyloidiasis
×8
1videocapsule
2ulcer
discussionceliac
technetium-99m
~170
1transversal
laplace’s
1foreign
1angiokeratomas
2angiokeratomas
129,252
2he
3745
3immunostains
40,665
discussionlymphocytic
2endoscopic
35w
4,6,8,11-14
gif-1t140
introductionsubmucosal
kd-640l
mh595
116/76
26-199
3,700/dl
3mg/kg
45-yearold
6-13
6-mercapropurine
16500
173000
1limb
8oc
introductionklippel-trénaunay
klippel-trénaunay
lady’s
skull–cervical
wilson’s-like
17,18,25-27
18,24
1clinicopathological
1microvascular
2,8,23
214:125
26-85
2me
2microsurface
3relationship
3representative
4-80
4diagnostic
5inter-observer
5j
6,10-12
703
cf-h260azi
introductiondifferentiating
i·ii·iii·iv·vi·vn
kudo’s
more”
n=360
pcf-q240zi
μm-thick
μm”
head’s
21-33
3,5,7,8
36,10
apoplexy”
berhaave’s
dissection”
esophagus”
“intramural
10/50
1splenic
ashdown’s
discussionmelioidosis
introductionburkholderia
2,4-6,9
2a/2b
2authors’
3mu
4,6,9
4-6,9
desmet’s
discussionhcc
kobayashi’s
lambert’s
‘j’
“j”
vater’s
25/hpf
4/447
4/66
447
6,7,9-15
9,16
esophagitis”
fontillón
perforation”
“boerhaave’s”
“crêpe-paper”
1885
2-14
aneurysm”
discussionenterococcus
“mycotic
08-5
1worsening
introductionimmunosuppression
2esophagogastroduodenoscopy
70-85
7:1
introduction“hemosuccus
pancreaticus”
1patchy
2endovascular
3gross
2manometry
3,4,6,7
4eus-guided
60-85
introductionachalasia
p4-p6
5-aminosalicylic
515,000
531,000
1860
1cm
3posttreatment
introductionblue
15xurl
2xurl
3xurl
discussionwg
g/l/24h
2narrow
segments”
2/10
50-62
5x3
e×10
e×20
ihc×10
ihc×20
pt2pn0pm0
pt4pn2pm1
123/88
18000/ml
2,3,9
48-h
58×41
discussionsg
introductionsuppurative
mg/125
11700
1472
1600
1680
6500
77-98
discussionspontaneous
≥250
0-iia
it-2
2angiography
30-120
Α
3mrcp
7×5
discussionpolycystic
introductionpolycystic
pkd1
polycystin1
sec63
1hematological
3q13
6p21
a1298c
c677t
pkd-1
pkd-2
pkhd-1
2choledochoscopy
introductioncontrary
muc1+
muc1-
muc1-/+
muc2+
muc2-
muc5+
052-4
12/46
13c
19/24
293-35
4-52
6-85
8-7
peutz-jegher’s
introductionpseudocysts
t2-imaging
1,6,9,11
28-128
40-129
708
stomach’s
‘bowing’
‘long’
1four
cloverleaf”
“duodenal
1adenomatous
2hemoclip
hx-600-900
maj-254
könig’s
30-140
discussionearly
h260z
ill-1
phm0
pt1a
pvm0
t1a
tub1
x80
“0-iia”
“0-iib”
“mapping”
1,530/mm3
10,620/mm3
10:1
13,530/mm3
15/hpf
280/mm3
300,000
406
asp816val
cd117+
h2-histamine
81-100
agna-1
anna-3
artery’s
crmp-5
discussionagd
pca-2
x109/l
2intraoperative
3photograph
5a-d
7discussionimplantation
ck20+
ck7-
infection’
introductioncharles
‘cancer
12,3,21
13c-urea
15,17-19
23,14,24
302
63:244-249summary“sequential”
9-2
ae’s
mg/12
n=338
“concomitant”
“real-world”
“sequential”
“which
146:412-419summaryvariceal
72/178
d’amico
12,000
1tight
3fluoroscopy
introductionobstruction
t3n0
t3n1
/μl
1patient’s
2h-e
3patient’s
508,000
6-38oc
mg/kg/8w
3radiation
717
introductioncurrent
target”
“clip-free”
“shooting
“target
“targeted”
-3350
2antegrade
brunner’s
gatorade®
glycol-3350
golytely®
introductionpolyethylene
n4
peg-3350
peyer’s
so2nh2
so42−
“sulfa”
2orbital
batson’s
cdx2
introductioncolorectal
1 mg/day
20 mg/day
2 mg/day
2 weeks
3 mg/day
48 months
4 months
55 years
59 years
vörös
,2000
1,5,11
1biobehavioral
1r01mh064154
2miller’s
6,8,11
amalgam’
baker’s
bowen’s
consent“written
daughter’s
differentiation’
factors”
family”
father-in-law’s
housekeeping”
illness’
illness”
individual’
interactions’
i’
journal”
miller’s
mind–body
minuchin’s
model’
not…
no…
one’s
organism’s
others’
others”
other’s
parents-in–law
parent–child
penn’s
psychosocial-mind–body
reactivity’
space’s
teenager’s
theory’
woman’s
wood’s
–and
‘differentiated’
‘emotional
‘enmeshed’
‘examined’
‘family
‘processes
‘psychosomatic
‘responsible
‘responsivity’
‘stress-related
‘togetherness
‘togetherness’
“alliance”
“biobehavioral
“boundaries”
“break”
“chronic
“could
“did
“differentiate”
“exploitation”
“exploited”
“exploiters”
“felt”
“how
“if
“individuality”
“i”
“limitations”
“nowadays
“no”
“objective”
“of
“onset
“overwhelmed”
“parentified”
“precipitating
“predisposing
“process
“psychosomatic
“psychosomatic”
“responsivity”
“self
“stress”
“triangulated”
“victims”
“victim”
“violate”
“was
“what
“when
”this
1,00
20-hz
9-day
appliedii24venlafaxine
appliediii22fluoxetine
appliediv26escitalopram
daily12escitalopram
daily12fluoxetine
daily14venlafaxine
daily9escitalopram
disordernone25
introductionrepetitive
mg/daynonenone25
treatmenti27escitalopram
‘switch’
0 ng/ml
10-mg/day
100-mg/day
100 mg/day
10 mg/day
14140++++4th
142 ng/ml
14 years
15-mg/day
150 mg/day
15140++++4th
15930++++4th
15 mg/day
18–44
1 ng/ml
200 mg/day
203
20 mg/day
215 ng/ml
232 ng/ml
243 ng/ml
250 mg/day
2 ng/ml
30-mg/day
310 ng/ml
332 ng/ml
353 ng/ml
358
4 ng/ml
5-h1a
5-ht2
519
51 ng/ml
5–6 months
746
749
7840++++4th
787 ng/ml
78 ng/ml
7 ng/ml
8 ng/ml
aripiprazole15 mg/day
aripiprazole30 mg/day
aripiprazole4610  
aripiprazole4915 
aripiprazole5020 
aripiprazole 1st
clozapine100 mg/d
clozapine100 mg/day
clozapine150 mg/d
clozapine150 mg/day
clozapine200 mg/day
clozapine250 mg/day
day2nd
discussionschizophrenia
male100 mg/day
male150 mg/day
week30 mg/day
week3rd
week4th
yale–brown
  case
‘pro-obsessive’
1,040 nmol/l
1,225 nmol/l
11-cm
135 nmol/l
155–599 nmol/l
1 pg/ml
20 mg
30 mg
441 nmol/24 h
50–170 nmol/day
5 pg/ml
836 nmol/l
858 nmol/l
8 pg/ml
999 nmol/24 h
–79
–85
0/0
023global
028apaired
043
049height156156156153153153 weight40
0p
0 ede-qrestricting
126weight
13*p
13-kg
153-cm
158-cm
1progress
2/0/2
2/1
2/4
234shape
4/2
4/4
5*p
5-ht-specific
5-ht1a
500eating
514
554
6/1
6/3
6/4
6p
7*p
718
836
b  04240424 bmi16
introductioneating
score3
subscale1
subscale3
subscale4
tandospirone time
valuea case
‘i
‘if
0/575
1/268
1/300
10–65
13–35×104
181500
188400
192430
1common
2×104
35–60
50congenital
611867
6361
anomalies+−+palatal
anomalies−−+slender
anomalies−−−craniofacial
calcification+na+immunodeficiency−na±common
disabilities+−+low
figuresna++hypocalcemia+++thrombocytopenia−−+enamel
presentation sugama
psychosis221518hallucinations
tuple1
woman28-year-old
woman48-yearcpaold
μl−1
100 kb
10 kb
110-862-kb
110no
117patient
1asd24malefiq
1pars
2,135
2,190 g
2014patient
24 years
256100
266900
26 years
2asd33malefiq
2p13
317-111
33 years
36 years
37 weeks
4,070 g
4,544
413 bp
45-kb
5036_4autismnamalebelow-average
609583
76kaminsky
80no
834-110
86piq
98viq
995 bp
asperger’s
chr2
cytoscan™
d13s217
d14s276
d14s985
d1s206
d1s450
d5s410
d5s630
d9s1776
d9s285
disorder12 language-based
dsm-5
fbn1
hg19
isca00000020asdnanaintellectual
nm_000272
nphp1
observedisca00000128asdnanaintellectual
observedisca00000949asdnanaintellectual
observedisca00001175asdnanaintellectual
quotientnphp1
stxbp1
variationsdsm-5
 pdd/adhd/obsessive
0–50
3 mg/day
5-ht2a
5-hydroxytryptamine
5 weeks
9-hydroxyrisperidone
9 years
dopamine-2
introductiontourette
‘a’
‘die
‘kill’
18months
23,300/mm3
3-year–old
3months
mohan’s
nephropathy17
reports,10
term20
120/
1939
4,5,6
80mmhg
f1a
f1b
introductionpneumomediastinum
32-year
35-weeks
45kg
5-minutes
95kg
baby’s
discussionmullerian
557mg/dl
complex2
discussionrhinosinusitis
drainage6
fibrosis3
introductionrhinosinusitis
kartagener’s
made8
missed7
sinusitis1
under-reported4
abdomimal5
discussiongastrointestinal
malignancies1
sarcomas1
tract2
1643
1:1situs
discussionsitus
introductionmatthew
literature1-4
population10
predilection10
v4-6
world5-9
–ceftriazone
“abnormal”
139mg
200mg
8,9,14in
9,13
9hiv
clinic8
gp120
gp160
gp41
husband’s
p18
p31
p51
p55
p66
1gram
300mls
4cm
5grams
angina1
benefit”
body’s
considerations3
contact14
discussionodontogenic
exposure14
introductionludwig’s
ludwig’s
membranes14
metabolism10
nature11
obstruction1
piercing1
teeth1
tissues14
volume-33
well18
“so
25file
35file
8-shaped
ah26
canals1
canals1,2
canals1,9,18
canals14
canals3,5,8
configuration7
distobuccal21
established2,6,7
exist9,13-15
fig2
fig3
morphology2,3,4
orifices2,6conclusiona
presence2,20,21
radiculous3
respectively25
restoration2
root20
roots23
roots7
size15
sizes10
studies9,14,15
tooth5
treatment19
“webbing”
116mm
13-1
15-33
3+1
47mm
52mm
9mm
week’s
4000/mm3
0–30
1transaxial
2transaxial
4coronal
introductionintradural
1692
4q27-31
6–24
ethane-1-hydroxy-1-diphosphate
introductionmuscle
1atrophic
1seizures
1¼
2/3rd
5½f4th
bfnc/ebn2
ebn1
ebn2
kcnq2
kcnq3
months22m4th
months24m4th
months25m4th
months26f4th
months29f4th
onsetcourse32m4th
year28f4th
year2½f4th
years3½m4th
“prototypic”
50cm
75kg
7–1015
recql4
23,000discussionfabry
2aperivascular
3nm
gb3
xq21-33
×1,00,00
×11,500
×120
×240
×350
4age70758270sexmalemalefemalefemaleethnicityassamesetripurikhasinepaliduration
61612headache
6rheumatoid
70-82
81089
esr/crp50/+35/+185/+135/+hb
2/60
discussionsotos
introductionsotos
nsd1
16569
27-41
discussionmitochondrial
introductionepilepsia
2h3
2red
346101213
7600/mm
introductioninvasive
r3
x400
z3
1events
1hyponatremia
5°f
introductiontoru
introductioncarbon
1cect
discussioncerebral
introductionflexor
introductionagraphia
mariën
reading—has
‘apraxic
‘hidden’
2-25
75-90
112131618
126111617
138-bp
142/
1438/mm3
1873/mm3
232-bp
2506/mm3
460/
461415
als–like
arm–like
c–specific
hiv-1–associated
infection–associated
introductionhiv-associated
muscles—a
subtype–specific
‘flail
0–20
11–17
13–19
206
6–19
7pg/ml
8,700/
ataxia”
dr3-hla
dr4-dq8
t3=125
t4=
tsh=4
“gluten
“softer”
≤11
13,800/cu
1causes
1mg
202i
24–90
254000/cu
28,950
283mg
2gm
3–4/hpf
4mg
58mg
5mg
664
7gm
discussionthus
l28
p69
protein-+1
introductiontransmissible
kg-9
kg9
t1-weighed
t2w-flair
x200
x360
×280
“definite”
“probable”
1composite
20–100
head”
leak”
‘orthostatic’
“closure”
“sagging”
“something
“thunderclap”
24–35
discussionstroke
2acolor
2bdigital
introductionplaque
1bfigure
2peripheral
8,400
802
d11
introductionparaplegia
124/
17–78
1:1024
1:2048
1:8192
203/μl
6:1
99/μl
discussionunlike
1a‐c
4-year-old-boy
1c‐f
2d-echocardigram
2nerve
3a‐d
3conjunctival
apoa1
b–e
v30m
10–12/
1sedated
2–3/day
4–5/day
61115
71213
7812
81213
sleep–wake
α-keto
2003figure
2006figure
3automated
4contrast
6/12
discussioncrion
74/min
introductionthrombolysis
3–4/5
4×3
anti–snake
days’
guillain-barrésyndrome
hla-b8
neuropathy—primarily
156u/l
1eeg
2eeg
30-65
50-136
=658
brain-1
coma”
etiology”
introductionelectroencephalogram
pattern”
“alpha
“fulminant
“spindle
1192
14,900
5,000–10,000
92,000
bends’
caisson’s
chokes’
15-2
348
48kg
6-5
9-47
9-55
902
999
introductionpseudohypoparathyroidism
pnormalmri t1hyperintensity
trousseau’s
wt=40
11/04
1116–18
3/07
8/06
9/05
anti-tnfα
introductionsarcoidosis
tnfα-blocking
10,000,000
1095
15/mm3
68–71
anti-ma-2
introductionopsoclonus–myoclonus
opsoclonus–myoclonus
‘opsoclonus’
3three-dimensional
4812–14
discussionscedosporium
‘graphium
1522
1:50
1sections
2grading
3evacuated
3–39
415
42021
4scanner
cases—the
conditions365/mheadache
course178/munconsciousness
dab/h2o2
e2m4v2
e2m5v3
expired267/faltered
introductionintracerebral
phf-1
×16
distal–2/5
proximal–3/5
t12–l1
t6–t8without
t7to
“blind”
coat’s
cysts”
disorder–the
finger–nose
heel–knee
introductionleukoencephalopathy
significance–the
×100postoperatively
“cerebroretinal
3celebisoy
3second
4diffusion-weighted
cca–peak
ica–psv
introductionisolated
mca–aca
mca–pca
palsy”
weakness”
ε-shaped
ω-
–posterior
“fractional
“pseudoperipheral
0*0
0*5
059
063
0sensory
0––cmap
1*0
14–6
2*0
247
2f-latency26
2sensory
2––––11
317
3nr*nr*nr*nr*nr*
3––––3
4––cmap
4––sensory
5*1
5*––mcv
5––––2
6*1
6snap
6––––17
7*––mcv
723
759
7f-latency24
7nr*nr*nr*nr*nr*nr*––case
8*0
853
858
8snap
8––sensory
8––––2
9––––1
discussiongbs
gd1a
gm1b
persons’
1gel
d15
sca-12
sca-2
sca-3
sca-6
sca-7
avanto1
01–4
38–39
discussionmycoplasma
20-year-history
introductionmeige
6-hourly
discussionrespiratory
reporta-68-year-old
0–21
1-γ
1287
140-kda
1412
1432
1vastus
2atrophic
3203
3415
3tumor
71314
anti-155/140
anti-155/140-kda
anti-mi-2
anti-pl-12
anti-pl-7
anti-u1-rnp
anti-u3-rnp
atrophy–indicated
jo-1
parameters–blood
tif-1γ
tif-iγ
×50
–42
1,670
10½
2agarose
45–47
50discussionthere
becker’s
buttoning–unbuttoning
down’s
gene–protein-phenotype
introductionduchenne
klinefelter’s
phenotypes”
1925
depression”
disorder”
hypersomnia”
introductionkleine-levin
“periodic
“post
25–60
28/30
50110
5038
53-year-old-man
56-year-old-man
introductionmcleod
×1000
100/cmm
1111517
1115
1121
1316
131617
1520
181315
213202125
231112
3815
6910152125
8-65
814
891315
8–52
9211725
cd-20-immunopositive
cd20-immunopositive
discussionihcpm
igg4-related
mm/1h
“idiopathic”
“secondary
3proton
introductiondesmoplastic
discussionhypertrophic
pachymeningitis’
‘idiopathic
‘primary’
‘secondary’
11/30
18-months
25–45
28-times
316
559
5–13
70–187
997
counter”
encephalopathy”
introductionhashimoto
“investigation
“over
≤34
ciss-3d
introductionocular
0,500
0gms
5-tesla
=500
introductiondiabetic
“sleeping”
1114
140/110
15,600/cumm
20-100
8/15
91014
“hyperperfusion
16/30
1904–1997
1image
2image
diaschisis”
facilitation”
family′s
hemispheres–hemispheric
ninds–adrda
region–the
theme–one
‘a
“fill
“hidden”
“its
“paradoxical
“released”
“reverse
”discussionde
discussioncysticercosis
19,100
b=1000
p90l10
s/m2
500/mm3
5850
introductionsnake
1three
2three
6800/cmm
grade-1
0–170
14–21
1electropherogram
4-years-old
7q35
a531v
clc-1
clcn1
clcn1gene
f413c
gly482
gly482arg
introductionmyotonia
m485v
probands’
r894x
–recessive
“warm-up”
5-year-history
6-month-follow-up
plus’
syndrome’
‘coat
‘labrune
5–15
1/20
235–9
25–11
26–11
2–49
2–49–11
nerve–electrode
3+++
335/mm
1mutilation
1q21-22
3sural
iq=97
“f”
140mg/l
200/100
69/26/3/2
day—each
discussioncathinone
g—over
introductionkhat
o’neill
rate-6
sana’a
1:5120
1:5120case
1eschar
1recent
2weil–felix
72000/
78000/mm3
8700
9500/mm3
introductionscrub
mmh2o
tetracycline500
weil–felix
“eschar”
“stupor
“typhos
“typhus”
≥1:320
+30°
2ecg
6-h
84/60
discussionlqts
kcne1
lange–nielsen
lange–nielson
romano–ward
–45°
12300/cumm
21011
2451011
2–410
341011
e4m3v3
introductionhyponatremia
200–250
3511
3a–d
3a–i
3i
511–15
arginine–vasopressin
demyelination”
marchiafava–bignami
“boomerang
“mini-boomerang”
1restriction
6/18
introductionmucocele
32/48
capgras’
discussiontsc
introductiontuberous
+25
24–170
2electrocardiogram
3head
5repeat
8-hourly
discussionhoney
introductionbees
1cerebrospinal
2wasting
40as
4striking
5involvement
6cerebrospinal
7aggregates
“bright”
“dark”
“resist
20–400
3emg
882
gad-65
gad-67
γ-aminobutyric
1315
3–18
1familytreebesides
2425
2pretreatment
30/hr
36–38
3post-treatment
french–canadian
introductionrestless
17p12
2eldest
346–11
5mv/d
a29
b44
bw4
discussionfamilial
dq7
drw53
grandparent–grandchild
km3
parent–offspring
uncle–nephew/niece
introductioninfantile
vitaminb12
1parasternal
3300
54/2322
5–18
5–56
crescendo–decresendo
introductionneurofibromatosis
–c2
“complications”
“dumbbell”-shaped
14/cumm
50/cu
5×4×4
8000/cumm
discussionspectrum
11990
1905
6811
discussionhp
glucose-112
proteinase-3-antineutrophil
/62
254,000/mm3
9400/mm3
discussionmoyamoya
intake–output
n/2
2389
introductionneuropathic
resorptive–hypertrophic
resorptive–productive
“charcot
pr3-anca
16300/mm3
210/130
312000/mm3
6–911
discussionpres
introductionposterior
t2a-weighted
346
3pedigree
discussionmlc
gm2
introductionmegalencephalic
mlc1
100–129
100–490
13–36
160–200
250–400
354–1100
49–151
50–320
800–1700
9100
discussioncryptoccocal
iga-126
igg-793
igm-38
1984–1985
31–90
introductionrabies
1372
85–100
9800/mm3
introductionorbital
0–54
5q13
introductionkennedy
xq11-12
124/80mmhg
1mimetic
26mg
2arteries
48mg
basilar”
ratio3
“top
11-months
24510
2–12
5-meter
cw2
dqa1
dqb1
dqb1*03
dr6
drb1*01
drb1*03
drb1*11
drb1*1301
drb3
hla-dqb1*03
-756/μl
108/μl
1091/μl
1275
150/μl
3074/μ
3888/μl
6060/μl
antibody–antigen
introductionepstein
sh2d1a/dshp/slam-associated
wbc/mm3
2noncontrast
nonelévaif
15–22
1951
1:140,000
introductionleigh
1top
1–70
μv/mm
cause–effect
discussionvpa
e4v5m6
hemoglobin-5
introductionhematological
pfa-100
weight-30
“t”
10000
1lft
after12
hla-b5801
introductionneurologists
normal-0
–no
94–97
introductionthoracic
2mrv
discussionsspe
1/1,000,000
100–400
1:21,000
discussionlsm
introductionlipids
nih–national
octn2
slc22a5
×5000the
13-24
18-fluoro-2-deoxy-d-glucose
18-fluorodeoxyglucocose–positron
1pre-18-fdg
2-deoxyglucose
21-54
4post-18-fdg
5pre
6-31
7-53
fluoro-18
for3
glut-3
t2/
10ms/d
111215
1motor
1muscle
3568
55:18
781112
barré
feedback”
introductionhyperkalemia
neuropathy”
“autodialysis
“demyelinating
1059_1060
21-22
2panel
4th–5th
capn3
cmt2b1
gln353his
gln354term
gln354termn
introductionemery-dreifuss
lgmd1b
sepn1
192/192
24/24
3histogram
5,5
apnea”
compumedics®
dışkapı
nights’
ondine’s
tcco2
weinman®
“obstructive
1flair
anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
nr1
nr1-nr2
17-45
4-35
discussionrich
eye”
t2-weightedw
“owl
14-18
1repetitive
25-80
2repetitive
block-95
difference-69
discussionmolecular
dok-7
fructose-6-phosphate
gfpt1
myasthenia”
score-0
weakness-39
“anabolic”
“limb
122/80
159-fold
199mtc
99mtc
a2bw22
aw19b17
barrι
bw46
discussionhypokalemic
findings’
grave’s
hla-drw8
introductionthyrotoxic
kcne3
t3-200
10-31
behçet’s
introductionnummular
1ventilation
chambers’
introductionliquefied
pc02
΄×
‘modern
“pose
1infarct
2hemorrhagic
6/36
e4m5v3
introductionmethanol
-1-
-5-
10370u/ml
122453-73-0
187,000
2-moderately
200-2,000
3,00,000/year
303268
4-bromo-2-
4-chlorophenyl
43492829
43492833
50-2000
8400
9,00,000
c15h11brclf3n2o
changes”
dns,5
ld50
period”
pyrrole-3-carboritrile
“chlorfenapyr
“latent
“radiological
3posterior
ears”
friedreich’s
prognosisb12
sectionsdiscussionb12
v”
“inverted
101327
1423
16,400
1624
1900
2324
2contrast-enhanced
2d-echocardiography
3t1
4-18
75,000/mm3
99m-labeled
air-86
count-35,000
hemoglobin-8
introductionlemierre
lemierre’s
pressure-100/60
pulse-110/min
rate-30/min
simon’s
“forgotten
“lemierre
16year-old
57year-old
antigen-dr4
introductionvogt
108/min
10mm
12q13
1871
2-19
30:15
32/20
4‘a’
allgrove’s
cortisol-3
discussionallgrove
introductionallgrove
low-1
normal-6
p5
schirmer’s
9q13
aoa1
aoa2
ivs4
ivs4-12delt
sca8
1hrct
3probable
introductionbacterial
“figure-of-eight”
13-18
14-15
15-16
1surface
2surface
3surface
6-20
discussionot
ot”
“ot
“pure
2click
2high
3higher
introductionniemann-pick
phenotype’
‘variant
11q15
1electroencephalogram
3t2
5periodic
introductionneuronal
5t2
6adc
7susceptibility-weighted
880/sq
introductionneurenteric
kernig’s
1orofacial
2post-axial
appearance”
introductionvaradi-papp
tmem216
tooth”
váradi
váradi-papp
“molar
“mollar
2transesophageal
85-95
discussionbav
‘o’
“o”
1/3rd
6l/mt-p
co226
co231
introductionstroke
o242
o250
o253
o2by
–chest
–ct-
–diffusion
–flair
2auditory
discussionhypernatremia
glass’
‘wine
‘wine-glass’
′wine-glass′
476
actin–myosin
history—uneventfulexaminationthe
kocher–debré–sémélaigne
1/2-year-old
2a1
host–organism
1–2/month
3–4/month
introductionsturge–weber
nevus’
sturge–weber
t1/t2
‘without
1g-j
1k
2-3/10
70-
74-
7–8/10
8-18
9–10/10
bifrontal–temporal
discussiondiverse
“monro-kellie
15-54
1:1600
22/30
2ce-mri
66-87
81314
hp10
worm”
10p
137–145
1non
3ultrasonography
6–54
discussionhdr
dysplasia”
gata3
introductionseizures
~32
“renal
2radionuclide
c6/
38–74
discussioncaa
l4-s1
s1-2
t2/swi
54/120
introductionnbia
pkan-2
sign”patient
tiger’
tiger”
‘eye
“eye
324
3non
4non
5nasopharyngeal
1fat-suppressed
2fat-suppressed
3fat-suppressed
discussionrocm
introductionmucormycosis
t2-hypointense
10-methylene
2decho
5summary
Χ
182,127,678-183,154,618
33q26
5678910
5coronal
6791014
78111213
agediscussionsox2
arr3q26
sox2
1ichthyosis
1index
835
aldh3a2
discussionsls
introductionsjögren-larsson
sjögren-larsson
y279n
130/100
134/110
2nd-3rd
34567891011121314
aos’
articulation”
speech”
‘crossed
“apraxia
10-34
2classification
2dsa
3summary
40-63
basket”
d12
d6
myelopathy’
phenomenon–
terminale’
‘avf’
‘congestive
‘filum
“liga”
30-35
virus-1
1reports
3456
3456789
c3–c4
discussionneurological
1457
3195
3electroencephalography
4/30
4mr
5/cumm
6-thio-gmp
6-thio-gtp
6-thio-imp
β-fast
μgm/day
3pre-operative
5post-operative
6/100,000
introductioncomplete
4postop
stage-3
t2w1
“moyamoya
1-0-2
1-2/week
1014
1015
141920
1medicationsalthough
2457
251718
2bilateral
3investigationsthe
457
9101314
910131416
me”
spike–wave
“case
“completely
“fixation
“save
”occasionally
15-24
16171819
1interictal
2ictal
3postictal
4-s
5-hz
as”
discussionfugue
epilepsy”
epilepticus”
features”
introductionfugue
onset”
states”
“as
“ase”
“atypical
“childhood
“de
“dissociative”
“epileptic”
“intelligent”
“psychogenic”
“typical
180/100
1video
2video
3video
60-80/min
60-80/minclick
90-110/min
90-110/minclick
discussionepilepsia
“clonic
3corresponding
4diffusion
55-day
6follow-up
content”
introductionmetronidazole
“axonal
30-50/day
68/100
80/100
82/100
aqp4
aquaporin-4
pnma1
1088
13/15
143-310
1post-intensive
2146
2diffusion-weighted
3331
857
alpha-amino-3-hydroxy-5-methylisoxazole-4-
contactin-2
discussionautoantibodies
introductionlimbic
“flu-like”
”on
“classical”
“fragile”
16q12-21
2elder
75-80
adamtsl-4
gpr56
introductionpolymicrogyria
101112
13,400/cmm
8/40
barre’
1diffusion
discussionpeduncular
here”
introductionpeduncular
l’hermitte
walk”
“come
136/min
1investigation
2ncv
discussionblankenhorn
introductionberiberi
“dry”
“wet”
14-72
220-960
2dexa
discussionosteomalacia
limbs-3-4/5
limbs-3/5
150-250
160-200
1pre-treatment
71112
introductionneuromyotonia
2absent
imagingt2w
mm/5
×400figure
–sm
3b–e
65-195
ohs”
“pressure-like”
“subdural
43-48
discussionsca17
introductionsca17
sca12
‘polyglutaminopathies’
1:42,000
1thirty-eight-year-old
2multiple
3-5/100000
bmp7
c2-3
c3-4
c4-d1
c4case
c5-6
d2-3
gdf3
gdf6
msx1
msx2
pax-1
pax-3
pax-7
spread”
“agents
0/30
14/30
278910
3ocular
4-2
51112
7/30
cases”
ii-1
iii-4
iii-7
“unaffected
18-years-old
4transverse
5uniform
679
col6a1
col6a2
col6a3
exon-14
introductionbethlem
shadow”
α6
δ
1021
123456789
1320
156000-373000
18q-syndrome
2-99
3-to
4000-10300
496000/mm3
50-75p
90/55
912131418
9600/mm3
discussiontwo
introductionshapiro
noël
taché
ıt
“becoming
“reverse”
18-month-girl
18-month-old
1demograpic
2enzymatic
3p26
739g
g247r
sumf1
13-23
1subdural
23,700
2subdural
5’-cacgaattccgcctgc-3’
5’-cactgaactcaagcccggcagtttcaa-3’
5’-gcgctcaacgttcagcc-3’
612-628
634-660
664-679
introductionsubdural
1vertebrae
2cord
3hypoplastic
5bilateral
discussionmps-iva
introductionatlantoaxial
n-acetylgalactosamine-6-sulfate
146/100
1914
1t1-weighted
2t1-weighted
71-92
31-86
37-day-old
4,529
47-155
5axial
64-294
8axial
introductionmaple
1conditions
4mri
images”
12349101112
1897
2,500-3,500
30-80
5111217
600-700
614
anterior-1
introductionhoffmann
lateral-1
left-29
left-31
left/right-34
posterior-1
right-29
right-34
3eeg
introductionyoung-onset
sign”figure
“pulvinar”
“typical”
15-35
75-160
mcg/24
“ripple”
0-100/dl
200-2,000/dl
2611
discussionleptomeningeal
gfap×40
hrp×200
p53×200
1,082
80-140
cells-6/mm3
introductionneurosyphilis
proteins-220
sugar-120
sugar-24
“preataxic”
208c
3-o-methyldopa
3-omd
33-79
5-hiaa
5-hydroxyindolacetic
5-methyltetrahydrofolate
5mthf
b6-requiring
his70tyr
introductionaromatic
1909
discussionbalint
introductionbalint
ft3-3
ft4-1
introductionelectrophysiological
−60
−85
2378
391011
4513
diﬀusion-weighted
introductionwernicke
103/ul
106/ul
1092
30/100,000
562
65-70
discussionet
v617f-positive
1117
12,600/cubic
2multivoxel
3large
4dot
cho/cr-3
discussionpathogenic
immunodeﬁciency
09-12
110-220
1841
20-171
2400-120000
243-894
250-400
34-5
35-145
35-65
4610
50-150
60-117
60-160
87-178
b-100
b-48
discussionabetalipoproteinemia
g/5
introductionbassen
q22-24
“abetalipoproteinemia”
“poikilocytes”
1fluid
anti-aqp-4
aqp-4
aqp-4-antibodies
c1–c5
days-80
discussionvomiting
t2/fluid
d1-5
d3-d5
d4-5
d8
discussionvertebral
1hmrs
2radon
3522
4200
introductionglutamate
1swelling
3wasp
discussionworldwide
introductionwasps
16-year-
39°cand
hla-dr4
introductionvogt-koyanagi-harada
vogt–koyanagi–harada
15,200
1f–i
2a–e
3a–e
7/15
e1v2m3
e1v2m4
t1w1
v1-v4
×obj
3follow-up
4computed
discussionmagnetic
1panel
2results
2west
780,000
introductionpolioviruses
state”
virus-6
“locked
1ncct
2ncct
4ncct
introductionair
1851
3-5/10,000
3volume-rendered
4plain
discussioncraniosynostosis
14q22
1l-2
2-hg
2-hga
2-hydroxyglutarate
2-hydroxyglutaric
2-oh
4t2
7910
conclusionsl-2-hga
d-2
d-2-hga
d-2-hydroxyglutaric
d-2-oh
d-2hg
introductionl-2-hydroxyglutaricaciduria
l-2-hga
l-2-hgdh
l-2-hydroxyglutarate
l-2-hydroxyglutaric
l-2-hydroxyglutaricacids
l-2_hga
l-2hg
α-ketoglutarate
“metabolite
2negative
3illustrative
glun1
glun1-3
glun1/glun2
glun1/glun3
glun2
glun2a
glun2a-d
glun2b
glun2c
glun2d
glun3
glun3a
nmda-nr1
“eight
130-150
1electrophysiological
90-100
introductionguillain-barre
0-35
1/214
1/500
1/603
2serous
44-year
discussionpcd
–avid
4-hz
introductionhirayama
‘hyper’
2photograph
3small
4wasting
abcd1
c22
c24
c24:0
c26
c26:0
discussionamn
introductionadrenoleukodystrophy
xq-28
124567
1678
241113
7815
discussionbobble-head
feeling’
movement…
phenomenon’
rhythmia”
‘learned
‘seemingly
“symptomatic
1278910
20/30
40-45
discussionsle
meningitis”
virus-2
~1400
“aseptic
3asheets
3bhistiocytic
3chistiocytic
3dcrt
cd1afigure
cd207
granuloma’
introductionintroduction
letterer–siwe
‘eosinophilic
1-q12
11-80
16-channel
3-q24
8q23
iv-1
v-1
“familial
“tremor”
1-21
107,290
1evaluation
3-4/5
42,670
695
888
c12
c12:1
c14
c14:1
c14:2
c16
c18
c18:1
discussioncpt
introductionmetabolic
si13l
technetium-99
×4000
×5000
18-fluorodeoxyglucose
2plain
7,199
discussionetiopathogenesisincreased
introductioncrohn
10900
14,500/mm3
1contrast
5-flucytosine
61415
introductionbrain
lacs/mm3
p62l35m3
10111213
14567
2a–b
3internal
4a–b
5a–c
6post-second
7eca
introductiondural
-141
-2,37,000/cmm
-255
-39
-6000/cmm
10111213141516171819
184/100
217pfs*8
244c
2mutations
3structure
5613
5′-ccccccccc-3′
5′-untranslated
5′-utr
641-649
649dupc
c1000
ensg00000167371
prrt2
r217pfs*8
snap25
tdiscussionprrt2
‘c’
4-15
antigm1
guillain-barrι
guillaine-barré
1vertically
135th
142nd
21-yr-old
26-bed
77th
780-g
cc17
introductionvancomycin-resistant
is1216v
is1542
orf2-vanr
st17
st18
st192
tn1546
vanc1
vanc2/c3
1,438-bp
128-270
15483t
228-bp
270/161/117-bp
320/207-bp
408-503
456/180-bp
644-bp
65-kda
68℃
745-bp
dsm44339t
dsm44395t
f1-05352
gu142931
hm229791
hm229792
hm229793
introductionmycobacterium
m11
tween®
2,350
20p11
20pter
20qter
38+2
40th
discussionclassically
+2~3mar
-22
14/300
14qter
176×109/l
24xcyte
31/300
3q25
45-47
83-yr-old
93/300
97/300
bcl1
bcl1/ccnd1
bcl1/igh
bcl1×2
bcl1×3
ccd22
ccnd1
ccnd1/igh
cd5-negative
cp10
igh×1
igh×4
introductionmantle
143/100
15-bp
15-nucleotide
280-294-bp
280_294dup
294
5-amino
5-residue
8-bp
cys94_his98
p102-b1/p140-b2
-1882
1,450/µl
2p12
4q31
5/5,280
ccg-1882
cd5-positive
igh/myc/cep8
introductionchromosomal
maml3
q31
q42
sh3d19
≥90
+14
+20
+4
+6
-18/del
-21
105,342,555-149,489,379
105,457,662-105,601,819
105,602,180-105,638,696
105,641,232-105,851,066
105,896,926-106,340,244
10q
110,058-2,709,520
123,388-1,552,576
128,203-170,736,131
12q34
132,743,455-140,130,559
141,654,474-141,656,709
141,689,169-141,720,856
141,891,008-141,910,446
143,575,014-143,589,342
149,490,002-180,619,169
16,653-62,359,694
164,137,293-184,179,657
177,781-3,194,314
188,160-69,114,099
188,204-134,425,038
19,129,891-19,224,501
19,528,022-105,443,403
1q26
1q35
2,610/µl
2,709,521-57,443,437
20,633,734-63,782,017
21,570,725-21,579,059
21,897,143-21,908,850
211,992,391-213,068,103
22,660,896-22,723,991
220,598-20,308,197
2q24
2q32
3,217,735-146,263,042
31p11
31q12
32p11
35,819-88,657,641
3p12
3p23
3q12
3q24
3q27
3q33
3q35
45,627-191,152,793
5,509,695-9,732,828
57,443,438-57,735,230
58-80
5q25
68,000/µl
69,466,291-132,741,575
72/200
73,877,826-74,040,678
74,080,966-124,118,656
8/18
88,832-73,841,067
89,255,778-89,830,449
8p23
cp14
discussionnear-triploidy
follows:1q21
follows:63-74
introductionmyelodysplastic
p10
q12q22
q22q35
yp11
yq12
×0
×1,10p12
×1,18p11
×1,2q34
×1,3p13q21
×1,5q21
×1,5q33
×1,6p25
×1,7q34
×1,8p23
×1,9q12q34
×1,9q34
×3,11p15
×3,14q11
×3,14q32
×3,15q11
×3,16p13
×3,19p12q13
×3,19p13
×3,20p13q13
×3,22q11
×3,3p13
×3,3p26
×3,3q26
×3,4p16
×3,5q14
×3,7q34
×3,9p24
0721646
1,438
1492r
1509
27f
38-yr-old
5'-aga
5'-g
744
ag-3
ctt-3
introductioncurrently
uk/tools/clustalw2
uuh-1007
uuh-10070721646
1/1,000
1/1,500
1/18,500
19×109/l
2991
338
50-yr-old
50×109/l
alleles-hp1
hp0
hp0hp2
hp1
hp2
hp2-1
phenotypes-hp1
11q-interstitial
11q14
11q23
129/200
13q22
153,225,007-180,652,396
1q23
2q33
2q35
33p15
37,018,986-39,492,610
37×109/l
423,554-11,003,428
5p
5p-
5p-terminal
5p15
5q-terminal
5q33
84,514,776-113,765,153
cep7/d7s486
d5s23×1
d5s721
d5s721×1
egr1/d5s23
egr1×2
introductionchromosome
n=200
q14
126650
175th
1:5,500
2,780
2063-1g
214700
34+5
525g
9-10
arg175
arg175ser
cl-/hco3-
discussioncld
nm_000111
query=nm_000111
slc26a3-mediated
1,808
10,000/µl
319×103/µl
5,780
discussionshml
introductionsinus
182×109/l
18q21/bcl2
325/400
35-50
83×109/l
8q34/myc
bcl2-igh
cd41
d8z2×2
discussiongray
myc×3
q22q13
scd3
10q24
11p13
12p13
13,022
14q11
1p32
1p34
3-35
36×109/l
5-yr
5q35
7p15
7q32-36
7q34
9q32
ccnd2
discussiont-all
hox11
hox11l2
introductiont-lymphoblastic
irs4
lmo1
lmo2
lyl1
rp11-105f23
rp11-815e21
tal1
tal2
tcr-α
tcr-β
tcr-δ
tel/aml1
tlx1
tlx3
x:7
α/δ
136,000/mm3
14053
33-55
5,920/mm3
64-yr-old
mya-646
117-bp
135×109/l
14-21
144-bp
205-bp
2℃/sec
3×109/l
400-mg
456-bp
50-µl
53℃
58℃
9-14
99℃
discussionmalaria
introductionmalaria
parasites/µl
pmol/µl
rfal1/rfal3
rmal1/rmal2
rova3/rova4
rviv1/rviv2
001011658
184100
23/47
234prism
271-275delcaaga
271600
3-generation
313400
93+5g
96℃
discussionx-linked
gln-91argfs*9
introductionspondyloepiphyseal
ivs+5g
nd-1000
trappc2
xp22
yq11
-100
10-6
1799
1799_1801deltga
1801
3'-end
3'-modified
36-69
47-yr-old
64-1
76-190
95-100
introductionpapillary
k601e
nm_004333
v600_k601delinse
1,270/µl
1,315
1,317
1,383-bp
11,000/µl
113/min
12739t
133/76
13b
18818t
42℃
5'-agg
5'-agt
5'-tgc
515-1,390
515fpl
71-yr-old
806r
860/µl
8fpl
9-806
abqt01000054
ac-3
at-3
cag-3
hb1t
introductionhelicobacter
l13464
lytic/10
mega4
organism-1
taa-3
u18766
/its-4
5'-tcc
602/639
615/617
ay213652
discussionphaeohyphomycosis
gc-3
gug66589
introductionphaeohyphomycosis
its-1
its-5
its1
its2
142×109/l
17-yr-old
4,253
41-yr-old
5-unit
53-yr-old
anti-ge2
anti-ge3
anti-ge3-mediated
anti-ge4
discussionge
ge2
ge3
ge4
1-q25
198/200
1q25
20q11
20q12
22-q13
23-q13
253,686-55,192,062
3-p12
31-q13
31q13
33-q36
38×109/l
39-yr-old
55,192,062-59,271,669
61×109/l
65,966,684-134,375,799
69-yr-old
6p25
9q13-q22
cdr1
d20s108×1
hg18
introductiondeletion
mg/m2×3
mg/m2×7
q22q34
α-naphthyl
-13/del
150-350×109/l
187/216
194/212
24-35
27×109/l
33×109/l
4-10×109/l
856
87-yr-old
89-yr-old
aml1-mds1-evi1
aml1/eto
aml1x3
enst00000344691
enst00000494292
etox2
evi1
mds1
p21
pelger-huët
q23
q26
q33
rpl22
runx1-mecom
-Δct
2-ΔΔct
239g→t
248c→t
25922
259g→a
5,938
72×109
96-well
=Δct
arg91→gln
asp87→asn
asp87→gly
introductionshigella
lc480
ser80→ile
ser83→leu
Δct
ΔΔct
0910-06083
1,415
111/69
16-99
180×109/l
21/min
5'-accgcggctgctggcac-3
5'-gaagagtttgatcatggctcag-3
5'-ggggaatattgcacaatgg-3
5'-gtagtccacgccgtaaa-3
5'-tcgcgttgcatcgaattaaa-3
5'-tgtgtgagcactgcaaagta-3
500-bp
7-yr
76-yr-old
79-yr-old
87-99
87/min
hgue-09/9434
msq-1
msq-2
msq-3
0-100
14-24
26s
5'-gcatatcaataagcggaggaaaag-3
5'-ggtccgtgtttcaagacgg-3
5'-gtcgtaacaaggttaacctgcgg-3
5'-tcctccgcttattgatatgc-3
discussionafs
hm595605
introductionfilamentous
nl1
nl4
-392a
-453_-452inst
-490g
0×109/l
1143g
1226-20a
1501g
154g
16+3
16-bp
1826+15t
2151+8t
2426g
2546delc
3031c
3472a
3627-1g
3935-16c
41weeks
710-12a
796a
arg1011cys
asp1209glufs*33
bach1
brip1
d13s317
d18s51
d21s11
d3s1358
d5s818
d7s820
d8s1179
fancd1
fancd2
introductionfanconi
lys1158glu
nc_000009
nc_000016
nl/cgi-din/primer3plus/primer3plus
nm_000135
nm_000136
nm_004629
p031-a2/p032
palb2
phefs*40
primer3
rad51c
ser849
slx4
xrcc9
16-membered-ring
1851-2675
2063
2064
2067
2617
3'-black
5'-fluorescein
5'-gaa
5'-tcg
55℃
:128
a2063
a2063g
a2064
a2064g
a2067g
accupower®premix
bhq1
c2617a
ca-3
caa-3
exicycler™
gen-bank®
l22
methods1
mic90
pcraccupower®
quencher-1
serodia®-myco
t2611c
14pter
19,350,350
19,351,869
2-month-old
2:2
31,088
31,098,692
31-yr-old
3rd-10th
4p/14q
4p15
4p16
4pter
7m
adjacent-1
adjacent-2
discussiontrisomy
g1-p1-a0
introductionparents
10-25th
1150c
1150th
234+1
234+1g
25-50th
252900
252920
252930
252940
4-methylumbelliferyl
6-32
6-sulfatase
8p11
arg384*
d40vfs*19
discussionmps
introductionmucopolysaccharidosis
ivs2+1g
nm_152419
nmol/17
r384*
α-glucosaminide
α-n-acetylglucosaminidase
β-d-glucosaminide
110/min
11386
33861
8-17
86×109/l
90/70
acha01000008
acha02000013
ast-n132
discussionsphingobacterium
introductionsphingobacterium
nr044077
s000752320
086×109/l
1-5×10-2
11/12
287×109/l
38×108/kg
53×108/kg
57×108/kg
64×106/kg
69×106/kg
83×108/kg
p22phox
p40phox
p47phox
p67phox
162000
16p12
17cen
187t
1q41
2-11
603860
ca2+-binding
cbegf2
cbegf3
cys63arg
edu/pph2/
hnf-1b
hnf1
mckd2
score=3
//46
1a-1
1a-3
1b-1
1b-3
1c-1
1c-3
28×109/l
58/100
816
a-2
b-2
cd65
d816
introductionmastocytosis
kit-d816
runx1-runx1t1
runx1-runx1t1-positive
runx1t1
runx1x2
11,306
15×109/l
20q-
214×109/l
218-472
3-5/high-power
506
5q-
7q-
8-yr-old
95-280
cd55
cd59
cep8
d7s486
e2a-pbx
introductionmds
03×109/l
1-424
1-435
409/421
420/420
423/424
424/436
44-yr-old
475-56
497-79
49d4
cgdga6
gu968696
hq246728
introductiongeosmithia
jf417491
β-tubulin
20/10
ala80val
blactx-m-55
blactx-m-57
ctx-m-14-producing
ctx-m-15
ctx-m-55
ctx-m-55-producing
ctx-m-55-type
discussionctx-m
ecp1
introductionshigellosis
isecp1
j53
n131
tängdén
vitek2
β-lactamase
β-lactamase-producing
β-lactamases
0℃
1'etoile
1,325
1,329
1/lpf
10-25/low
111/76
17931t
25296t
351×109/l
46-yr-old
5/9
6310134
acvo01000020
cp002280
introductionrothia
1312c
arg438cys
cdmp1
factor-5
gdf5
gene=gdf5
introductionbrachydactyly
nm_000557
protein-1
12/12
24×109
38-72
395×109
419×109
45×109
59-yr-old
biomed-2
cd16-
cd19-
cd4+t-cell
cd7+
discussiont-lgl
introductiont-cell
p21q27
q14q22
tia1
tia1+
βf1+
1,466
5'-ccagcagccgcggtaatacg-3
5'-taccagggtatctaatcc-3
518f
60-yr-old
800r
b1/nap1/027
introductionclostridium
1,305/1,312
1,350
152/102
306×109/l
32/16
408/410
43242t
44290t
46068t
51512t
7h10
biomèrieux
introductionnocardia
0-14
1,024
100-490
2-10
297×109/l
30mci
50-320
770
800-1,700
99m-hydroxymethylene
dock8
introductionselective
.
,
)
(
a
about
again
all
almost
also
although
always
among
an
and
another
any
are
as
at
be
because
been
before
being
between
both
but
by
can
could
did
do
does
done
due
during
each
either
enough
especially
etc
for
found
from
further
had
has
have
having
here
how
however
i
if
in
into
is
it
its
itself
just
kg
km
made
mainly
make
may
mg
might
ml
mm
most
mostly
must
nearly
neither
no
nor
obtained
of
often
on
our
overall
perhaps
pmid
quite
rather
really
regarding
seem
seen
several
should
show
showed
shown
shows
significantly
since
so
some
such
than
that
the
their
theirs
them
then
there
therefore
these
they
this
those
through
thus
to
upon
use
used
using
various
very
was
we
were
what
when
which
while
with
within
without
would